A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase: PHASE1
Conditions: Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Sponsor: AstraZeneca

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
1 of 175
Clinical Study Protocol 
Study Intervention
AZD8853
Study Code
D9450C00001
Version
3.0
Date
11 Apr 2022
A Phase I/IIa First-in-human, Open-label Study to Evaluate the 
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary 
Efficacy of AZD8853 in Participants with Selected 
Advanced/Metastatic Solid Tumours
Sponsor Name: AstraZeneca
Legal Registered Address: AstraZeneca AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifier Number(s): 
IND number: 157890
EudraCT number: 2021-005438-41
This Clinical Study Protocol has been subject to a peer review according to AstraZeneca 
Standard procedures. The Clinical Study Protocol is publicly registered, and the results are 
disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in 
compliance with prevailing laws and regulations.
Protocol Number: D9450C00001
Amendment Number: 2
Study Intervention: AZD8853
Study Phase: I/IIa 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
2 of 175
Short Title: A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in 
Participants with Selected Advanced/Metastatic Solid Tumours
Study Physician Name and Contact Information will be provided separately
International Co-ordinating Investigator:
Yale Cancer Center
333 Cedar Street
WWW 211
New Haven, CT 06510
United States
PPD

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
3 of 175
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document
Date
Amendment 2
11-Apr-2022
Amendment 1
03-Dec-2021
Original Protocol
15-Oct-2021
The summary of changes for Amendment 2 is provided below. Refer to Appendix K for a 
summary of the previous amendments.
Amendment 2 11 April 2022
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of European Union. 
Overall Rationale for the Amendment:
The primary reasons for this protocol amendment were to update the definition of study 
population and the removal of prospective GDF15 testing/pre-screening. In addition, to 
implement changes based on template requirements and other updates to aid sense and flow of 
the document.
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Section 1.1 (Synopsis; 
Key objectives and 
Endpoints Applicable 
to all Substudies) & 
Section 3 (Objectives 
and Endpoints)
Updated secondary 
efficacy endpoint 
description for change 
in ctDNA levels 
between baseline and 
post-treatment.
Clarification of secondary 
efficacy endpoint description 
for change in ctDNA levels 
from baseline to between 
baseline and post-treatment.
Non-substantial
Section 1.1 (Synopsis; 
Overall Design) & 
Section 10.4.1 
(Substudy 1 Design)
Updated the definition 
for selected 
advanced/metastatic 
solid tumours from 
second to fourth line 
setting to second or 
later line setting of 
unresectable, locally 
advanced (Stage III) or 
metastatic (Stage IV) 
NSCLC that have 
progressed on anti-
PD-1/PD-L1 inhibitors 
Criteria adjusted for clarity, 
consistency, and to relax the 
criteria considering the study 
phase and population.
Substantial

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
4 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
with or without 
platinum-containing 
chemotherapy.
Synopsis 1.2 (Schema, 
Figure 2) & Section 
10.1.1 (Schema, 
Figure 3)
Removal of description 
requiring selection of 
participants with high 
GDF15 levels.
New data shows that up to 
% of the study participants 
may have high GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not 
have any impact on 
participant safety.
Substantial
Section 1.1 (Synopsis; 
Overall Design; 
Table 2) & Section 
10.4.1 (Substudy 1 
Design)
Updated the number of 
participants required 
for Part B1 and B2 to 
“approximately” 
10 MSS-CRC and 
“approximately” 
10 NSCLC participants 
for PD cohort and “up 
to” 10 participants for 
CD8+ PET cohort.
Clarification on the number of 
participants required for Part 
B1 and B2.
Non-substantial
Main study
Section 2.1 (Study 
Rationale)
Removal of description 
requiring selection of 
participants with high 
GDF15 levels. 
New data shows that up to 
% of the study participants 
may have high GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not
have any impact on 
participant safety.
Substantial
Section 2.2.1 (Tumour 
Selection Type)
Updated text to include 
information from 
ongoing trials 
suggesting 
% of 
pre-treated patients in 
these indications have 
 GFD15 
levels.
Clarification and further 
information regarding 
background to tumour 
selection.
Non-substantial
Section 4.2 (Scientific 
Rationale for Study 
Design), Section 5.1 
(Inclusion Criteria), old 
section 5.4 (Pre-Screen 
and Screen Failures), 
Removal of description 
requiring pre-screening 
for GDF15 levels.
New data shows that up to 
% of the study participants 
may have 
 GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not 
Substantial
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
5 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Section 6.3 (Measures 
to Minimise Bias: 
Randomization and 
Blinding), Section 6.5 
(Concomitant 
Therapy), and Section 
8 (Study Assessments 
and Procedures)
have any impact on 
participant safety.
Section 4.4 (End of 
Study Definition)
Deletion of definition 
for completion of 
study.
The study design does not 
allow participants to be 
considered completed.
Non-substantial
Section 5.1 (Inclusion 
Criteria)
Criterion 8, addition of 
the Cockcroft-Gault 
formula for calculating 
creatinine clearance.
Since creatinine clearance is 
included as an inclusion 
criterion, its calculation needs 
to be standardized for 
collection in eCRF. 
Non-substantial
Section 5.2 (Exclusion 
Criteria)
Criterion 10, updated 
to exclude body weight 
loss > 10% within 
30 days of screening.
Clarification of language 
regarding inclusion of 
participants with body weight 
loss.
Non-substantial
Criterion 20, deletion 
of old bullet a) related 
to previous suspected 
or confirmed 
COVID-19 diagnosis.
Clarification of language 
regarding inclusion of 
participants with prior 
COVID-19.
Non-substantial
Criterion 20, updates 
made to old bullet b) 
now a) in relation to 
COVID-19 cases prior 
to Cycle 1 Day 1.
Clarification of language 
regarding inclusion of 
participants with prior 
COVID-19.
Non-substantial
Section 5.3.2 (Activity)
Text updated to clarify 
that strenuous exercise 
is not allowed 48 hours 
prior to each GDF15 
blood collection.
Clarification that this 
restriction applies only to 
visits with GDF15 blood 
collection.
Non-substantial
Section 6.5 
(Concomitant Therapy)
Update to Table 8 for 
prohibited concurrent 
chemotherapy during 
the study.
Clarification that concurrent 
use of hormones for 
non-cancer-related conditions 
and local treatment of isolated 
lesions may be acceptable 
upon consultation with study 
physician.
Non-substantial

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
6 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Update to Table 8 for 
prohibited metformin 
use during the study.
Based on available research 
data, 
 
 
 
 
 
Substantial
Section 6.5.1 (Rescue 
Medicine) & Section 
10.6.6 (Rescue 
Medication)
Deletion of this 
template section for 
rescue medicine.
Rescue medicine is not 
specified for this study.
Substantial
Section 8.1 (Efficacy 
Assessments, Skeletal 
Muscle Index)
Updated text for CT or 
MRI scans that will be 
obtained for SMI 
assessment.
Clarification that CT or MRI 
scans for SMI assessment will 
be obtained using the same 
modality and timepoints as 
the disease assessment scans.
Non-substantial
Section 8.2.1 (Physical 
Examinations)
Text has been added to 
categorise participants 
appetite as poor, 
average, or good and 
change in appetite as 
worse, about the same, 
or improved.
Clarification of data to be 
collected in eCRF.
Non-substantial
Section 8.2.5 (Clinical 
Safety Laboratory 
Assessments)
Deletion of time of 
collection from text.
Clarification of local 
laboratory assessment needs.
Non-substantial
Table 10, deletion of 
carbonate and 
phosphate from 
clinical chemistry 
variable list. The 
addition of lactate 
dehydrogenase.
Clarifications of local 
laboratory assessment needs.
Non-substantial
Table 10 addition of a 
footnote microscopy.
Clarification that it is 
investigator discretion for 
microscopy for abnormal 
dipstick results.
Non-substantial
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
7 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Section 8.3.1 (Time 
Period and Frequency 
for Collecting AE and 
SAE Information)
Addition of text for 
collection of any SAE, 
including death, at any 
time during survival 
follow-up that is 
suspected to have a 
causal relationship to 
study intervention.
Clarifications of local 
laboratory assessment needs.
Non-substantial
Section 8.3.9 (Disease 
Under Study)
This section is deleted.
To prevent duplication and 
aid clarity, AEs reporting for 
disease under study is already 
covered in Section 8.3.5. 
Non-substantial
Section 8.4 (Overdose)
Updated time window 
for reporting relevant 
information to 
AstraZeneca Patient 
Safety within 1 to 
5 days for overdose 
associated SAEs.
Clarification of time window 
to between 1 and 5 days from 
1 or 5 days.
Non-substantial
Section 9.6 (Safety 
Review Committee)
Updated text for SRC 
required data, 
confirming that every 
effort is to be made to 
provide available PK 
data for SRC meetings.
Clarification that PK data is 
not a requirement for SRC 
meetings but every effort 
should be made to provide 
available PK data.
Non-substantial
Substudy 1
Section 10.1.2 
(Schedule of Activities, 
Table 12)
Removal of 
pre-screening for 
GDF15 levels ≥
 
pg/mL.
New data shows that up to 
% of the study participants 
may have 
 GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not 
have any impact on 
participant safety.
Substantial
Assignment of 
participant 
identification number, 
metformin use history, 
and demographic 
information moved to 
screening.
Updated as required following 
the removal of pre-screening 
visit.
Non-substantial
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
8 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Addition of Part A/C 
 
and Part B mandatory 
paired biopsy at 
screening. Addition of 
new footnote e stating 
that if they are taken 
during screening they 
will not need to be 
taken for Cycle 1 
Day 1 pre-dose.
Clarification of the time 
window for collection of 
paired biopsies.
Non-substantial
Updated footnote b to 
include CT or MRI 
scans for SMI 
assessment.
Updated for consistency with 
updates in Section 8.1.
Non-substantial
Deletion of old 
footnote e)
To prevent repetition, the 
detailed description of 
archival tissue block 
collection is only included in 
Section 10.8.6.2.
Non-substantial
Addition to footnote f) 
stating that the if 
participants hold or 
discontinue treatment 
prior to Day 29, they 
should still perform 
PET scan if they are
able.
Clarification of collection 
requirements.
Non-substantial
Section 10.1.2 
(Schedule of Activities, 
Table 13)
Included new footnote 
a confirming safety 
assessments are 
relative to most recent 
dosing.
Clarification of collection 
requirements.
Non-substantial
Updated time windows 
for disease assessments 
to include ±1D for V4 to 
V8, and ±3D for V12 and 
V13+.
Added ±1 and ±3 day windows 
to be consistent with prior 
collection timepoints.
Non-substantial
Updated time window 
for disease assessment 
at V8/V9 and V12.
Clarification of time window 
for disease assessment. 
Non-substantial
Updated footnote d 
(now e) to include CT 
Updated for consistency with 
updates in Section 8.1.
Non-substantial
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
10 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Section 10.5 
(Substudy 1 
Population)
Removal of screening 
description from 
informed consent 
signing.
Clarification of informed 
consent to be signed.
Substantial
Section 10.5.1
(Substudy 1 Inclusion 
Criteria)
Update to criterion 2 
for tumour-specific 
requirements in 
NSCLC, MSS-CRC, 
and UC.
Improve clarity of criteria and 
to improve enrolment.
Substantial
Deletion of old 
criterion 3 for centrally 
confirmed 
pre-treatment GDF15 
levels ≥ 
 pg/mL.
New data shows that up to 
% of the study participants 
may have 
 GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not 
have any impact on 
participant safety.
Non-substantial
Addition of new 
criterion 3 confirming 
that participation in 
this trial is determined 
to be the best option 
for next treatment 
option based on prior 
response to standard of 
care.
Clarification of criteria 
considering the study phase.
Non-substantial
Updated criterion 4 to 
reduce the detail and 
refer to Section 
10.8.6.2 and laboratory 
manual.
To prevent repetition, the 
detailed description of 
archival tissue block 
collection is only included in 
Section 10.8.6.2.
Non-substantial
Section 10.6.6.1.1. 
(Starting Dose)
Updated text to 
remove “single 
sentinel” from starting 
dose description.
Clarification of starting dose 
and process for dosing of 
participants in the first cohort.
Non-substantial
Section 10.6.10
(Definition of DLT 
Evaluable Participant)
Updated text to state 
that participants who 
do not remain in the 
Clarification of definition of 
DLT evaluable participant.
Non-substantial
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
11 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
study up to the DLT 
evaluation period will 
be considered non-
evaluable for DLT 
assessment.
Section 10.8 (Substudy 
1 Study Assessments 
and Procedures), 
Section 10.8.5.3 
(GDF15 Assay for 
Prospective Testing)
Removal of description 
requiring pre-screening 
for GDF15 levels.
New data shows that up to 
% of the study participants 
may have 
 GDF15 levels 
(above the current cut off); in 
addition, the removal of the 
GDF15 cut off level does not 
have any impact on 
participant safety.
Substantial
Section 10.8.6.1 (Fresh 
Tumour Biopsy)
Addition of text 
confirming that 
screening and 
on-treatment biopsies 
should be taken from 
the same lesion.
Clarification of sampling 
process for biopsies.
Non-substantial
Section 10.8.6.1.2 
(Optional Fresh Paired 
Tumour Biopsies)
Updated to state that if 
 
 
 
, every effort 
should be made to 
collect while on 
treatment.
Clarification regarding missed 
second biopsy and that for the 
CD8+ PET cohort, the first 
and second biopsy should be 
taken within 
 hours after 
the respective first and second 
CD8+ PET scans.
Non-substantial
Section 10.8.6.2 
(Mandatory Archival 
Tumour Samples)
Updates made to the 
requirement of archival 
tumour tissue, number 
of slides/sections, and 
reference to laboratory 
manual for process, 
storage and shipment.
Clarification to confirm all the 
required details in one 
location. 
Non-substantial
Appendix A3 
(Informed Consent 
Process)
Text updated to 
confirm that separate 
Part B ICFs will be 
needed for sites in the 
CD8+ PET part of the 
study.
Clarification made to avoid 
confusion in terms of when a 
separate ICF is required for 
CD8+ PET part of study.
Non-substantial
Appendix E3 
(Identification of 
Deletion of process for 
central laboratory.
Hy’s law assessments will be 
done locally and not via 
central laboratory.
Non-substantial
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
12 of 175
Section # and Name
Description of 
Change
Brief Rationale
Substantial/Non-
substantial
Potential Hy’s Law 
Cases)
Appendix E8 
(Laboratory Tests)
Table E8 header 
updated to “Local 
Laboratory Tests”
Hy’s law assessments will be 
done locally and not via 
central laboratory.
Non-substantial
Appendix K (Protocol 
Amendment History)
Addition of this 
appendix.
Included as per template 
guidance.
Non-substantial
Throughout
Minor administrative 
changes.
Revisions made to correct 
errors in format, typography, 
or language.
Non-substantial

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
13 of 175
TABLE OF CONTENTS
TITLE PAGE........................................................................................................................ 1
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE ..................................... 3
TABLE OF CONTENTS .................................................................................................... 13
1
PROTOCOL SUMMARY ................................................................................ 19
1.1
Synopsis ........................................................................................................... 19
1.2
Schema............................................................................................................. 26
1.3
Schedule of Activities ....................................................................................... 28
2
INTRODUCTION............................................................................................ 29
2.1
Study Rationale ................................................................................................ 29
2.2
Background ...................................................................................................... 30
2.2.1
Tumour Type Selection..................................................................................... 30
2.3
Benefit/Risk Assessment................................................................................... 31
2.3.1
Risk Assessment ............................................................................................... 31
2.3.2
Benefit Assessment........................................................................................... 34
2.3.3
Overall Benefit/Risk Conclusion....................................................................... 35
2.3.4
Benefit/Risk Pertaining to Study Conduct During the COVID-19 Pandemic ..... 35
3
OBJECTIVES AND ENDPOINTS................................................................... 37
4
STUDY DESIGN ............................................................................................. 38
4.1
Overall Design.................................................................................................. 38
4.1.1
Master Protocol Structure ................................................................................. 38
4.1.2
Substudy Naming Conventions ......................................................................... 38
4.1.3
Study Conduct Mitigation During Study Disruptions Due to Cases of Civil 
Crisis, Natural Disaster, or Public Health Crisis ................................................ 39
4.2
Scientific Rationale for Study Design ............................................................... 39
4.3
Justification for Dose........................................................................................ 40
4.4
End of Study Definition.................................................................................... 40
4.4.1
Study Stopping Criteria..................................................................................... 40
5
STUDY POPULATION.................................................................................... 42
5.1
Inclusion Criteria .............................................................................................. 42
5.2
Exclusion Criteria ............................................................................................. 43
5.3
Lifestyle Considerations ................................................................................... 46
5.3.1
Contraception ................................................................................................... 46
5.3.2
Activity............................................................................................................. 47
5.4
Screen Failures ................................................................................................. 48
6
STUDY INTERVENTION ............................................................................... 49
6.1
Study Intervention(s) Administered................................................................... 49
6.1.1
Investigational Medicinal Product – AZD8853 ................................................. 49
6.1.1.1
Identity of Investigational Medicinal Product.................................................... 49

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
14 of 175
6.2
Preparation/Handling/Storage/Accountability ................................................... 49
6.2.1
Investigational Medicinal Product Inspection.................................................... 50
6.2.2
AZD8853 Preparation and Administration ........................................................ 50
6.2.3
Treatment Administration ................................................................................. 51
6.2.4
Monitoring of Dose Administration................................................................... 52
6.2.5
Reporting Product Complaints .......................................................................... 52
6.2.6
Additional Study Drugs .................................................................................... 52
6.2.7
Labelling .......................................................................................................... 52
6.2.8
Storage ............................................................................................................. 53
6.2.9
Treatment Compliance...................................................................................... 53
6.2.10
Accountability .................................................................................................. 53
6.3
Measures to Minimise Bias: Randomization and Blinding ................................ 53
6.4
Study Intervention Compliance......................................................................... 53
6.5
Concomitant Therapy........................................................................................ 54
6.6
Dose Modification ............................................................................................ 56
6.7
Intervention after the End of the Study.............................................................. 57
7
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL........................................................... 58
7.1
Discontinuation of Study Intervention............................................................... 58
7.1.1
Temporary Discontinuation............................................................................... 59
7.2
Participant Withdrawal from the Study.............................................................. 59
7.3
Lost to Follow-Up............................................................................................. 60
8
STUDY ASSESSMENTS AND PROCEDURES.............................................. 61
8.1
Efficacy Assessments........................................................................................ 61
8.2
Safety Assessments........................................................................................... 63
8.2.1
Physical Examinations...................................................................................... 63
8.2.2
ECOG Performance Status................................................................................ 63
8.2.3
Vital Signs ........................................................................................................ 64
8.2.4
Electrocardiograms........................................................................................... 64
8.2.5
Clinical Safety Laboratory Assessments............................................................ 65
8.2.6
30-Day Follow-up Visit .................................................................................... 66
8.2.7
90-Day Follow-up Visit .................................................................................... 67
8.2.8
Survival Follow-up ........................................................................................... 67
8.3
Adverse Events and Serious Adverse Events..................................................... 67
8.3.1
Time Period and Frequency for Collecting AE and SAE Information................ 67
8.3.2
Follow-up of AEs and SAEs ............................................................................. 67
8.3.3
Causality Collection.......................................................................................... 68
8.3.4
Adverse Events Based on Signs and Symptoms ................................................ 69
8.3.5
Adverse Events Based on Examinations and Tests ............................................ 69
8.3.6
Adverse Events of Special Interest.................................................................... 69
8.3.7
Hy’s Law.......................................................................................................... 71
8.3.8
Disease Progression.......................................................................................... 71
8.3.9
Reporting of Serious Adverse Events ................................................................ 71

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
15 of 175
8.3.10
Pregnancy......................................................................................................... 72
8.3.10.1
Maternal Exposure............................................................................................ 72
8.3.10.2
Paternal Exposure............................................................................................. 73
8.3.11
New Cancers..................................................................................................... 73
8.3.12
Deaths .............................................................................................................. 73
8.3.13
Medication Error............................................................................................... 74
8.4
Overdose .......................................................................................................... 74
8.5
Human Biological Samples............................................................................... 75
8.5.1
Pharmacokinetics.............................................................................................. 75
8.5.1.1
Determination of Drug Concentration ............................................................... 76
8.5.2
Immunogenicity Assessments ........................................................................... 76
8.5.3
Pharmacodynamics........................................................................................... 76
8.6
............................................................. 76
8.7
................................................................ 76
8.8
...................................... 77
9
STATISTICAL CONSIDERATIONS................................................................ 78
9.1
Statistical Hypotheses....................................................................................... 78
9.2
Sample Size Determination............................................................................... 78
9.3
Populations for Analyses................................................................................... 78
9.4
Statistical Analyses ........................................................................................... 79
9.4.1
General Considerations..................................................................................... 79
9.4.2
Safety Analyses ................................................................................................ 79
9.4.3
Efficacy Analyses ............................................................................................. 80
9.4.4
Other Analyses.................................................................................................. 82
9.4.4.1
Immunogenicity, Pharmacokinetics and Pharmacodynamics ............................. 82
9.5
Interim Analyses............................................................................................... 83
9.6
Safety Review Committee................................................................................. 83
10
SUBSTUDY 1.................................................................................................. 84
10.1
Substudy 1 Summary........................................................................................ 84
10.1.1
Schema............................................................................................................. 84
10.1.2
Schedule of Activities ....................................................................................... 85
10.2
Substudy 1 Introduction.................................................................................... 96
10.3
Substudy 1 Objectives and Endpoints ............................................................... 96
10.4
Substudy 1 Study Design .................................................................................. 97
10.4.1
Substudy 1 Design............................................................................................ 97
10.4.2
Substudy 1 Justification for Dose...................................................................... 99
10.4.3
End of Substudy 1 Definition.......................................................................... 100
10.5
Substudy 1 Population .................................................................................... 100
10.5.1
Substudy 1 Inclusion Criteria.......................................................................... 100
10.5.2
Substudy 1 Exclusion Criteria......................................................................... 102
10.6
Substudy 1 Study Intervention ........................................................................ 103
10.6.1
Study Intervention(s) Administered................................................................. 103
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
17 of 175
10.9.4.1
General Considerations................................................................................... 119
10.9.4.2
Efficacy Analyses ........................................................................................... 119
10.9.4.3
Safety Analyses .............................................................................................. 120
10.9.4.4
Other Analyses................................................................................................ 120
10.9.5
Interim Analyses............................................................................................. 120
11
SUPPORTING 
DOCUMENTATION 
AND 
OPERATIONAL
CONSIDERATIONS ...................................................................................... 122
12
REFERENCES............................................................................................... 172
LIST OF FIGURES
Figure 1
AZD8853 Phase I/IIa Study in Selected Advanced/Metastatic Solid 
Tumours .................................................................................................. 26
Figure 2
Substudy 1 Schema: AZD8853 Monotherapy in Participants with 
NSCLC, MSS-CRC and UC .................................................................... 27
Figure 3
Substudy 1 Schema: AZD8853 Monotherapy in Participants with 
NSCLC, MSS-CRC and UC .................................................................... 84
Figure 4
CD8+ PET and Biopsy Timelines .......................................................... 162
LIST OF TABLES
Table 1
Objectives and Endpoints (All Substudies) .............................................. 21
Table 2
Description of Study Parts ....................................................................... 22
Table 3
Risk Assessment...................................................................................... 32
Table 4
Objectives and Endpoints......................................................................... 37
Table 5
Substudy Naming Conventions................................................................ 38
Table 6
Criteria for Adequate Organ and Marrow Function .................................. 43
Table 7
Highly Effective Methods of Contraception (< 1% Failure Rate) ............. 47
Table 8
Prohibited Concomitant Medications ....................................................... 55
Table 9
Permitted Concomitant Medications ........................................................ 56
Table 10
Laboratory Safety Variables..................................................................... 66
Table 11
Populations for Analyses ......................................................................... 78
Table 12
Schedule of Activities - Screening ........................................................... 85
Table 13
Schedule of Activities – Study Visits ....................................................... 88
Table 14
Schedule of Activities – End of Treatment............................................... 94
Table 15
Substudy 1 Objectives and Endpoints ...................................................... 96

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
18 of 175
Table 16
mTPI-2 Decision Rules.......................................................................... 106
Table 17
Sampling Schedule for Electrocardiograms............................................ 112
Table 18
Sampling Schedule for PK Samples....................................................... 112
Table 19
Sampling Schedule for ADA Samples.................................................... 113
Table 20
Sampling Schedule for GDF15 Target Engagement Samples ................. 114
Table 21
Populations for Analyses ....................................................................... 119
Table 22
Details of Analyses................................................................................ 119
Table 23
Summary of Imaging Modalities for Tumour Assessment...................... 145
Table 24
RECIST v1.1 Evaluation of Target Lesions ........................................... 153
Table 25
RECIST 1.1 Evaluation of Non-Target Lesions ..................................... 154
Table 26
RECIST v1.1 Overall Visit Response..................................................... 155
LIST OF APPENDICES
Appendix A
Regulatory, Ethical, and Study Oversight Considerations....................... 122
Appendix B
Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ...................................................................... 128
Appendix C
Handling of Human Biological Samples ................................................ 133
Appendix D
..................................................... 135
Appendix E
Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law......................................................................... 138
Appendix F
Guidelines For Evaluation of Objective Tumour Response Using 
RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumours).. 145
Appendix G
Changes Related to Mitigation of Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis ............................ 157
Appendix H
National Institute of Allergy and Infectious Disease and Food Allergy 
and Anaphylaxis Network guidance for anaphylaxis diagnosis............... 159
Appendix I
CD8+ PET Imaging ............................................................................... 160
Appendix J
Abbreviations ........................................................................................ 165
Appendix K
Protocol Amendment History................................................................. 170
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
19 of 175
1
PROTOCOL SUMMARY
1.1
Synopsis
Protocol Title:
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, 
Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected 
Advanced/Metastatic Solid Tumours.
Short Title:
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants 
with Selected Advanced/Metastatic Solid Tumours.
Rationale:
Chemotherapy and radiotherapy have historically been used for the treatment of patients with 
advanced/metastatic cancers; however, these strategies are usually not effective in controlling 
disease in the long term. Disease aggression is in part driven by the tumour immune 
microenvironment (TME) and in recent years there has been a focus on targeting different 
aspects of the TME to inhibit pro-tumourigenic immunosuppression and promote anti-tumour 
inflammatory responses. Therapeutics that target the programmed cell death-1 
(PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint pathway have seen 
significant success in a number of solid tumour types by reversing cluster of differentiation 
(CD)8+ T cell exhaustion and driving a cytotoxic response. A caveat of this approach is that 
only a subset of participants will demonstrate long-term disease control, and so it is imperative
to identify additional pathways for therapeutic development to promote anti-tumour immune 
response.
Growth differentiation factor 15 (GDF15), a transforming growth factor beta (TGF-)
superfamily cytokine, has been shown to affect the TME and is associated with a poor 
prognosis in a number of solid tumour types.
 
 
 As an antagonist to GDF15, 
the monoclonal antibody AZD8853 neutralizes the effects of GDF15 in preclinical tumour 
models. Effectively targeting GDF15 culminates in an enhanced cytotoxic anti-tumour 
immune response and reverses immunosuppression in the TME.
This study is primarily designed to evaluate the safety and tolerability of AZD8853. The study 
will include several "Substudies", the first of which will evaluate AZD8853 as monotherapy at 
increasing doses in participants with selected advanced/metastatic solid tumours who have 
elevated serum GDF15 levels and who have progressed or are refractory to at least one line of 
standard systemic therapy. This first Substudy will also characterise the pharmacokinetics 
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
20 of 175
(PK) and immunogenicity of AZD8853 and explore potential biological activity by assessing 
pharmacodynamic (PD) biomarkers and anti-tumour activity. 
 
. The results from this study will guide future Substudies 
with AZD8853, which have yet to be defined. 
AZD8853 is currently being developed as monotherapy but may be investigated in 
combination with other approved anti-cancer agents and/or investigational agents for greater 
efficacy in future Substudies, based upon emerging data. These combination Substudies may 
be added once a recommended Phase 2 dose (RP2D) for monotherapy has been defined based 
on emerging supportive preclinical and/or clinical data and scientific rationale in the first 
Substudy.
The overarching primary hypothesis for this study is that AZD8853 will demonstrate an 
acceptable safety, PK and PD profile, and evidence of preliminary efficacy in participants with 
selected advanced/metastatic solid tumours.
Key Objectives and Endpoints Applicable to all Substudies
The objectives and endpoints that are common for all Substudies are listed in Table 1. See the 
individual Substudies in the clinical study protocol for the objectives and endpoints specific to 
each of the Substudies.
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
22 of 175
Substudy 1
Substudy 1 will be a first time in human (FTiH), open-label, multicentre study, in which 
AZD8853 will be evaluated as monotherapy for safety, PK, PD, and preliminary efficacy in 
participants with selected advanced/metastatic solid tumours defined as:

Second or later line setting of unresectable, locally advanced (Stage III) or metastatic 
(Stage IV) non-small-cell lung cancer (NSCLC) that have progressed on anti-PD-1/PD-
L1 inhibitors with or without platinum-containing chemotherapy.

Third or later line setting of Stage IV microsatellite stable-colorectal cancer (MSS-CRC)
that have progressed on prior standard of care treatment.

Second or later line setting of Stage IV urothelial carcinoma (UC) that have progressed on
prior treatment with platinum and/or checkpoint inhibitors (CPI).
Substudy 1 will comprise 3 main parts (A, B and C), as shown in Table 2:
Table 2
Description of Study Parts
Study Part
Description
Number of Participants Planned
Part A (AZD8853) Dose Escalation
Part A: Dose Escalation
•
Dose escalation of AZD8853 in 
participants with selected 
advanced/metastatic solid tumours
•
Up to 45 participants 
(assuming up to 5 dosing 
cohorts and 3-9 participants 
per cohort).
•
.
Part B (AZD8853) PD/MoA Expansion
Part B1 (Biopsy and CD8+ 
PET)
•
PD cohort at alternative dose
•
Up to approximately 
20 participants
(approximately 
10 MSS-CRC and 
approximately 10 NSCLC
participants). 
•
Mandatory biopsies.
•
CD8+ PET
•
Up to 10 participants (a 
subset of the 20 participants 
above).
Part B2 (Biopsy and CD8+ 
PET)
•
PD cohort at MTD/HPDD
•
Up to approximately 
20 participants
(approximately 
10 MSS-CRC and 
approximately 10 NSCLC 
participants). 
•
Mandatory biopsies.
•
CD8+ PET
•
Up to 10 participants (a 
subset of the 20 participants 
above).
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
23 of 175
Study Part
Description
Number of Participants Planned
Part C (AZD8853) Efficacy Expansion*
Part C1
•
First indication at MTD/HPDD
Up to 40 participants.
.
Part C2
•
Second indication at MTD/HPDD 
or
•
First indication at alternative dose
Up to 40 participants.
.
Abbreviations: CD8 = cluster of differentiation 8; HPDD = highest protocol-defined dose; MoA = mechanism of 
action; MTD = maximum tolerated dose; MSS-CRC = microsatellite stable-colorectal cancer; 
NSCLC = non-small-cell lung cancer; PD = pharmacodynamics; PET = positron emission tomography.
* If the RP2D cannot be adequately determined from Part B and additional data (eg, efficacy) is required to guide 
RP2D determination, then 2 dose levels in one indication will be investigated. If the RP2D is determined at the 
end of Part B, RP2D will be evaluated in 2 indications.
Disclosure Statement:
Substudy 1
This is a multi-part, open-label, dose escalation, PD/mechanism of action (MoA) expansion,
and efficacy expansion Substudy.
Number of Participants:
Substudy 1
Across all parts of Substudy 1 up to a total of 165 eligible participants may be enrolled and 
treated with AZD8853, consisting of up to 45 participants in Part A, up to 40 participants in 
Part B and up to 80 participants in Part C.
Intervention Groups and Duration:
Refer to the relevant Substudy for details.
Safety Review Committee: Yes
A safety review committee (SRC) will be responsible for making dose escalation or dose 
de-escalation decisions and recommendations regarding further conduct of the study, during 
all phases of the study. The SRC will provide ongoing safety surveillance of the study, with 
regularly scheduled reviews of safety and other relevant data to monitor the ongoing safety 
profile of the study intervention. 
Statistical Methods
Safety
Dose escalation will follow the modified toxicity probability interval (mTPI-2) algorithm and 
will be based on the dose limiting toxicity (DLT) evaluable population (all enrolled 
participants who complete the DLT evaluation period of 21 days after receiving at least 75%
of the first infusion of study intervention, or who experience any DLT). Safety and tolerability 
will be assessed in terms of DLTs, adverse events (AEs), serious AEs (SAEs), vital signs, 
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
24 of 175
clinical chemistry/haematology parameters, dose interruptions/discontinuations, and 
electrocardiogram (ECG) data. These variables will be collected for all participants. All safety 
analyses will be performed on the Safety Population (all participants who receive at least 
one dose of study intervention) and will be summarised using descriptive statistics. Adverse 
events will be coded using the latest version of Medical Dictionary for Regulatory Activities 
(MedDRA) and graded according to National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE) v5.0.
Efficacy
The efficacy endpoints for tumour response (objective response rate [ORR], disease control 
rate [DCR] at 15 weeks, duration of response [DoR], and percentage change in tumour size)
will be summarised for the Response Evaluable Population (all dosed participants who have
measurable disease at baseline) using Response Evaluation Criteria in Solid Tumours
(RECIST) v1.1 by Investigator assessment. The efficacy endpoints of progression-free 
survival (PFS) and overall survival (OS) will be summarised based on the Safety Population. 
The RECIST tumour response data will be used to programmatically determine each 
participant’s visit response and to derive the endpoints of ORR, DoR, DCR at 15 weeks, 
percentage change in tumour size, and PFS. Endpoints will be summarised using descriptive 
statistics and Kaplan Meier methods as appropriate.
Additionally, the percentage change in circulating tumour deoxyribonucleic acid (ctDNA)
from pre-treatment (baseline) to each post baseline timepoint as well as the maximum change 
will be summarised using descriptive statistics on the Safety Population. 
Pharmacokinetics
The PK analysis of the serum data for AZD8853 will be performed using the PK Population 
(all participants who receive at least one dose of study intervention with at least one reportable 
concentration). The actual sampling times will be used in the parameter calculations and the 
PK parameters will be derived using standard non-compartmental methods, if the data 
permits. It is anticipated that maximum concentration (Cmax), area under the curve (AUC), 
and other PK parameters will be calculated if the data allows. 
Relevant descriptive statistics will be used to summarise PK parameters and concentrations.
Immunogenicity
Immunogenicity results will be analysed descriptively on the Immunogenicity Population (all 
participants who receive at least one dose of study intervention with at least one reportable 
immunogenicity measurement) by summarising the number and percentage of participants 
who develop detectable anti-drug antibodies (ADAs) against AZD8853 at protocol-specified 
timepoints. The immunogenicity titre may be reported for samples confirmed positive for the 
presence of ADAs. The effect of immunogenicity on PK, efficacy, and safety may be 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
25 of 175
evaluated, if the data allow.
Depending on the extent of any impact, summaries of data relating to participants diagnosed 
with coronavirus disease 2019 (COVID-19), any impact of COVID-19 on study conduct (in 
particular missed visits, delayed or discontinued study treatment, and other protocol 
deviations) may be generated.
Further details of all analyses will be provided in a separate statistical analysis plan.
Interim analyses will be conducted separately for each Substudy and are described in the 
relevant Substudy.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
26 of 175
1.2
Schema
Please see the individual schema for each study Substudy within the respective Clinical Study 
Protocol section.
Figure 1
AZD8853 Phase I/IIa Study in Selected Advanced/Metastatic Solid 
Tumours

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
28 of 175
1.3
Schedule of Activities
Please see the individual schedule of activities for each study Substudy within the respective 
CSP section.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
29 of 175
2
INTRODUCTION
AZD8853 is a humanized IgG1 mAb with an 
 
. AZD8853 specifically binds to and neutralizes GDF15, a TGF-β 
superfamily cytokine that is overexpressed in certain solid malignant tumours. GDF15
functions to regulate inflammation and has an immunosuppressive effect on T cells, DCs and 
myeloid-derived cell subsets. Neutralizing GDF15 leads to increased T cell proliferation and 
DC activation, thereby enhancing the immune response.
2.1
Study Rationale
Chemotherapy and radiotherapy have historically been used for the treatment of patients with 
advanced/metastatic cancers; however, these strategies are usually not effective in controlling 
disease in the long term. Disease aggression is in part driven by the TME and in recent years 
there has been a focus on targeting different aspects of the TME to inhibit pro-tumourigenic 
immunosuppression and promote anti-tumour inflammatory responses. Therapeutics that 
target the PD-1/PD-L1 immune checkpoint pathway have seen significant success in a number 
of solid tumour types by reversing CD8+ T cell exhaustion and driving a cytotoxic response. 
A caveat of this approach is that only a subset of participants will demonstrate long-term 
disease control, and so it is imperative to identify additional pathways for therapeutic 
development to promote anti-tumour immune response.
GDF15, a TGF-β superfamily cytokine, has been shown to affect the TME and is associated 
with a poor prognosis in a number of solid tumour types (Wischhusen et al, 2020; Liu et al, 
2016; Mehta et al, 2014; Mehta et al, 2015; Traeger et al, 2019). High expression of GDF15 in 
the TME has been shown to lead to decreased DC activation, decreased cytotoxic CD8+ T cell 
infiltration and increased CD4+ Treg expansion (Wischhusen et al, 2020; Wang et al, 2021; 
Roth et al, 2010). As an antagonist to GDF15, the monoclonal antibody AZD8853 neutralizes 
the effects of GDF15 in preclinical tumour models. Effectively targeting GDF15 culminates in 
an enhanced cytotoxic anti-tumour immune response and reverses immunosuppression in the 
TME.
Substudy 1 of this study is primarily designed to evaluate the safety and tolerability of 
AZD8853 as monotherapy at increasing doses in participants with selected 
advanced/metastatic solid tumours who have elevated serum GDF15 levels and who have 
progressed or are refractory to at least one line of standard systemic therapy. Substudy 1 will 
also characterise the PK and immunogenicity of AZD8853 and explore potential biological 
activity by assessing PD biomarkers and anti-tumour activity. 
 
. The results from this Substudy will guide future clinical 
studies with AZD8853.
AZD8853 is currently being developed as monotherapy, but may be investigated in 
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
30 of 175
combination with other anti-cancer agents or other types of agents for greater efficacy in the 
future. New Substudies for combination treatments may be added once monotherapy RP2D 
has been defined based on emerging supportive preclinical and/or clinical data and scientific 
rationale.
The overarching primary hypothesis for this study is that AZD8853 will demonstrate an 
acceptable safety, PK, and PD profile, and evidence of potential efficacy in participants with 
selected advanced/metastatic solid tumours.
2.2
Background
The TME plays an important role in tumourigenesis and overall disease aggression and thus 
has been targeted by many immune therapies. Patient prognosis is affected by both the extent 
of immune cell infiltration and how inflammatory or immune-suppressed these immune cells 
are (Tang et al, 2021; Waldman et al, 2020). To date, the most successful immunotherapies 
have focused on modulating cytotoxic T cell responses. However, tumour progression is
controlled by several immune cell types and soluble factors that can be released by both 
tumour and non-tumour cells and research endeavours have sought to identify novel 
therapeutics that can target multiple aspects of the TME. 
GDF15 has been linked to the development of cancers (Wischhusen et al, 2020; Bauskin et al, 
2006). High levels of GDF15 alter the TME toward an immunosuppressive, 
tumour-“promoting” microenvironment. 
 
 
(unpublished AstraZeneca clinical trial analyses). 
 
 
Preclinical in vivo research has shown that anti-GDF15 treatment causes infiltration of T cells 
and activation of DCs, leading to an anti-tumour response in anti-PD-L1 resistant models. 
This suggests that anti-GDF15 may provide an alternative therapy for patients whose tumours
have previously failed to respond to anti-PD-L1 therapy. Since anti-GDF15 is hypothesised to 
have the dual effect of recruiting T cells to the TME and alleviating immune suppression, this 
novel therapeutic is expected to remodel the TME and, therefore, improve the anti-tumour
immune response in patients who have a TME that is either poorly infiltrated with T cells or 
highly immunosuppressive.
2.2.1
Tumour Type Selection
In cancer, elevated serum GDF15 levels have been reported in many solid malignancies, 
including colon (Mehta et al, 2015), lung (Liu et al, 2016) and bladder cancer (Traeger et al, 
2019). According to unpublished work conducted by AstraZeneca with 
 
 
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
31 of 175
 Similarly, higher levels of GDF15 were found in NSCLC samples, where high serum 
levels correlated with fewer cytotoxic CD8+ T cells and reduced DC gene expression 
signatures. Lastly, the correlation was also found in bladder cancer samples, where high 
GDF15 levels correlated with low CD8+ T cell numbers (IHC) and low cytotoxic activity and
NK cell gene expression signatures. Furthermore, emerging data from ongoing clinical trials 
conducted by AstraZeneca suggest that 
% of pre-treated patients in these indications 
have elevated GDF15 levels (>
 pg/mL). Lastly, in all of these tumour types elevated 
GDF15 levels have been correlated with poor outcomes (Mehta et al, 2015; Liu et al, 2016; 
Traeger et al, 2019).
2.3
Benefit/Risk Assessment
Detailed information about the known and anticipated benefits and potential risks of 
AZD8853 are found in the IB.
2.3.1
Risk Assessment
This is the FTiH trial for AZD8853; no clinical data are available and there are no identified 
risks at this time. The study will be performed in accordance with ethical principles that have 
their origin in the Declaration of Helsinki and are consistent with ICH/GCP requirements, and 
applicable regulatory requirements.
Preclinical Work
The initial single dose (intravenous) PK and PD non-GLP study was performed in male 
cynomolgus monkeys where animals were dosed mg/kg, 
 mg/kg, or 
 mg/kg followed 
by a 4-week recovery period. Single doses were well tolerated with no adverse clinical 
reactions or clinical pathology observed; specifically, there were no changes to coagulation, 
complement, or immune subsets.
A 3-month GLP toxicology study was performed in cynomolgus monkeys with an 8-week 
recovery period. Both male and female monkeys were dosed 
mg/kg, 
mg/kg, or 
mg/kg AZD8853 by weekly intravenous (15 min) infusion for 14 administrations. There 
were no AZD8853-related changes in body weight, or neurological, ECG, respiratory or BP 
examinations. There were no changes in clinical pathology (haematology, clinical chemistry, 
urinalysis or cytokine analysis), nor immunophenotyping. No AZD8853-related organ weight 
changes were noted. Minimal to slight vascular/perivascular inflammatory changes were noted 
in the kidney, heart, and gall bladder of an individual animal administered the 
 dose of 
mg/kg which is suggestive of secondary immune complex formation related vascular 
injury. There were no histopathological changes observed in the remaining 5 animals at the 
 dose of 
mg/kg or the 
 dose of 
 mg/kg, respectively. Refer to the IB for 
detailed information about the GLP toxicology studies.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
32 of 175
Potential Risks
Based upon the GLP toxicology studies to date, there are no identified risks for AZD8853. 
The potential risks for AZD8853 include 
 
 
 
 
. These risks are based on animal data, including 
 mice models,
described in the literature. Immune complex disease is a potential risk based on preclinical 
findings in the GLP toxicology study. Additional potential risks include 
 
, which can occur after infusions with mAbs. The 
TMG are provided as a separate document. The risk assessment for AZD8853 is provided in 
Table 3.
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
33 of 175
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
34 of 175
2.3.2
Benefit Assessment
In nonclinical pharmacology studies, AZD8853 was able to 
 
. In 
addition, AZD8853 was able to
 
 
 
Overall, the 
preclinical data from both in vitro and in vivo models suggest that AZD8853 has the potential 
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
35 of 175
to induce clinical response in participants with selected advanced/metastatic cancers.
2.3.3
Overall Benefit/Risk Conclusion
There remains an unmet need for improved therapies for patients with advanced/metastatic 
solid tumours. The design of this current study aims to minimize potential risks to participants 
based on the inclusion and exclusion criteria, restrictions on concomitant medication during 
the study, continuous safety monitoring (including review of all available safety, PK, and 
other relevant data by the SRC), and TMGs. The potential risks are designated AESIs and 
hence are subject to intensive safety monitoring. Thus, the benefit/risk assessment for this 
Phase I/IIa study appears acceptable based upon the poor outcomes for this patient population 
and the strength of the scientific hypothesis under evaluation. 
More detailed information about the known and anticipated benefits and potential risks of 
AZD8853 may be found in the IB.
2.3.4
Benefit/Risk Pertaining to Study Conduct During the COVID-19 
Pandemic
Cancer patients have an increased risk of exposure to SARS-CoV-2 due to frequent hospital or
clinic visits for treatment and monitoring. A retrospective cohort study of 
28 COVID-19-infected cancer participants from 3 hospitals in Wuhan, China, reported that a 
 of participants
%; N = ) were suspected to have acquired the infection by 
hospital-associated transmission (Yu et al, 2020; Zhang et al, 2020). Participants with cancer 
may have a higher risk of a poorer outcome if infected with SARS-CoV-2 than individuals 
without cancer but current evidence appears insufficient to support a conclusive association 
between cancer in general and COVID-19 (Xia et al, 2020).
This study will enrol participants with selected advanced/metastatic solid tumours. 
Participants in this study will receive AZD8853 treatment that leads to inhibition of GDF15 as 
part of the treatment strategy. Overall, the intervention received and procedures during the 
course of this study are considered to have low risk for increasing susceptibility to 
SARS-CoV-2 infection.
Furthermore, at this stage of disease, participants would typically have frequent 
healthcare-related visits, irrespective of participation in a clinical study. Therefore, it is 
anticipated that participation in this clinical study should not significantly increase a 
participant’s risk of exposure to COVID-19.
Novel treatment options are needed to improve the long-term prognosis for participants with
advanced/metastatic solid cancer tumours, which are associated with chemoresistance, 
extremely poor prognosis, and a high risk of developing cancer-related death. AZD8853 could 
be a potential treatment option in this patient population with high unmet medical need. The 
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
36 of 175
scheduled safety assessment visits that are considered in excess of standard-of-care are 
intended to monitor the participants involved in the study. Thus, although there may be 
increased risk to participants by exposure to COVID-19 during study visits, this is offset by 
the benefit of participating in a clinical trial.
In accordance with EMA and FDA guidelines (EMA-CTFG-EC, 2021; FDA 2021), a risk 
assessment will be conducted in collaboration with Investigators for each site and participant
prior to site initiation/participant enrolment and on an ongoing basis throughout the study to
assess whether additional measures may be necessary to ensure participant safety and data
validity. Measures may include postponement of study start on a global, country, or site level
or suspension of recruitment of participants in locations with an increased risk of COVID-19
related disruption.
If there is a need to reconsent study participants for the implementation of new urgent changes
in study conduct, additional guidance on alternative means of obtaining reconsent to avoid
unnecessary study visits is provided in Appendix A. Any deviations to the CSP necessary to 
safeguard participant safety or data validity as a result of COVID-19-related disruption will be 
recorded and any permanent changes requiring an amendment to the CSP will be 
communicated to regulatory authorities and IRBs/IECs in line with relevant local guidance 
and procedures.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
38 of 175
4
STUDY DESIGN
4.1
Overall Design
4.1.1
Master Protocol Structure
The overall study design will include a Master Protocol with Substudies. Information relating 
to the overall study, including study objectives, rationale, master inclusion and exclusion 
criteria, safety assessments, and AE reporting can be found in the Master Protocol
(ie, Sections 1-9). In addition to the Master Protocol, individual “Substudies” will contain 
elements specific to each individual Substudy. Substudy 1 as described below, includes both a 
dose escalation and 2 expansions for monotherapy. The content of additional Substudies has
not yet been defined and will be further added based on emerging supportive preclinical data.
The information in this Master Protocol cannot be superseded by information in the 
Substudies. Any change to the study master elements (ie, this Master Protocol) or Substudies
will be submitted to Regulatory Authorities and ethics committees according to the local 
legislation/requirements.
Study drug-specific information including doses and justifications, toxicity management, dose 
modifications and concomitant medications can be found in the relevant Substudy(ies).
4.1.2
Substudy Naming Conventions
Initially, the study will consist of one Substudy (Substudy 1) evaluating the safety, PK, PD,
and preliminary efficacy of AZD8853 as monotherapy in participants with selected 
advanced/metastatic solid tumours. Additional Substudies may be added by substantial 
amendment evaluating AZD8853 in different combination cohorts. These different 
combination cohorts will be determined by emerging preclinical data using combinations of 
approved therapies and/or investigational agents which have established safety data in 
humans.
Table 5
Substudy Naming Conventions
Substudy
Tumour Type
Intervention
Substudy 1 – Monotherapy Escalation and Expansion 
NSCLC
MSS-CRC
UC
AZD8853
Potential combination therapy Substudies a
Substudy X – AZD8853 + [combination treatment #1]
TBD
AZD8853 +
[combination treatment #1]
Substudy Y – AZD8853 + [combination treatment #2]
TBD
AZD8853 +
[combination treatment #2]
a
Anticipated combination cohort Substudies will be numbered per the order added to the study protocol 
(Substudy 2, Substudy 3, etc).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
39 of 175
Abbreviations: MSS-CRC = microsatellite stable-colorectal cancer; NSCLC = non-small-cell lung cancer; 
TBD = to be decided; UC = urothelial carcinoma.
4.1.3
Study Conduct Mitigation During Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The guidance given below supersedes instructions provided elsewhere in this CSP and should 
be implemented only during cases of civil crisis, natural disaster, or public health crisis 
(eg, during quarantines and resulting site closures, regional travel restrictions, and 
considerations if site personnel or study participants become infected with SARS-CoV-2 or 
similar pandemic infection) which would prevent the conduct of study-related activities at 
study sites, thereby compromising the study site staff or the participant’s ability to conduct the 
study. The Investigator or designee should contact the study Sponsor to discuss whether the 
mitigation plans below should be implemented.
To ensure continuity of the clinical study during a civil crisis, natural disaster, or public health 
crisis, changes may be implemented to ensure the safety of study participants, maintain 
compliance with GCP, and minimise risks to study integrity.
Where allowable by local health authorities, ethics committees, healthcare provider guidelines 
(eg, hospital policies) or local government, these changes may include the following options:

Obtaining reconsent for the mitigation procedures (note, in the case of verbal reconsent, 
the ICF should be signed at the participant’s next contact with the study site).

Rescreening: Additional rescreening for screen failure and to confirm eligibility to 
participate in the clinical study can be performed for previously screened participants. 
The Investigator should confirm this with the designated study physician.

Home or remote visit: Performed by a site qualified HCP or HCP provided by a TPV.

Telemedicine visit: Remote contact with the participants using telecommunications 
technology including phone calls, virtual or video visits, and mobile health devices.
For further details on study conduct during civil crisis, natural disaster, or public health crisis, 
refer to Appendix G.
4.2
Scientific Rationale for Study Design
This is a FTiH study primarily designed to evaluate the safety and tolerability of AZD8853 at 
increasing doses in participants with selected metastatic/advanced solid tumour and for whom 
no standard-of-care exists. The study will also characterise the PK of AZD8853 and explore 
potential biological activity by assessing PD and 
 and anti-tumour 
activity. The results from this study will form the basis for decisions for future studies. The 
ability to acquire appropriate consent to collect biological samples is of utmost importance in 
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
40 of 175
order to establish an archive and allow future meta-analysis of data derived from a number of 
studies with AZD8853.
The Master Protocol with Substudy structure allows for the optimization of both dose and 
schedule of AZD8853 as monotherapy and in combination with anti-cancer agents, including 
intensive safety monitoring followed by expansion cohorts in specific indications. In addition, 
the Master Protocol with Substudy structure allows flexibility to open and close different 
AZD8853 combinations at a different pace based on emerging data. This allows for a more 
fluid development of AZD8853 in combinations and indications with the greatest potential to 
benefit participants.
Key aspects of the study, such as starting dose of AZD8853 in Substudy 1, the dose escalation, 
stopping criteria, cohort sizes, and study endpoints are based upon accepted methodology for 
Phase I/II oncology studies.
4.3
Justification for Dose
Information on dose justification is provided in the respective Substudies.
4.4
End of Study Definition
The end of the study is defined as 18 months after the last enrolled participant received his/her 
last dose of study intervention or when the Sponsor stops the study, whichever occurs first.
4.4.1
Study Stopping Criteria
AstraZeneca reserves the right to temporarily suspend or permanently terminate this study or 
components of the study at any time. The reasons for temporarily suspending or permanently 
terminating the study may include, but are not limited to the following:

Fatal event deemed related to study therapy (probable or certain causality after full 
etiological work-up). This will also result in a comprehensive review of safety.

Unexpected and life-threatening events deemed related to study therapy.

Sponsor decision that the study participants are placed at undue safety risk.

Participant enrolment is unsatisfactory.

Noncompliance that might significantly jeopardize the validity or integrity of the study.

Sponsor decision to terminate development of the study intervention.
If AstraZeneca determines that temporary suspension or permanent termination of the study or 
components of the study is required, AstraZeneca will discuss the reasons for taking such 
action with all participating Investigators. When feasible, AstraZeneca will provide advance 
notice to all participating Investigators of the impending action.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
41 of 175
If the study or components of the study are suspended or terminated for safety reasons, 
AstraZeneca will promptly inform all Investigators and/or institutions conducting the study. 
AstraZeneca will also promptly inform the relevant regulatory authorities of the 
suspension/termination along with the reasons for such action. Where required by applicable 
regulations, the Investigator must inform the IRB/IEC promptly and provide the reason(s) for 
the suspension/termination. If the study or components of the study is suspended for safety 
reasons and it is deemed appropriate by AstraZeneca to resume the study or components of the 
study, approval from the relevant regulatory authorities (and IRBs/IECs when applicable) will 
be obtained prior to resuming the study.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
42 of 175
5
STUDY POPULATION
All criteria and considerations listed in this section are for the master study design and apply 
to all Substudies of the study. Additional Substudy-specific criteria and considerations are 
listed in the study population section of the relevant Substudy.
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1
Inclusion Criteria
The below are the master inclusion criteria for all Substudies of the study; all participants 
must meet the criteria described in the relevant Substudy in addition to those described below. 
Where Substudy-specific criteria are more stringent than master study criteria, the 
Substudy-specific criteria take precedent.
Participants are eligible to be included in the study only if all of the following criteria apply:
Informed Consent
1. Capable of giving signed informed consent as described in Appendix A which includes 
compliance with the requirements and restrictions listed in the ICF and in this protocol.
2. Provision of signed and dated, written informed consent prior to any mandatory 
study-specific procedures, sampling, and analyses.
3. Provision of signed and dated written 
 Information informed 
consent prior to collection of samples for 
 that supports the 
.
Age
4. Participant must be at least 18 years of age inclusive, at the time of signing the informed 
consent.
Type of Participant and Disease Characteristics
5. Have a life expectancy of ≥ 12 weeks.
6. Participants must have at least one lesion, that qualifies as a RECIST v1.1 TL at baseline. 
Tumour assessment by CT scan or MRI must be performed within 28 days prior to 
treatment.
a) A previously irradiated lesion can be considered a TL if the lesion is well defined, 
measurable per RECIST v1.1, and has clearly progressed during or after most recent 
therapy.
b) Participants undergoing paired tumour biopsies must have additional NTLs that can 
be biopsied at acceptable risk as judged by the Investigator or if no other lesion is 
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
43 of 175
deemed suitable for biopsy, then a RECIST v1.1 TL used for biopsy must be ≥ 2 cm 
in longest diameter (Please see requirements outlined in Appendix F).
7. ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks.
8. Adequate organ and bone marrow function measured within 14 days prior to first dose as 
defined in Table 6.
Note that one rescreen is permitted for participants if required, in line with Section 5.4. 
Table 6
Criteria for Adequate Organ and Marrow Function
Parameter
Value
Haematological
Haemoglobin
≥ 9.0 g/dL (5.59 mmol/L) with no blood transfusions 
(packed red blood cells) in the past 28 days.
Absolute neutrophil count
≥ 1.5 × 109/L (1,500 per mm3)
Platelet count
≥ 100 × 109/L (100,000 per mm3) with no platelet 
transfusions in the past 10 days.
Hepatic
Total bilirubin
≤ 1.5 × ULN in the absence of Gilbert’s syndrome
≤ 3 × ULN if the participant has Gilbert’s syndrome
Alanine transaminase and 
aspartate transaminase
≤ 3.0 × ULN.
≤ 5 × ULN in case of liver metastasis.
Renal
Calculated creatinine 
clearance a
≥50 mL/minute2 (≥45 mL/minute2 for urothelial 
carcinoma participants).
a
As determined by Cockcroft-Gault (using actual body weight):
Males:
Creatinine CL =
Weight (kg) x (140 – Age)
(mL/min)
72 x Serum creatinine (mg/dL)
Females:
Creatinine CL =
Weight (kg) x (140 – Age) x 0.85
(mL/min)
72 x Serum creatinine (mg/dL)
Abbreviations: ULN = upper limit of normal. 
5.2
Exclusion Criteria
The below are the master exclusion criteria for all Substudies of the study; all participants 
must meet the criteria described in the relevant Substudy in addition to those described below. 
Where Substudy-specific criteria are more stringent than master study criteria, the 
Substudy-specific criteria take precedent. 
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. Participants with a history of thromboembolic events within 6 months of Cycle 1 Day 1
unless they received adequate treatment. Please discuss with the Study Physician to 
determine study eligibility.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
44 of 175
2. Unresolved toxicities of ≥ Grade 2 (CTCAE v5.0) from prior therapy (excluding vitiligo, 
alopecia, endocrine disorders that are controlled with replacement hormone therapy, 
asymptomatic laboratory abnormalities). Participants with ≥Grade 2 neuropathy will be 
evaluated on a case-by-case basis after consultation with the Study Physician.
3. Symptomatic CNS metastasis or leptomeningeal disease.
4. Ongoing or an active infection, including tuberculosis (clinical evaluation that includes 
clinical history, physical examination and radiographic findings, and tuberculosis testing 
in line with local practice), hepatitis B (known positive HBsAg result), hepatitis C, or HIV 
(positive HIV 1/2 antibodies). 
5. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc 
and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible 
only if polymerase chain reaction is negative for HCV RNA.
6. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive 
heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac 
arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions 
associated with diarrhoea, or psychiatric illness/social situations that would limit 
compliance with study requirement, substantially increase risk of incurring AEs or 
compromise the ability of the participant to give written informed consent.
7. Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the 
exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or 
Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid 
arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: 
(a) Participants with vitiligo or alopecia.
(b) Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on 
hormone replacement.
(c) Any chronic skin condition that does not require systemic therapy.
(d) Participants without active disease in the last 5 years may be included but only after 
consultation with the Study Physician.
(e) Participants with celiac disease controlled by diet alone.
8. Other invasive malignancy within 2 years except for non-invasive malignancies.
9. Known allergy or hypersensitivity to IMP formulations, imaging agents (per Investigator’s 
discretion; if the participant can receive steroids and is stable prior to imaging), or any of 
the study intervention excipients.
10. Body weight loss > 10% within 30 days of screening visit.
11. Type 2 diabetes managed by metformin (please refer to Table 8).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
45 of 175
Prior/Concomitant Therapy
12. Current or prior use of immunosuppressive medication within 14 days before the first 
dose of study intervention is excluded. The following are exceptions to this criterion:
a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular 
injection).
b) Systemic corticosteroids at physiological doses not to exceed 10 mg/day of 
prednisone or its equivalent or 2 mg/day of dexamethasone or equivalent for 
participants with CNS metastases. Participants with brain metastases unless treated, 
asymptomatic, stable, and not requiring continuous corticosteroids at a dose of 
> 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study.
c) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
13. Prior therapy targeting GDF15 or GRFAL.
14. Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment. 
Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone 
replacement therapy) is acceptable.
Prior/Concurrent Clinical Study Experience
15. Enrolment into another interventional clinical trial where:
a) Study intervention was administered within 28 days, or 5 half-lives of the previous 
intervention, whichever is shorter, prior to the first dose of AZD8853.
b) Concurrent enrolment in another clinical study unless it is an observational 
(non-interventional) clinical study or during the follow-up period of an interventional 
study.
Other Exclusions 
16. History of organ transplant.
17. Receipt of live attenuated vaccine within 30 days prior to the first dose of study 
intervention. Note: Participants, if enrolled, should not receive live vaccine while 
receiving study intervention and up to 30 days after the last dose of study intervention.
18. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first 
dose of study intervention or anticipation of the need for major surgical procedure during 
the course of the study. Note: Local surgery of isolated lesions for palliative intent is 
acceptable.
19. Mean QTcF ≥ 470 ms calculated from 3 ECGs (within 5 minutes).
20. COVID-19:
a) Negative COVID-19 test is required for participants who have clinical signs and 
symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnoea, sore throat, 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
46 of 175
fatigue, loss of sense of smell or taste). If the participant tests positive for COVID-19, 
a subsequent negative test result and symptom resolution are required before Cycle 1 
Day 1.
b) COVID-19 vaccination should not be given for 72 hours prior to administration of the 
first dose of AZD8853 or during the DLT period.
21. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff 
and/or staff at the study site).
22. Female participants who are pregnant or breastfeeding, or male or female participants of 
reproductive potential who are not willing to employ effective birth control from screening 
to 3 months after the last dose of AZD8853 (Section 5.3).
23. Judgment by the Investigator that the participant should not participate in the study if the 
participant is unlikely to comply with study procedures, restrictions, and requirements.
5.3
Lifestyle Considerations
5.3.1
Contraception
The following restrictions apply while the participant is receiving study treatment and for the 
specified times before and after:

Female participants of childbearing potential who are sexually active with a non-sterilized 
male partner must use at least one highly effective method of contraception (see Table 7) 
from the time of screening and must agree to continue using such precautions for 
3 months after the last dose of AZD8853. Male partners of a female participant must use 
male condom plus spermicide throughout this period. Cessation of birth control after this 
point should be discussed with a responsible physician. Female participants should refrain 
from breastfeeding throughout this period. In addition, female participants must refrain 
from egg donation while on study and for 3 months after the final dose of AZD8853.

Non-sterilized male participants who are sexually active with a female partner of 
childbearing potential must use male condom plus spermicide from screening through 
3 months after the last dose of study drug. Male participants should refrain from sperm 
donation for 3 months after the last dose of AZD8853. Female partners of a male 
participant must use a highly effective method of contraception throughout this period.

Females of childbearing potential are defined as those who are not surgically sterile 
(ie, bilateral tubal ligation, salpingectomy, bilateral oophorectomy, or complete 
hysterectomy) or post-menopausal (defined as 12 months with no menses without an 
alternative medical cause).

Acceptable non-hormonal birth control methods include:
a) Total/True abstinence: When the participant refrains from any form of sexual 
intercourse and this is in line with their usual and/or preferred lifestyle; this must 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
47 of 175
continue for the total duration of the study and for at least 3 months after the last dose 
of study drug. Note: Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods, or declaration of abstinence solely for the duration of a study) 
and withdrawal are not acceptable methods of contraception.
b) Vasectomized sexual partner PLUS male condom. With participant assurance that 
partner received post-vasectomy confirmation of azoospermia.
c) Tubal occlusion PLUS male condom.
d) Intrauterine device PLUS male condom. Coils must be copper-banded.
e) Highly effective methods of contraception are described in Table 7. A highly effective 
method of contraception is defined as one that results in a low failure rate (ie, less 
than 1% per year) when used consistently and correctly. Note that some contraception 
methods are not considered highly effective (eg, male or female condom with or 
without spermicide; female cap, diaphragm, or sponge with or without spermicide; 
non-copper containing intrauterine device; progestogen only oral hormonal 
contraceptive pills where inhibition of ovulation is not the primary mode of action 
[excluding Cerazette/desogestrel, which is considered highly effective]; and triphasic 
combined oral contraceptive pills).
Table 7
Highly Effective Methods of Contraception (< 1% Failure Rate)
Barrier/Intrauterine Methods
Hormonal Methods
•
Copper T intrauterine device
•
Levonorgestrel-releasing 
intrauterine system (eg,
Mirena®)a
•
Implants: Etonogestrel-releasing implants (eg, Implanon® or 
Norplant®).
•
Intravaginal Devices: Ethinylestradiol/etonogestrel-releasing 
intravaginal devices (eg, NuvaRing®).
•
Injection: Medroxyprogesterone injection (eg, Depo-Provera®).
•
Combined Pill: Normal and low dose combined oral contraceptive 
pill.
•
Patch: Norelgestromin/ethinylestradiol-releasing transdermal 
system (eg, Ortho Evra®).
•
Minipill: Progesterone based oral contraceptive pill using 
desogestrel: Cerazette® is currently the only highly effective 
progesterone-based pill.
a
This is also considered a hormonal method.
5.3.2
Activity
Participants will abstain from strenuous exercise for 48 hours before each GDF15 blood 
collection timepoint. Participants may participate in light recreational activities during the 
study (eg, watching television, reading) (Kleinert et al, 2018; Campderrós et al, 2020).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
48 of 175
5.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled in the study and do not receive study treatment. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the CONSORT publishing requirements and to respond to queries from 
regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, any SAE and medications administered for a given SAE.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. Each participant may undergo only one rescreen in the study. Rescreened 
participants should be assigned the same participant number as for the initial screening. 
Rescreening should be documented so that its effect on study results, if any, can be assessed. 
Individuals who fail screening should have the reason recorded in the eCRF to indicate them 
as screen failures.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
49 of 175
6
STUDY INTERVENTION
Study intervention is defined as any IMP(s), marketed product(s) or placebo intended to be 
administered to or medical device(s) utilised by a study participant according to the study 
protocol. Additional details can be found in the Handling Instructions.
6.1
Study Intervention(s) Administered
6.1.1
Investigational Medicinal Product – AZD8853
Intervention name
AZD8853
Type 
Biologic
Dose formulation
Concentrate for solution for infusion 
mg/mL
AZD8853 in 
mM 
, 
mM 
, 
% (w/v) 
, 
pH 
Unit dose strength
 mg/vial (
 mg/mL)
Minimum dosage level
Maximum dosage level
300 mg
3000 mg
Route of administration
i.v. infusion
Use
Experimental
IMP or NIMP
IMP
Sourcing
Provided centrally by the Sponsor
Packaging and labelling
Study intervention will be provided in vials in a carton. 
Each vial and carton will be labelled in accordance with 
country regulatory requirements.
Abbreviations: IMP = investigational medicinal product; i.v. = intravenous; NIMP = non-investigational 
medicinal product.
6.1.1.1
Identity of Investigational Medicinal Product
The IMP kit has a unique number that is printed on all labels within the kit (ie, the outer carton 
label and the label of each container within the carton). Each carton and vial are labelled with 
the same unique sequence number range.
6.2
Preparation/Handling/Storage/Accountability
1. The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.
2. Only participants enrolled in the study may receive study intervention and only authorised 
site staff may supply or administer study intervention. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
50 of 175
3. All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labelled storage conditions 
with access limited to the Investigator and authorised site staff.
4. The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).
6.2.1
Investigational Medicinal Product Inspection
Each vial selected for dose preparation should be inspected. 
AZD8853 will be supplied by AstraZeneca as a
 
and 
administered via i.v. infusion.
If any defects are noted with the IMP(s), the Investigator and site monitor should be notified 
immediately. Refer to the Product Complaint section (Section 6.2.5) for further instructions.
6.2.2
AZD8853 Preparation and Administration
The dose of AZD8853 for administration must be prepared by the Investigator’s or site’s 
designated IMP manager using aseptic technique.
Total time from needle puncture of the AZD8853 vial to the start of administration should not 
exceed:

24 hours at 2°C to 8°C (36°F to 46°F)

4 hours at room temperature 
If the final product is stored at both refrigerated and ambient temperatures, the total time must 
not exceed 24 hours. No incompatibilities between AZD8853 and polyolefin i.v. bags have 
been observed for i.v. administration. 
Doses of AZD8853 will be administered using an i.v. bag containing 
, with a 
final AZD8853 concentration ranging from 
mg/mL and delivered through an i.v.
administration set with a 
-μm filter. Add required volume of AZD8853 for dose 
level (using calculation below) to the i.v. bag. 
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
51 of 175
The volume of AZD8853 (in mL) to add to the i.v. bag is calculated as follows:
 	
 	 () = 
	  ()
50 /
where 50 mg/mL is the nominal AZD8853 drug product concentration.
The i.v. bag size should be ≤ 
 mL and be selected such that the final concentration is 
within 
 mg/mL. Mix the bag by gently inverting to ensure homogeneity of the dose in 
the bag.
Standard infusion time for AZD8853 is 1 hour; however, if there are interruptions during 
infusion, the total allowed infusion time should not exceed 4 hours at room temperature.
Do not co-administer other drugs through the same infusion line.
Flush the i.v. line with a volume of i.v. diluent equal to the priming volume of the infusion set 
used after the contents of the i.v. bag are fully administered or complete the infusion according 
to institutional policy to ensure the full dose is administered.
If either preparation time or infusion time exceeds the time limits, a new dose must be 
prepared from new vials. AZD8853 does not contain preservatives, and any unused portion 
must be discarded.
6.2.3
Treatment Administration
No premedication for the prevention of IRRs prior to the first infusion of AZD8853 is 
permitted (ie, primary prophylaxis). Any planned premedication with acetaminophen 
(paracetamol), histamine (H1 and H2)-receptor antagonists, with subsequent infusions of 
AZD8853 following an IRR (ie, secondary prophylaxis) is permitted. Steroids should not be 
used as routine premedication for Grade 1 or 2 IRRs. If more than one participant during the 
course of the study develops a Grade ≥ 3 IRR during the first infusion, the SRC may 
recommend premedication for all subsequent participants to be implemented for the first 
infusion as follows: paracetamol/acetaminophen (500 to 1000 mg orally) and 
diphenhydramine (25 to 50 mg orally or i.v.; or an alternative antihistamine at an adequate 
dose), should be administered approximately 30 minutes prior to infusion with AZD8853. For
additional premedication guidelines for the prevention of IRR, refer to Section 6.5.
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
52 of 175
6.2.4
Monitoring of Dose Administration
Participants will be monitored during and after infusion of AZD8853. Vital signs will be 
measured according to the schedules described in Section 8.2.3. In the event of an IRR, or any 
other AE, see TMGs for toxicity management and dose modification.
As with any biological product, allergic reactions to dose administration are possible. 
Therefore, appropriate drugs and medical equipment to treat acute anaphylactic reactions must 
be immediately available, and study personnel must be trained to recognize and treat 
anaphylaxis. 
The Investigator’s or site’s designated IMP manager is required to maintain accurate IMP
accountability records. Upon completion of the study, copies of IMP accountability records 
will be returned to AstraZeneca. All unused IMPs will be returned to an AstraZeneca 
authorized depot or disposed of upon authorization by AstraZeneca according to the 
investigational site policy.
6.2.5
Reporting Product Complaints
Any defects with the IMP must be reported immediately to the Sponsor Product Complaint 
Department by the site with further notification to the site monitor. All defects will be
communicated to the Sponsor and investigated further with the Product Complaint 
Department. During the investigation of the product complaint, all IMP must be stored at 
labelled conditions unless otherwise instructed.
Contact information for reporting product complaints:
Email: productcomplaints@astrazeneca.com
Phone: +1-301-398-2105
Mail:
AstraZeneca
Attn: Product Complaint Department
One MedImmune Way,
Gaithersburg, MD USA 20878
6.2.6
Additional Study Drugs
Provided in respective Substudy.
6.2.7
Labelling
Labels for the IMP will be prepared in accordance with good manufacturing practice and local 
regulatory guidelines. Label text will be translated into local languages, as required.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
53 of 175
6.2.8
Storage
AZD8853 vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. All IMPs 
should be kept in a secure and dry place. Drug product should be kept in original packaging 
until use to prevent prolonged light exposure.
6.2.9
Treatment Compliance
Investigational product is administered by study site personnel, who will monitor compliance.
Details of treatment with IMPs for each participant will be recorded in the eCRF.
6.2.10
Accountability
The Investigator’s or site’s designated IMP manager is required to maintain accurate IMP
accountability records. Upon completion of the study, copies of IMP accountability records 
will be returned to the Sponsor. All unused IMP will be returned to a Sponsor-authorized 
depot or disposed of upon authorization by the Sponsor.
6.3
Measures to Minimise Bias: Randomization and Blinding
This is an open-label study; no blinding is required. Each potential participant is assigned a 
unique participant identification number at the screening visit after signing consent. Once a 
participant is assigned a unique identification number, it cannot be reused for another 
participant. Study intervention will be dispensed at the study visits summarised in the relevant 
Substudy. Returned study intervention should not be re-dispensed to the participants.
If an unscheduled assessment is performed, and the participant has not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits. This 
schedule is to be followed to minimise any unintentional bias caused by some participants
being assessed at a different frequency than other participants. 
6.4
Study Intervention Compliance
When participants are dosed at the site, they will receive study intervention directly from the 
Investigator or designee, under medical supervision. The date, and time, of dose administered 
in the clinic will be recorded in the source documents and recorded in the eCRF. The dose of 
study intervention and study participant identification will be confirmed at the time of dosing 
by a member of the study site staff other than the person administering the study intervention.
A record of the volume of AZD8853 infusion administered to each participant must be 
maintained and reconciled with study intervention and compliance records. Intervention start 
and stop dates, including dates for intervention delays and/or dose reductions will also be 
recorded in the eCRF.
Deviations from the prescribed dosage regimen should be recorded in the eCRF. The 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
54 of 175
Investigational Product Storage Manager is responsible for managing the study intervention 
from receipt by the study site until the destruction or return of all unused study intervention.
6.5
Concomitant Therapy
Any medication or vaccine (including OTC or prescription medicines, vitamins, and/or herbal 
supplements) that the participant is receiving at the time of screening or receives during the 
study must be recorded along with:

Reason for use

Dates of administration including start and end dates

Dosage information including route of administration, dose and frequency
The Study Physician should be contacted if there are any questions regarding concomitant or 
prior therapy.
Participants must be instructed not to take any medications, including OTC products, herbal or 
natural remedies, vitamins and supplements, without first consulting with the Investigator. 
Authorised/approved COVID-19 vaccines can be given to participants enrolled in this study as 
long as these do not represent a prohibited concomitant medication. Investigators should 
follow the CSP, their local prescribing information, and policies when considering if 
vaccination against COVID-19 is appropriate for their participants enrolled in an AstraZeneca 
clinical study. COVID-19 vaccination should not be given for 72 hours prior to administration 
of the first dose of AZD8853 or during the DLT period.
For any authorised/approved COVID-19 vaccine, specific considerations should be given to 
the relevant labelling information (ie, “Indications,” “Contraindications,” “Warnings and 
Precautions,” “Adverse Reactions”) on its use in this study. In any case, COVID-19 
vaccination details must be captured in the eCRF as concomitant medication, and adverse 
reactions reported.
Prohibited concomitant therapies are listed in Table 8 and permitted concomitant therapies are 
listed in Table 9. Concomitant medication additional to those listed in Table 8 may be 
considered on a case-by-case basis by the Investigator in consultation with the Study 
Physician if required. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
55 of 175
Table 8
Prohibited Concomitant Medications
Prohibited Medication/Class of Drug
Usage
Any investigational therapy including anti-cancer 
therapy other than those under investigation in this 
study
Should not be given concomitantly while the 
participants are on study intervention
mAbs against CTLA-4, PD-1, or PD-L1 other than 
those under investigation in this study
Should not be given concomitantly while the 
participants are on study intervention
Any concurrent chemotherapy, radiotherapy, 
immunotherapy, or biologic or hormonal therapy for 
cancer treatment other than those under investigation 
in this study
Should not be given concomitantly while the 
participants are on study intervention, unless specified 
in a Substudy. (Concurrent use of hormones for 
non-cancer-related conditions [eg, insulin for diabetes 
and hormone replacement therapy] is acceptable. 
Local treatment of isolated lesions for palliative intent 
may be acceptable [eg, by local surgery or 
radiotherapy]) upon consultation with study physician.
Live attenuated vaccines
Should not be given through 30 days after the last 
dose of study intervention 
Immunosuppressive medications including, but not 
limited to, systemic corticosteroids at doses 
exceeding 10 mg/day of prednisone or equivalent, 
methotrexate, azathioprine, and tumour necrosis 
factor-α blockers
Should not be given concomitantly or used for 
premedication prior to the immunotherapy infusions. 
The following are allowed exceptions:
•
Use of immunosuppressive medications for the 
management of study intervention-related AEs
•
Short-term premedication for participants
receiving combination agent where the 
prescribing information for the agent requires the 
use of steroids for documented hypersensitivity 
reactions
•
Use in participants with contrast allergies
•
In addition, use of inhaled, topical, and intranasal 
corticosteroids is permitted
A temporary period of steroids will be allowed if 
clinically indicated and considered to be essential for 
the management of non-immunotherapy related events 
experienced by the participant (eg, chronic obstructive 
pulmonary disease, radiation, nausea, etc)
Metformin
Metformin has been shown to induce GDF15 gene 
expression, thereby elevating circulating GDF15 
levels significantly. One study showed that a one-time 
dose of metformin increased mean circulating GDF15 
levels about 2.5-fold (Coll et al, 2020). To prevent 
falsely high GDF15 level results, participants must not 
take metformin for at least 72 hours prior to the 
screening GDF15 blood sample and should be 
switched to an acceptable alternative; the participant
must demonstrate controlled diabetes mellitus on this 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
56 of 175
Table 8
Prohibited Concomitant Medications
Prohibited Medication/Class of Drug
Usage
alternative at least 7 days prior to starting the study 
intervention on Cycle 1 Day 1.
Herbal and natural remedies
Should not be given concomitantly unless agreed by 
the Sponsor
Abbreviations: AE = adverse event; CTLA-4 = cytotoxic T-lymphocyte associated antigen; 
PD-1 = programmed cell death-1; PD-L1 = programmed cell death ligand-1.
Table 9
Permitted Concomitant Medications
Supportive Medication/Class of Drug
Usage
Premedication for management of diarrhoea, nausea, 
and vomiting
Permitted after but not before the first dose of study 
intervention
Blood transfusions
Permitted at any time during the study
Erythropoietin
Prophylactic erythropoietin should not be started 
during Cycle 1 of the study but may be started during 
Cycle 2 and after. Participants already receiving 
erythropoietin at the time of screening may continue 
it provided they have been receiving it for more than 
one month at the time study treatment has started.
G-CSF
G-CSF should not be used prophylactically during 
Cycle 1, but may be considered after Cycle 1 
Megestrol acetate
Permitted for appetite stimulation
Bisphosphonates, and denosumab
Permitted for treatment of bone metastases
Concomitant medications or treatments 
(eg, acetaminophen or diphenhydramine) deemed 
necessary to provide adequate prophylactic or 
supportive care, except for those medications 
identified as “prohibited,” as listed in Table 8
To be administered as prescribed by the Investigator
Best supportive care (including antibiotics, nutritional 
support, correction of metabolic disorders, optimal 
symptom control, and pain management [including 
palliative radiotherapy to non-target lesions, etc])
Should be used, when necessary, for all participants
Inactivated viruses, such as those in the influenza 
vaccine, and COVID-19 vaccine
Permitted. COVID-19 vaccination should not be 
given for 72 hours prior to administration of the first 
dose of AZD8853 or during the DLT period.
Abbreviations: DLT = dose limiting toxicity; G-CSF = granulocyte colony stimulating factor, 
COVID-19 = coronavirus disease 2019.
6.6
Dose Modification
If, in the opinion of the Investigator, a participant experiences a clinically significant and/or 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
57 of 175
unacceptable adverse reaction, then the dose may be temporarily or permanently halted. 
Supportive therapy will be administered as required. Relevant reporting and discussion with 
the Study Physician will take place before resumption of dosing.
See the relevant Substudy for details on dose modification.
6.7
Intervention after the End of the Study
No intervention is planned after the end of the study. However, provisions will be in place for 
participants still enrolled at the end of the study to continue to receive study intervention if, in 
the opinion of the Investigator, they are continuing to receive benefit from treatment. Such 
participants will continue to be monitored for all SAEs up to 90 days after the last dose of 
study intervention, or until commencing new anti-cancer therapy, whichever is sooner.
In the event that a roll-over or safety extension study is available at the time of the final DCO 
and database closure, participants currently receiving treatment with study intervention may 
be transitioned to such a study, and the current study would reach its end. The roll-over or 
safety extension study would ensure treatment continuation with visits and assessments per its 
protocol. Any participant who would be proposed to move to such a study would be asked to 
sign a new ICF.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
58 of 175
7
DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL
7.1
Discontinuation of Study Intervention
It may be necessary for a participant to permanently discontinue (definitive discontinuation) 
study intervention. If study intervention is permanently discontinued, the participant will 
remain in the study to be evaluated for safety to the end of the 90-day follow-up period 
(Section 8.2.7), or withdrawal of consent or starting another anti-cancer therapy, whichever is 
earlier. Participants will be evaluated for efficacy until documented disease progression or 
withdrawal of consent, whichever is earlier. Participants will be followed for subsequent 
anti-cancer therapy until withdrawal of consent or death, whichever is earlier. See the relevant
Substudy SoA for data to be collected at the time of discontinuation of study intervention and 
follow-up and for any further evaluations that need to be completed.
Note that discontinuation from study intervention is NOT the same as a withdrawal from the 
study.
The participant should continue attending subsequent study visits and data collection should 
continue according to the CSP. If the participant does not agree to continue in-person study 
visits, a modified follow-up must be arranged to ensure the collection of endpoints and safety 
information. This could be a telephone contact with the participant for the follow-up visit, a 
contact with a relative or treating physician, or information from medical records. The 
approach taken should be recorded in the medical records. A participant who agrees to 
modified follow-up is not considered to have withdrawn consent or to have withdrawn from 
the study.
Participants may be discontinued from study intervention in the following situations:

Objective disease progression assessed by Investigator (a confirmatory scan for disease 
progression is up to the Investigator’s discretion).
Note: If the participant has been discontinued from the AZD8853 intervention before 
disease progression, it is required for disease assessment to continue (see the relevant 
Substudy SoA), until documented disease progression.

Adverse event as defined in Section 8.3.

Participant or Investigator decision. The participant is free to discontinue treatment at any 
time, without prejudice to further treatment. When the reason does not impact safety, the 
Study Physician together with the Investigator will consider the risk/benefit to the 
participant of stopping treatment. 

Pregnancy (see Section 8.3.10).

Non-compliance with the CSP (Investigator or participant).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
59 of 175

Participant incorrectly initiated on study treatment.

Unexpected, significant, or unacceptable risk to the participants enrolled in the study.

Sponsor termination of study for reasons including but not limited to unfavourable 
risk/benefit or change in drug development plan.
7.1.1
Temporary Discontinuation
Applicable criteria and procedures for stopping and re-starting study intervention will be 
defined in individual Substudies.
7.2
Participant Withdrawal from the Study
All participants will be followed until either death, lost to follow-up, or withdrawal of consent, 
or end of study whichever occurs first.

A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioural, 
compliance, or administrative reasons. This is expected to be uncommon.

A participant who considers withdrawing from the study must be informed by the 
Investigator about modified follow-up options (eg, telephone contact, a contact with a 
relative or treating physician, or information from medical records).

If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.

If a participant withdraws from the study, it should be confirmed if he/she still agrees for 
existing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried out in line with what was stated in the informed consent and local regulation. The 
Investigator must document the decision on use of existing samples in the site study 
records and inform the Global Study Team. Please refer to Appendix C for further details.
Participants who are withdrawn from the study but are evaluable per the definition in the 
Populations for Analyses section of the relevant Substudy will not be replaced. 
In addition, participants will be withdrawn from the study in the event that the Sponsor
terminates this study.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
60 of 175
7.3
Lost to Follow-Up
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:

The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study.

Before a participant is deemed lost to follow-up, the Investigator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and,
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record.

Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
Discontinuation of specific sites or of the study as a whole are handled as described in
Appendix A.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
61 of 175
8
STUDY ASSESSMENTS AND PROCEDURES

Study procedures and their timing are summarised in the SoA for the relevant Substudy. 
Protocol waivers or exemptions are not allowed for any of the Substudies.

Immediate safety concerns should be discussed with the Study Physician immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.

Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.

Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilised for screening or baseline 
purposes provided the procedures meet the protocol-specified criteria and were performed 
within the time frame defined in the SoA.
8.1
Efficacy Assessments
RECIST v1.1 guidelines for measurable, non-measurable, TLs and NTLs, and the objective 
tumour response criteria are presented in Appendix F of this CSP. Tumour assessments will be 
based on RECIST v1.1 (Eisenhauer et al, 2009) and will be performed according to the 
schedule presented in each Substudy.
Standard radiographic imaging using RECIST is used to assess both response (in participants 
with measurable disease) and progression. An ORR as per RECIST v1.1 criteria requires 
confirmation of PR and CR and must occur no fewer than 4 weeks after initial documentation 
of PR or CR. Disease progression will be defined as per RECIST v1.1; however, if the 
participant is clinically stable, a confirmatory scan for progression is left up to the discretion 
of the Investigator.
Tumour assessments use images from CT (preferred) or MRI, with i.v. contrast, of the chest, 
abdomen, and pelvis, and should additionally investigate areas that may be involved based on 
signs and symptoms of individual participants, collected during screening/baseline and at 
regular (follow-up) intervals during study intervention. Brain scans (MRI preferred) are 
mandatory at screening/baseline for all NSCLC participants in this study, participants with 
known brain metastasis, and as clinically indicated for other participants. Post-baseline MRI 
of the brain will only have to be performed in participants with brain metastases at baseline, 
while participants without brain metastases do not need additional brain scans for subsequent 
tumour assessments unless clinically indicated. The imaging modality used for baseline 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
62 of 175
tumour assessment should be kept the same consistently at each subsequent follow-up 
assessment throughout the study if possible. It is important to follow the tumour assessment 
schedule as closely as possible (refer to the SoA in the respective Substudy) relative to dose of 
study intervention. 
Screening/baseline imaging should be performed no more than 28 days before start of study 
intervention and ideally should be performed as close as possible to and prior to the start of 
study intervention. Scans obtained as part of standard clinical practice, prior to informed 
consent, but within the 28-day period are acceptable. Tumour assessments should be 
performed per the SoA in the respective Substudy until objective disease progression as 
defined by RECIST v1.1 (refer to Appendix F) and assessed by the Investigator, or withdrawal 
of consent. Response (CR or PR) should be confirmed by a repeat, consecutive scan at least 
4 weeks after the first documentation of response.
If the Investigator is in doubt as to whether progression has occurred, particularly with 
response to NTLs or the appearance of a new lesion, it is advisable to continue treatment until 
the Investigator reassesses the participant’s status at the next scheduled assessment 
(confirmation), or sooner if clinically indicated. Scans confirming progression should not be 
conducted within 1 week after a progression biopsy to allow for reduction in inflammation.
If scans are performed outside of scheduled visit window and the participant has not 
progressed, every attempt should be made to perform the subsequent scans at their scheduled 
visits whilst the participant remains on study treatment. If the participant interrupts treatment 
or incurs a treatment delay, scans should continue to occur at the protocol-defined frequency. 
It is important to follow the SoA as closely as possible.
Tumour markers will not be used for tumour response assessments as per RECIST v1.1. 
Tumour markers should be obtained as per standard-of-care.
Storage of Scans
Sites will be required to store electronic copies of all scans (CT, or other scans for efficacy,
and PET scans), and the Sponsor will arrange for centralized storage of all imaging data. All 
imaging assessments, including unscheduled visit scans, will be collected on an ongoing basis,
and sent to the Sponsor or designee for storage. The centralized storage of imaging data would 
allow independent centralized third party blinded review of disease assessments. In this 
regard, and at the discretion of the Sponsor, an independent central review of all scans used in 
the assessment of tumours by RECIST v1.1 may be conducted. Guidelines for imaging 
collection and storage will be provided in a separate document.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
63 of 175
Skeletal Muscle Index
To study the effects of AZD8853 on cancer cachexia, SMI will also be collected in this study. 
To collect this information, participants should have CT or MRI scan with slices at T12 or L3 
(Yang et al, 2021,Wang et al, 2020, Rybar et al, 2016). These should be obtained using the 
same modality and at the same timepoint as the disease assessment scans.
8.2
Safety Assessments
Planned timepoints for all safety assessments are provided in the respective Substudy SoA and 
are detailed below.
8.2.1
Physical Examinations
Physical examination will be performed at timepoints as specified in the respective Substudy
SoA.

Demographics will be performed at the screening visit. 

A full physical examination should be completed at screening, other SoA specific study 
visits and EOT and will include, at a minimum: the general appearance of the participant, 
and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, 
musculoskeletal system, lymphatic system, and nervous system. Height will be assessed 
at screening only. 

Investigators should pay special attention to clinical signs related to previous serious 
illnesses and new or worsening abnormalities that may qualify as AEs. Investigators must 
ask about participant’s appetite (poor, average, or good) at every physical examination
and should ask about changes in appetite (worse, about the same, or improved) since the 
last assessment for all physical examinations after screening.

A standard medical, medication, and surgical history including smoking history (smoking 
pack-years) will be obtained with review of the selection criteria with the participant.
8.2.2
ECOG Performance Status
Performance status will be assessed at timepoints as specified in the respective Substudy SoA 
according to ECOG criteria as follows:

0 = Fully active, able to carry out all pre-disease activities without restrictions.

1 = Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature eg, light housework, office work.

2 = Ambulatory and capable of self-care, but unable to carry out any work activities. Up 
and about more than 50% of waking hours.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
64 of 175

3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.

4 = Completely disabled, cannot carry on self-care, totally confined to bed or chair.

5 = Dead
8.2.3
Vital Signs
Vital signs measurements (body temperature, BP, heart [pulse] rate, respiration rate, and body 
weight) will be performed at timelines specified in the respective Substudy SoA.

Blood pressure and pulse/heart rate measurements will be assessed in supine position with 
a completely automated device. Manual techniques will be used only if an automated 
device is not available.

Blood pressure, respiratory rate, and pulse measurements should be preceded by at least 
10 minutes of rest for the participant in a quiet setting.

Vital signs are to be taken before any blood collection. 

Body temperature will be taken prior to all infusions (within 2 hours before start of the 
infusion).

Body weight is only required pre-dose.
8.2.4
Electrocardiograms
Electrocardiograms will be performed at timepoints specified in the respective Substudy SoA.
Local 12-lead digital ECGs will be obtained after the participant has been resting semi-supine 
for at least 10 minutes. Triplicate ECGs will be collected within a 5-minute period. All ECGs 
should be recorded with the participant in supine position.
If an abnormal ECG finding at screening or baseline is considered to be clinically significant 
by the Investigator, it should be reported as a concurrent condition. If a clinically significant 
abnormal ECG finding occurs on study, the Investigator should contact the Study Physician.
The ECG parameters to be determined will include (but will not be limited to) the following: 

Heart rate

RR interval: duration in msec between 2 R peaks of 2 consecutive QRS complexes

PR interval: duration in msec from the beginning of wave P to onset of ventricular 
depolarisation (Q and R)

QRS interval: duration in msec of the QRS complex

QT interval: duration in msec from the beginning of Q wave to the end of the T-wave

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
65 of 175

QTcF: QT[msec]/RR[sec]1/3
Any abnormal finding in the ECG tracing will be evaluated by the Investigator and will be 
specifically documented and registered in the eCRF. Throughout the study, clinically relevant 
new findings or worsening of a pre-existing finding in the ECGs (parameters or abnormal 
findings in the tracing) must be considered an AE and must be recorded in the AE eCRF.
8.2.5
Clinical Safety Laboratory Assessments
Blood and urine samples for determination of clinical chemistry, haematology, coagulation, 
virology, and urinalysis will be taken at the timepoints indicated in the respective Substudy
SoA.
Additional safety samples may be collected if clinically indicated at the discretion of the 
Investigator. The date of collection and results (values, units, and reference ranges) will be 
recorded on the appropriate eCRF.
The analysis of safety samples will be performed at a local laboratory at or near to the 
Investigator site. Sample tubes and sample sizes may vary depending on laboratory method 
used and routine practice at the site.
For all participants, results of safety laboratory testing (haematology, coagulation and clinical 
chemistry at a minimum) must be available within 24 hours prior to dosing and must be 
reviewed by the Investigator prior to administration of AZD8853. Samples can be collected 
the day before AZD8853 administration. If clinically indicated, additional clinical laboratory 
tests and evaluations may be performed by the Investigator and these need to be entered into 
the eCRF. 
The laboratory variables to be measured for haematology, clinical chemistry, urinalysis, 
coagulation, virology, and pregnancy testing are listed in Table 10.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
66 of 175
Table 10
Laboratory Safety Variables
Haematology (whole blood)
Clinical Chemistry (serum or plasma)
B-Hb
S/P-Creatinine
S/P-Chloride
B-WBC count with differential
S/P-Bilirubin total
S/P-Magnesium
B-Platelet count
S/P-Direct and indirect bilirubin S/P-Phosphorus
B-Haematocrit
S/P-Alkaline phosphatase
S/P-Cholesterol
B-Absolute neutrophil count
S/P-Aspartate transaminase
S/P-Amylase
B-Absolute lymphocyte count
S/P-Alanine transaminase
S/P-Lipase
S/P-Albumin
S/P-TSH
Urinalysis (dipstick)
S/P-Free T3
S/P-Free T4
Colour and appearance
S/P-Potassium
S/P-Bicarbonate
U-
Hb/Erythrocytes/Blood 
U-
Protein/Albumin
S/P-Calcium, total
S/P-Total protein
U-Glucose
U-pH
S/P-Sodium
S/P-Blood urea nitrogen
U-Specific gravity
U-Ketones
S/P-Creatine phosphokinase
S/P-Glucose (fasting preferred)
U-Microscopy including WBC/high-power 
field, RBC/high-power field a
S/P-HbA1c
S/P-Triglycerides
S/P-lactate dehydrogenase
Coagulation
INR
PT
aPTT, absolute or relative
D-Dimer
Fibrinogen
Virology
Hepatitis B virus core antibodies
Hepatitis A serology
Hepatitis C serology
HIV-1 and 2 antibodies
Hepatitis B virus surface antigen
Pregnancy Test (women of childbearing potential only)
β-hCG
a
Microscopy should be performed at Investigator’s discretion for abnormal dipstick.
Abbreviations: aPTT = activated partial thromboplastin time; B = blood; Hb = haemoglobin; 
HbA1c = haemoglobin A1c; hCG = human chorionic gonadotropin; HIV = human immunodeficiency viruses; 
INR = international normalised ratio; P = plasma; PT = prothrombin time; RBC = red blood cells; S = serum; 
TSH = thyroid-stimulating hormone; T3 = triiodothyronine; T4 = thyroxine; U = urinalysis; WBC = white blood 
cells.
8.2.6
30-Day Follow-up Visit
A follow-up visit will be performed 30 (± 7) days from the EOT visit (see the SoA for the 
relevant Substudy).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
67 of 175
8.2.7
90-Day Follow-up Visit
A follow-up visit will be performed 90 (± 7) days from the time that all study intervention is 
permanently discontinued (see the SoA for the relevant Substudy). Assessment of disease 
progression (CT or MRI) will not be performed at this visit if previously confirmed disease 
progression has been documented.
8.2.8
Survival Follow-up
All participants will be followed for survival until death, lost to follow-up, withdrawal of 
consent, or end of study whichever occurs first. Participants will be followed for survival by 
telephone calls, email, or clinic visits approximately every 12 weeks. During this period, 
information will be collected in the eCRF on survival status and any new anti-cancer 
therapies, and on any SAEs considered related to study intervention or study procedures.
8.3
Adverse Events and Serious Adverse Events
The Investigator is responsible for ensuring that all staff involved in the study are familiar 
with the content of this section
The definitions of an AE or SAE can be found in Appendix B.
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorised representative). 
The Investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE.
8.3.1
Time Period and Frequency for Collecting AE and SAE Information
AEs/SAEs will be collected from the time of signature of the screening ICF throughout the 
treatment period and including the follow-up period of 90 days (± 7 days) after last dose of 
study intervention.
If the Investigator becomes aware of any SAE, including death, at any time during survival 
follow-up, with a suspected causal relationship to the study intervention, the Investigator shall 
report the SAE in the eCRF.
If the Investigator becomes aware of an SAE with a suspected causal relationship to the study 
intervention that occurs after the end of the clinical study in a participant treated by him or 
her, the Investigator shall, without undue delay, report the SAE to the Sponsor.
8.3.2
Follow-up of AEs and SAEs
Any AEs that are unresolved at the participant’s last assessment in the study are followed up 
by the Investigator for as long as medically indicated, but without further recording in the 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
68 of 175
eCRF. These AEs must still be reported to the Sponsor and records must be kept with the 
participant’s record. AstraZeneca retains the right to request additional information for any 
participant with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.
Adverse event variables
The following variables will be collected for each AE:

AE (verbatim)

The date and time when the AE started and stopped

CTCAE grade/changes in CTCAE grade

Whether the AE is serious or not

Investigator causality rating against the study intervention(s) (yes or no)

Action taken with regard to study intervention(s)

AE caused participant’s withdrawal from study (yes or no)

Outcome, including administration of any treatment
In addition, the following variables will be collected for SAEs:

Date AE met criteria for SAE

Date Investigator became aware of SAE

AE is serious due to

Date of hospitalisation

Date of discharge

Probable cause of death

Date of death

Autopsy performed

Causality assessment in relation to study procedure(s)

Causality assessment to other medication
8.3.3
Causality Collection
The Investigator should assess causal relationship between study intervention and each AE, 
and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a reasonable possibility 
that the event may have been caused by the IMP?’
For SAEs, causal relationship should also be assessed for all other study medication and study 
procedures. Note that for SAEs that could be associated with any study procedure the causal 
relationship is implied as ‘yes’.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
69 of 175
A guide to the interpretation of the causality question is found in Appendix B to the CSP.
8.3.4
Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by the participant or reported in response to the open question 
from the study site staff: ‘Have you had any health problems since the previous visit/you were 
last asked?’ or revealed by observation will be collected and recorded in the eCRF. When 
collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
8.3.5
Adverse Events Based on Examinations and Tests
The results from the CSP mandated laboratory tests and vital signs will be summarised in the 
CSR. 
Deterioration as compared to baseline in protocol-mandated physical examinations, laboratory 
values, vital signs, ECGs should therefore only be reported as AEs if they fulfil any of the 
SAE criteria, are the reason for discontinuation of treatment with the study intervention or are 
considered to be clinically relevant as judged by the Investigator (which may include but not 
limited to consideration as to whether treatment or non-planned visits were required or other 
action was taken with the study intervention, eg, dose adjustment or drug interruption).
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign 
will be considered as additional information. Wherever possible the reporting Investigator
uses the clinical, rather than the laboratory term (eg, anaemia versus low haemoglobin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in 
non-mandated parameters should be reported as AE(s).
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE unless unequivocally 
related to disease progression.
8.3.6
Adverse Events of Special Interest
An AESI is an AE of scientific and medical interest specific to understanding of a study 
intervention and may require close monitoring and rapid communication to AstraZeneca by 
the Investigator. An AESI may be serious or non-serious. The reporting of AESIs allows 
ongoing surveillance of these events to characterise and understand them in association with 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
70 of 175
the use of a study intervention. 
Adverse events of special interest will be recorded in the eCRF using a recognised medical 
term or diagnosis that accurately reflects the event. Adverse events will be assessed by the 
Investigator for severity, relationship to the study intervention, possible aetiologies, and 
whether the event meets criteria for an SAE and therefore requires immediate notification to 
AstraZeneca. If an AE evolves into a condition that meets the regulatory definition of 
“serious,” it will be reported as described in Section 8.3.9.
Based on the available preclinical data, review of the cumulative literature, and biological 
plausibility, the following events are considered to be AESIs:

 





Other AEs which are considered to be AESIs with AZD8853 include, but are not limited to:




The immune system can respond to foreign protein, even to humanised mAb by producing
human-anti-human antibodies, which may result in formation of immune complexes and their
deposition in blood vessels, joints, and glomeruli causing symptomatic disease (eg,
). Participants will be monitored clinically and for
the presence of ADAs. Participants who experience an AE suspected to be immune complex
related will discontinue study intervention. Immune complex disease will be managed in 
accordance with standard-of-care.

. 
have some common manifestations and may be difficult to distinguish from each other. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
71 of 175
are commonly observed during or shortly after the first time of 
exposure to therapeutic mAbs delivered through i.v. infusion. These reactions are less 
common following subsequent exposures. Unlike 
, 
 is a rare event, usually 
occurring after subsequent exposure to an antigen, and it is most commonly accompanied by 
. The Investigator is advised to carefully 
examine symptoms of adverse reactions observed during or shortly after exposure to 
AZD8853 and consider the above-mentioned facts prior to making a final diagnosis. Reactions 
occurring at the time of or shortly after subsequent infusions of study intervention are to be 
judged by the Investigator at his/her own discretion. For the Investigator’s convenience and to 
facilitate consistency in judgements, a copy of the
 
is 
provided in Appendix H. Refer to TMGs for management of participants with 
 
(including 
) and 
. In the event of an 
, the site should document
which medications have been infused at the time of onset of the 
 in addition to signs and
symptoms.
8.3.7
Hy’s Law
Cases where a participant has elevations in liver biochemistry may require further evaluation 
and occurrences of AST or ALT ≥ 3 × ULN together with total bilirubin ≥ 2 × ULN may need 
to be reported as SAEs. Please refer to Appendix E for further instruction on cases of increases 
in liver biochemistry and evaluation of Hy’s Law.
8.3.8
Disease Progression
Disease progression can be considered as a worsening of a participant’s condition attributable 
to the disease for which the study intervention is being studied. It may be an increase in the 
severity of the disease under study and/or increases in the symptoms of the disease. The 
development of new or progression of existing metastasis to the primary cancer under study 
should be considered as disease progression and not an AE. Events which are unequivocally 
due to disease progression, should not be reported as AEs during the study.
8.3.9
Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the study 
intervention, or to the study procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study, then Investigators or other site personnel inform 
the appropriate AstraZeneca representatives within one day ie, immediately but no later than 
24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all the 
necessary information is provided to the AstraZeneca Patient Safety data entry site within 
1 calendar day of initial receipt for fatal and life-threatening events and within 5 calendar
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
72 of 175
days of initial receipt for all other SAEs.
For fatal or life-threatening AEs where important or relevant information is missing, active 
follow-up will be undertaken immediately. Investigators or other site personnel will inform 
AstraZeneca representatives of any follow-up information on a previously reported SAE 
within 1 calendar day ie, immediately but no later than 24 hours of when he or she becomes 
aware of it.
Once the Investigators or other site personnel indicate an AE is serious in the EDC system, an 
automated email alert is sent to the designated AstraZeneca representative.
If the EDC system is not available, then the Investigator or other study site staff reports a SAE 
to the appropriate AstraZeneca representative by telephone.
The AstraZeneca representative will advise the Investigator/study site staff how to proceed.
For further guidance on the definition of a SAE, see Appendix B.
The reference document for definition of expectedness/listedness is the IB for AZD8853.
8.3.10
Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except if the 
pregnancy is discovered before the participant has received any study intervention.
If a pregnancy is reported, the Investigator should inform AstraZeneca within 24 hours of 
learning of the pregnancy.
Abnormal pregnancy outcomes (eg, spontaneous abortion, foetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.
8.3.10.1
Maternal Exposure
If a participant becomes pregnant during the course of the study, study intervention should be 
discontinued immediately.
Pregnancy itself is not regarded as an AE unless there is a suspicion that the IMP under study 
may have interfered with the effectiveness of a contraceptive medication. Congenital 
anomalies/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions without complications should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal 
birth or congenital anomaly/birth defect) should be followed up and documented even if the 
participant was discontinued from the study.
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
73 of 175
informs the appropriate AstraZeneca representatives within 1 day, ie, immediately but no 
later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 
5 calendar days for SAEs (see Section 8.3.9) and within 30 days for all other pregnancies.
The same timelines apply when outcome information is available.
8.3.10.2
Paternal Exposure 
Male participants should refrain from fathering a child or donating sperm during the study and 
3 months following the last dose (see inclusion criteria, Section 5.1).
Pregnancy of the participant’s partners is not considered to be an AE. However, the outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal 
birth or congenital anomaly), occurring from the date of the first dose until 3 months after the 
last dose should, if possible, be followed up and documented in the Pregnancy Report Form. 
Consent from the partner must be obtained before the Pregnancy Report Form is completed.
If a pregnancy occurs in a participant’s partner within the timeframe specified above, then 
Investigators or other site personnel will inform the appropriate Sponsor representative 
immediately, or no later than 24 hours of when he or she becomes aware of it.
The same timelines apply when outcome information is available.
8.3.11
New Cancers
The development of a new cancer should be regarded as an SAE. New primary cancers are 
those that are not the primary reason for the administration of the study intervention and have 
been identified after the participant’s inclusion in this study. They do not include metastases of 
the original cancer.
8.3.12
Deaths
All deaths that occur during the study intervention period, or within the protocol-defined 
follow-up period after the administration of the last dose of study intervention, must be 
reported as follows:

Death clearly resulting from disease progression should be reported to the Study 
Monitor/Physician at the next monitoring visit and should be documented in the eCRF. It 
should not be reported as an SAE.

Where death is not due (or not clearly due) to progression of the disease under study, the 
AE causing the death must be reported as an SAE within 24 hours. It should also be 
documented in the eCRF. The report should contain a comment regarding the 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
74 of 175
co-involvement of progressive disease, if appropriate, and should assign main and 
contributory causes of death.

Death with an unknown cause should always be reported as an SAE. It should also be 
documented in the eCRF. A post-mortem may be helpful in the assessment of the cause of 
death, and if performed, a copy of the post-mortem results should be forwarded to 
AstraZeneca Patient Safety or its representative within the usual time frames.

Deaths occurring after the protocol-defined safety follow-up period (90 days) after the 
administration of the last dose of study intervention should be documented in the eCRF. If 
the death occurred as a result of an event that started after the defined safety follow-up 
period and the event is considered to be due to a late-onset toxicity to study intervention, 
then it should also be reported as an SAE.
8.3.13
Medication Error
If a medication error occurs in the course of the study, then the Investigator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day, ie, immediately 
but no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative will work with the Investigator to ensure that all 
relevant information is completed within 1 (Initial Fatal/Life-Threatening or follow-up 
Fatal/Life-Threatening) or 5 (other serious initial and follow-up) calendar days if there is an 
SAE associated with the medication error (see Section 8.3.9) and within 30 days for all other 
medication errors.
The definition of a Medication Error can be found in Appendix B 4.
8.4
Overdose
For this study, any dose of study intervention greater than the dose that was intended to be 
given will be considered an overdose. All overdoses should be recorded as follows:

An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE Modules in the eCRF and on the Overdose eCRF Module.

An overdose without associated symptoms is only reported on the Overdose eCRF 
Module.
If an overdose on an AstraZeneca study drug occurs in the course of the study, the Investigator
or other site personnel inform appropriate AstraZeneca representatives immediately, but no 
later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative will work with the Investigator to ensure that all 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
75 of 175
relevant information is provided to the AstraZeneca Patient Safety data entry site within 
24 hours for overdoses associated with an SAE (see Section 8.3.9) and within 30 days for all 
other overdoses.
8.5
Human Biological Samples
Instructions for the collection and handling of biological samples will be provided in the 
study-specific laboratory manual. Samples should be stored in a secure storage space with 
adequate measures to protect confidentiality. For further details on Handling of Human 
Biological Samples see Appendix C.
Samples will be stored for a maximum of 15 years from the date of the issue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 

Pharmacokinetic samples will be disposed of after the Bioanalytical Report finalization or 
6 months after issuance of the draft Bioanalytical Report (whichever is earlier), unless 
consented for future analyses.
−
Pharmacokinetic samples may be disposed of or anonymised. Additional analyses 
may be conducted on the anonymised, PK samples to further evaluate and validate 
the analytical method. Any results from such analyses may be reported separately 
from the CSR.

Remaining ADA sample aliquots will be retained at AstraZeneca or its designee for a 
maximum of 15 years following issue of the CSR. Additional use includes but is not 
limited to further characterisation of any ADAs, confirmation and/or requalification of the 
assay as well as additional assay development work. The results from future analysis will 
not be reported in the CSR.
8.5.1
Pharmacokinetics

Serum samples will be collected for measurement of serum concentrations of AZD8853
as specified in the SoA of relevant Substudies. 

Samples may be collected at additional timepoints during the study if warranted and 
agreed upon between the Investigator and the Sponsor, eg, for safety reasons. The timing 
of sampling may be altered during the course of the study based on newly available data 
(eg, to obtain data closer to the time of peak or trough matrix concentrations) to ensure 
appropriate monitoring. 

Serum samples will be used to analyse the PK of AZD8853. Samples collected for 
analyses of AZD8853 serum concentration may also be used to evaluate safety or efficacy 
aspects related to concerns arising during or after the study.

Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory 
Manual. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
76 of 175
Refer to relevant Substudy for the sampling schedule for PK samples.
8.5.1.1
Determination of Drug Concentration
Samples for determination of drug concentration in serum will be assayed by bioanalytical test 
sites operated by or on behalf of AstraZeneca, using an appropriately validated bioanalytical 
method. Full details of the analytical method used will be described in a separate bioanalytical 
report.
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples. The results from the evaluation, if performed, will be reported in a 
separate Bioanalytical Report.
8.5.2
Immunogenicity Assessments
Samples for determination of ADA in serum will be assayed by bioanalytical test sites 
operated by or on behalf of AstraZeneca, using an appropriately validated bioanalytical 
method. Tiered analyses will be performed to include screening, confirmatory, and titre assay 
components. Full details of the methods used will be described in a separate report. ADA 
samples may also be further tested for characterization of the ADA response, including 
possible assessment of neutralising antibody. Samples will be collected, labelled, stored, and 
shipped as detailed in the Laboratory Manual.
Refer to relevant Substudy for the sampling schedule for ADA samples.
8.5.3
Pharmacodynamics
Refer to relevant Substudy for information on pharmacodynamics.
8.6
Refer to relevant Substudy for information on 
.
8.7
 Initiative Sample
Collection of 
 is also part of this study as 
specified in the SoA and is subject to agreement in the ICF addendum. 
Blood sample for
 will be collected from participants who have consented to 
participate in the 
 of the study. Participation is optional. 
Participants who do not wish to participate in the 
 may still participate in the 
study.
See Appendix D for information regarding the 
. Details on 
processes for collection and shipment and destruction of these samples can be found either in
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
77 of 175
the appendices or in the Laboratory Manual. 
For storage and destruction of 
 see Appendix D.
8.8
Participants will be given the option to complete a 
 after consenting to the main 
study to collect 
 
 The goals of 
this 
 research are to
 
 
. Certain main study data not related to disease or treatment, 
such as demographics, informed consent review metrics, etc., may be re-used from the EDC 
and/or eConsent platform. This 
 does not collect clinical data about the 
participant's disease, symptoms, treatment effect or adverse events. Therefore, data from this 
 will not be reported in the CSR. The data will be anonymized and 
aggregated and may be published in an academic journal or presented at scientific meetings. 
No individual, identifying, protected health information will be included in any publications 
or presentations. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
78 of 175
9
STATISTICAL CONSIDERATIONS
The statistical analyses will be performed by AstraZeneca or a CRO under the direction of the 
Early Biometrics Oncology, AstraZeneca. A comprehensive SAP will be prepared.
9.1
Statistical Hypotheses
Refer to the relevant Substudy for information.
9.2
Sample Size Determination
Refer to the relevant Substudy for information.
9.3
Populations for Analyses
For purposes of analysis, the study populations are defined as provided in Table 11. For all 
efficacy analyses, and for baseline and demography, participants will be classified according 
to the dose they were assigned to (ie, the planned treatment).
Table 11
Populations for Analyses
Population/Analysis Set
Description
Endpoint/Output
Enrolled
All participants who sign the ICF.
Disposition
Safety
All participants who receive at least one dose of 
study intervention.
Exposure
Safety endpoints
PFS
OS
ctDNA
DLT Evaluable
Enrolled participants who complete the DLT 
evaluation period (defined as 21 days after 
receiving the first infusion of study intervention
and has completed safety evaluation requirements) 
with at least 75% dosing or who experience any 
DLT.
DLT
Response Evaluable
All dosed participants who have measurable 
disease at baseline.
ORR
DoR
DCR
Tumour size
Pharmacokinetics 
All participants who receive at least one dose of 
study intervention with at least one reportable 
concentration.
PK concentrations
PK parameters
Immunogenicity
All participants who receive at least one dose of 
study intervention with at least one reportable 
immunogenicity measurement.
Immunogenicity endpoints

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
79 of 175
Abbreviations: ctDNA = circulating tumour deoxyribonucleic acid; DCR = disease control rate; DLT = dose 
limiting toxicity; DoR = duration of response; ICF = informed consent form; PFS = Progression Free Survival;
PK = pharmacokinetics; OS = overall survival; ORR = objective response rate.
9.4
Statistical Analyses
The SAP will be finalised prior to database lock and it will include a more technical and 
detailed description of the statistical analyses described in this section. This section only 
includes the planned statistical analyses for the master objectives.
Refer to the relevant Substudy for more information on the statistical analyses for 
Substudy-specific objectives.
9.4.1
General Considerations
Descriptive statistics will be used for all variables. Continuous variables will be summarised 
by the number of observations, mean, standard deviation, median, minimum, and maximum. 
Categorical variables will be summarised by frequency counts and percentages for each 
category. Unless otherwise stated, percentages will be calculated based on the population total.
Time to event variables will be presented using the Kaplan-Meier methodology, including 
median time calculated from the Kaplan-Meier curves.
In general, the last observed measurement prior to first dose of study intervention will be 
considered the baseline measurement.
Depending on the extent of any impact, summaries of data relating to participants diagnosed 
with COVID-19, any impact of COVID-19 on study conduct (in particular missed visits, 
delayed or discontinued study treatment, and other protocol deviations) may be generated. 
More details will be provided in the SAP.
9.4.2
Safety Analyses
Safety and tolerability will be assessed in terms of DLTs, AEs/SAEs, ECOG status, vital signs, 
clinical chemistry/haematology parameters, dose interruptions/discontinuations and ECG data.
These variables will be collected for all participants. All safety analyses will be performed on 
the Safety Population, except for the evaluation of DLTs that will be performed on the DLT 
Evaluable Population. Additional subgroup analysis of safety may be performed, as specified 
in the SAP.
Medical Dictionary for Regulatory Activities will be used to code AEs. Adverse events will be 
graded according to the NCI CTCAE v5.0. The number of participants in each dose cohort 
(Part A) and each expansion (Parts B and C) experiencing each AE will be summarised by 
MedDRA SOC and preferred term. The number and percentage of participants with AEs in 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
80 of 175
different categories (eg, causally related, CTCAE Grade ≥3, etc) will be summarised by dose 
regimen; events in each category will be further summarised by MedDRA SOC and preferred 
term. Serious adverse events will be summarised separately, if a sufficient number occurs.
Adverse event summary tables will include only treatment-emergent AEs. Adverse events will 
be defined as treatment-emergent if they have an onset or worsen (by Investigator report of a 
change in intensity) during the study treatment or the safety follow-up period (defined as 
90 days after last dose of study treatment) but prior to subsequent anti-cancer therapy. Adverse 
events occurring outside this period will only be listed.
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs and AEs leading to discontinuation. Based on
the expert’s judgement, significant AEs of particular clinical importance may, after 
consultation with the Global Patient Safety Physician, be considered OAEs and reported as 
such in the CSR. A similar review of laboratory/vital signs (pulse and BP)/ECG data will be 
performed for identification of OAEs. Examples of these could be marked haematological and 
other laboratory abnormalities, and certain events that lead to intervention (other than those 
already classified as serious), dose reduction, or significant additional treatment.
Duration of exposure will be summarised.
All safety data including clinical chemistry, haematology, coagulation, urinalysis, vital signs, 
and ECG data will be listed individually by participant and appropriately summarised. For all 
laboratory variables that are included in the current version of CTCAE, the CTCAE grade will 
be calculated. Details of any deaths will be listed for all participants. Graphical presentations 
of safety data will be presented as appropriate. Dose-limiting toxicities will be displayed in a 
listing.
9.4.3
Efficacy Analyses
The efficacy endpoints for tumour response (ORR, DCR at 15 weeks, DoR, and percentage 
change in tumour size) will be summarised for the Response Evaluable Population using 
RECIST v1.1 by Investigator assessment. The efficacy endpoints of PFS and OS will be 
summarised on the Safety Population.
Additional subgroup analysis of efficacy may be performed as specified in the SAP.
The RECIST tumour response data will be used to programmatically determine each 
participant’s visit response and derive the endpoints ORR, DoR, DCR at 15 weeks, percentage 
change in tumour size, and PFS. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
81 of 175
Best Overall Response
The BoR is calculated based on the overall visit responses from each RECIST assessment. It 
is the best response a participant has following start of treatment but prior to starting any 
subsequent cancer therapy and up to and including RECIST progression or the last evaluable 
assessment in the absence of RECIST progression. Categorisation of BoR will be based on 
RECIST using the following response categories: CR, PR, SD, progressive disease, and NE. 
Objective Response Rate
The ORR is defined as the percentage of participants with a confirmed CR or PR, with the 
denominator defined as the number of participants in the Response Evaluable Population. 
Objective response rate and its 90% CIs (Clopper Pearson method; Clopper et al, 1934) will 
be summarised.
Duration of Response
The DoR is defined as the time from the date of first documented response (which is 
subsequently confirmed) until the date of documented progression or death in the absence of 
disease progression. The time of the initial response will be defined as the latest of the dates 
contributing towards the first visit that was CR or PR that was subsequently confirmed. 
Participants who have not progressed or died at the time of analysis will be censored at the 
time of the latest date of assessment from their last evaluable RECIST assessment.
It will be summarised using descriptive statistics and Kaplan-Meier plots, where there are 
sufficient numbers of responders.
Disease Control Rate at 15 Weeks 
The DCR at 15 weeks is defined as the percentage of participants who have a BoR of CR or 
PR in the first 16 weeks (to allow for late assessment within the assessment window) or who 
have SD for at least 14 weeks after the start of treatment (to allow for early assessment within 
the assessment window). The DCR and its 90% CIs (Clopper Pearson method; Clopper et al, 
1934) will be summarised.
Percentage Change in Tumour Size
The percentage change in TL tumour size from baseline will be summarised using descriptive 
statistics by timepoint. Best percentage change will also be summarised.
Waterfall plots showing the percentage change at 15 weeks and the best percentage change 
from baseline in sum of the diameters of TLs will be produced. Spider plots showing the 
percentage change from baseline in tumour size for each participant over time will be 
produced.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
82 of 175
Progression-free Survival
The PFS is defined as the time from the start of study intervention until the date of objective 
disease progression or death (by any cause in the absence of progression), regardless of 
whether the participant withdraws from study intervention or receives another anti-cancer 
therapy prior to progression. Participants who have not progressed or died at the time of 
analysis will be censored at the time of the latest date of assessment from their last evaluable 
RECIST assessment.
The PFS time will always be derived, based on scan/assessment dates, not visit dates.
The RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates. The following rules will be applied:

Date of progression will be determined, based on the earliest of the dates of the 
component that triggered the progression. 

When censoring participants for PFS, the participant will be censored at the latest of the 
dates contributing to a particular overall visit assessment.
Progression-free survival will be summarised descriptively, and Kaplan-Meier plots will be 
provided.
Overall Survival
Overall survival is defined as the time from the start of treatment until death due to any cause. 
Any participant not known to have died at the time of analysis will be censored based on the 
last recorded date on which the participant was known to be alive.
Overall survival will be summarised descriptively, and Kaplan-Meier plots will be provided.
Change in ctDNA
Percentage change in ctDNA from baseline to each post baseline timepoint as well as the 
maximum change will be analysed descriptively on the Safety Population.
9.4.4
Other Analyses 
9.4.4.1
Immunogenicity, Pharmacokinetics and Pharmacodynamics
The PK analysis of the serum data for AZD8853 will be performed on the PK Population. The 
actual sampling times will be used in the parameter calculations and the PK parameters will be 
derived using standard non-compartmental methods, if the data permits. It is anticipated that 
Cmax, AUC, and other PK parameters will be calculated if the data allows. 
Relevant descriptive statistics will be used to summarise PK parameters and concentrations. In 
addition, population PK modelling may be conducted and reported separately.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
83 of 175
Immunogenicity results will be analysed descriptively on the Immunogenicity Population by 
summarising the number and percentage of participants who develop detectable ADAs against 
AZD8853 at protocol-specified timepoints. The immunogenicity titre may be reported for 
samples confirmed positive for the presence of ADAs. The effect of immunogenicity on PK, 
efficacy, and safety may be evaluated, if the data allow. 
Refer to the relevant Substudy for information on PD analyses. Further details on the analysis 
of immunogenicity, PK and PD will be provided in the SAP.
9.5
Interim Analyses 
Interim analyses will be conducted separately for each Substudy and are described in the 
relevant Substudy.
9.6
Safety Review Committee
A study-specific SRC will be responsible for making dose-escalation or dose de-escalation 
decisions and recommendations regarding further conduct of the study, during all parts of the 
study. The SRC will provide ongoing safety surveillance of the study, with regularly 
scheduled reviews of safety and other relevant data to monitor the ongoing safety profile of 
the study intervention. 
The SRC may also meet to review data at other timepoints (eg, in response to AEs assessed as 
medically relevant by the Study Physician). The SRC will review the totality of the AE, SAE, 
and laboratory safety data from a minimum of 3 participants who have completed the 21-day 
DLT period, and all relevant available data, including PK, prior to adjudicating on 
dose‑escalation/de-escalation decisions based on the dose-escalation rules. For each dose 
cohort, every effort will be made to have all available PK data to the SRC at the time of the 
dose escalation decision. All decisions by the SRC will be documented and shared with all 
participating sites in writing. The SRC will be composed of Sponsor representatives and 
Investigators. The composition and procedures of the SRC will be fully described in the SRC 
charter.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
85 of 175
10.1.2
Schedule of Activities
Table 12
Schedule of Activities - Screening
Study Period
Screening
Details in Section
Visit Number
V1
Procedure/Study Day
Days -28 to -1 a
Screening informed consent (Main Study)
X
10.5,
Appendix A 3
Assignment of participant identification number (PID / E-Code) in IRT
X
6.3
Metformin Use History, including date of last dose
X
5.2, Table 8
X
8.8
Confirm eligibility for enrolment in Main Study 
X
10.5.1; 10.5.2
Medical and Disease History
Demographics
X
8.2.1
Medical/surgical history, including smoking history
X
8.2.1
Disease history and characteristics, including biomarkers and 
X
8.2.1
Prior cancer treatment, including surgeries, radiotherapy, and systemic therapy
X
8.2.1
Disease Assessments
Disease assessment by RECIST v1.1 and SMI assessment b
X c
10.8.1
CT or MRI, Brain (Required for NSCLC participants, participants with known brain metastasis, and as 
clinically indicated for other participants)
X c
10.8.1
Study Procedures and Examinations
Physical examination, including assessment of appetite 
X
8.2.1
ECOG performance status
X
8.2.2
Vital signs, including weight
X
8.2.3
Height
X
8.2.1
Local 12-lead ECG (triplicate)
X
8.2.4
Assessment of AEs/SAEs
X
8.3
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
86 of 175
Study Period
Screening
Details in Section
Visit Number
V1
Procedure/Study Day
Days -28 to -1 a
Concomitant medications
X
6.5
Safety Laboratories
Clinical chemistry
X
8.2.5
HbA1c
X
8.2.5
Thyroid function tests (TSH, free T4, free T3)
X
8.2.5
Haematology
X
8.2.5
Urinalysis
X
8.2.5
Serum pregnancy test (WOCBP)
X
8.2.5
Coagulation parameters (PT/aPTT/INR/d-dimer/fibrinogen)
X
8.2.5
Virology (Hepatitis A, B, and C, HIV-1 and HIV-2) d
X
8.2.5
Biomarker Evaluations
 
X
10.8.6.2
Part A/C: 
e
X
10.8.6.1.2
Part B: Mandatory paired biopsy e
X
10.8.6.1.1
Serum for GDF15 target engagement
X
10.8.5.3.1
Whole blood for 
 (refrigerated)
X
10.8.6.4
Whole blood for flow cytometry
X
10.8.6.5
Whole blood for 
X
10.8.6.3
X
10.8.6.7
X
10.8.6.7
Plasma for circulating tumour DNA
X
10.8.6.6
Part B only: CD8+ PET (select and validated sites only)
CD8+ PET tracer administration
X f
Appendix I
Whole body PET scan
X f
Appendix I
a
The screening period may last no longer than 28 days from Cycle 1 Day 1. 
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
87 of 175
b
To include CT or MRI slices through T12 and L3.
c
Previous scans for baseline disease and brain imaging that were performed within 4 weeks of dosing and meet the protocol requirements do not need to be repeated.
d
Participants with active hepatitis A, active hepatitis B, or active hepatitis C are excluded; however, participants who have chronic hepatitis B or hepatitis C receiving 
suppressive antiviral therapy are allowed to be enrolled if ALT is normal and viral load is controlled. Controlled hepatitis B viral load is defined as serum hepatitis B virus 
DNA < 2000 IU/mL by PCR. Controlled hepatitis C viral load is defined as undetectable hepatitis C RNA by PCR either spontaneously or in response to a successful prior 
course of anti-hepatitis C therapy. NOTE: Participants with controlled hepatitis B viral load must remain on antiviral therapy, per institutional practice, to ensure adequate 
viral suppression during the study treatment and follow-up period.
e
Fresh paired biopsy samples will be taken as specified in all mandatory paired biopsy cohorts in Parts B but are optional for all other participants. 
 
. If they are taken during screening they will not need to be taken for Cycle 1 
Day 1 pre-dose.
f
Whole body PET imaging to occur before the initial dosing of study intervention (≤ 14 day) on Cycle 1 Day 1. Imaging to be done only after the participant’s eligibility for 
the study has been confirmed. PET imaging must be before pre-treatment biopsy. CD8+ PET Tracer [89Zirconium (Zr)-deferoxamine (Df)-crefmirlimab] to be ordered at 
least 72 hours before administration and PET imaging appointments should be booked accordingly. Tracer to be administered preferably 24 (±3) hours but not more than 
72 hours prior to whole body PET imaging. The duration between administration of the tracer and the PET scan should be the same at screening and at Day 29. If a 
participant holds or discontinues study treatment prior to Day 29, if able, the participant should still perform the PET scan as scheduled.
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; CD8 = cluster of differentiation 8; CT = computed 
tomography; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; GDF15 = growth differentiation factor 15; 
HbA1c = haemoglobin A1c; HIV = human immunodeficiency virus; IRT = interactive response technology system; INR = international normalised ratio; MRI = magnetic 
resonance imaging; NSCLC = non-small-cell lung carcinoma; 
 cell; PET = positron emission tomography; PT = prothrombin time; 
PID = participant identification number; RECIST = response evaluation criteria in solid tumours; RNA = ribonucleic acid; SAE = serious adverse event; T3 = triiodothyronine; 
T4 = thyroxine; TSH = thyroid-stimulating hormone; V = visit; WOCBP = woman of childbearing potential.
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
88 of 175
Table 13
Schedule of Activities – Study Visits
Visit Number
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13-Vn
Details
in
Section
Procedure/Study 
Day
D1
Pre-
Dose
D1
Post-
Dose
D2
D8
D15
D22
D29
D36
D43
D64
D85
D106
D127+
Q3W
Week
1
1
1
2
3
4
5
6
7
10
13
16
19+
Cycle Number 
and
Cycle Day a
C1D1
b
C1D1
C1D2
C1D8
(±1D)
C1D15
(±1D)
C2D1
(±1D)
C2D8
(±1D)
C2
D15
(±1D)
C3D1
(±3D)
C4D1
(±3D)
C5D1
(±3D)
C6D1
(±3D)
C7D1-CnD1
(±3D)
Eligibility
Confirm 
eligibility for 
enrolment in Main 
Study
X
10.5.1; 
10.5.2
Study Procedures and Examinations
Physical 
examination, 
including appetite 
assessment
X
X
X
X
X c
X c
X
X
X
X
X
8.2.1
Local 12-lead 
ECG
X
X
X
X
X
Q12W
10.8.2.1
Table 17
Vital signs, 
including body 
weight
X
X d
X
X
X
X c
X c
X
X
X
X
X
8.2.3
ECOG 
Performance 
Status
X
X
X
X
X c
X c
X
X
X
X
X
8.2.2
Assessment of 
AEs/SAEs
X
X
X
X
X
X
X c
X c
X
X
X
X
X
8.3

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
89 of 175
Visit Number
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13-Vn
Details
in
Section
Procedure/Study 
Day
D1
Pre-
Dose
D1
Post-
Dose
D2
D8
D15
D22
D29
D36
D43
D64
D85
D106
D127+
Q3W
Week
1
1
1
2
3
4
5
6
7
10
13
16
19+
Cycle Number 
and
Cycle Day a
C1D1
b
C1D1
C1D2
C1D8
(±1D)
C1D15
(±1D)
C2D1
(±1D)
C2D8
(±1D)
C2
D15
(±1D)
C3D1
(±3D)
C4D1
(±3D)
C5D1
(±3D)
C6D1
(±3D)
C7D1-CnD1
(±3D)
Concomitant 
medications
X
X
X
X
X
X c
X c
X
X
X
X
X
6.5
Disease Assessments
Disease 
assessment by 
RECIST v1.1 and 
SMI assessment e
X
W6 D1-D7
X f
W15
D1-D7
W24±6D then 
Q9W±6D until 
W52, then 
Q12W±6D
10.8.1
CT or MRI, Brain 
(required for 
participants with 
known brain 
metastasis and as 
clinically 
indicated for other 
participants)
X
W6 D1-D7
X f
W15
D1-D7
W24±6D then 
Q9W±6D until 
W52, then 
Q12W±6D
10.8.1
Safety Laboratories
Clinical chemistry
b
X
X
X
X
X
X
X
X
X
8.2.5
HbA1c
X
X
Q12W
8.2.5
Thyroid function 
(TSH, free T4, 
free T3) b, i
X
X
X
X
X
X
X
8.2.5

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
90 of 175
Visit Number
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13-Vn
Details
in
Section
Procedure/Study 
Day
D1
Pre-
Dose
D1
Post-
Dose
D2
D8
D15
D22
D29
D36
D43
D64
D85
D106
D127+
Q3W
Week
1
1
1
2
3
4
5
6
7
10
13
16
19+
Cycle Number 
and
Cycle Day a
C1D1
b
C1D1
C1D2
C1D8
(±1D)
C1D15
(±1D)
C2D1
(±1D)
C2D8
(±1D)
C2
D15
(±1D)
C3D1
(±3D)
C4D1
(±3D)
C5D1
(±3D)
C6D1
(±3D)
C7D1-CnD1
(±3D)
Haematology b
X
X
X
X
X
X
X
X
X
8.2.5
Urinalysis b
X
X
X
X
X
X
X
8.2.5
Pregnancy test 
(WOCBP Only) j
X
X
X
X
X
X
X
8.2.5
Coagulation 
parameters 
(PT/aPTT/INR/d-
Dimer/fibrinogen)
b
X
X
X
X
X
X
X
X
X
8.2.5
Virology 
(Hepatitis B 
and C) k
X
Q12W
8.2.5
Biomarker Evaluations g
Part A/C: 
 
X l
X m
X m
10.8.6.1.2
Part B: Mandatory 
paired biopsy
X l
X m
X m
10.8.6.1.1
Serum for GDF15 
target engagement
X
X
X
X
X
X
X n
X
X
X
X
10.8.5.3.1, 
Table 20
Whole blood for 
 
(refrigerated)
X
X n
On 
progression
10.8.6.4
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
91 of 175
Visit Number
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13-Vn
Details
in
Section
Procedure/Study 
Day
D1
Pre-
Dose
D1
Post-
Dose
D2
D8
D15
D22
D29
D36
D43
D64
D85
D106
D127+
Q3W
Week
1
1
1
2
3
4
5
6
7
10
13
16
19+
Cycle Number 
and
Cycle Day a
C1D1
b
C1D1
C1D2
C1D8
(±1D)
C1D15
(±1D)
C2D1
(±1D)
C2D8
(±1D)
C2
D15
(±1D)
C3D1
(±3D)
C4D1
(±3D)
C5D1
(±3D)
C6D1
(±3D)
C7D1-CnD1
(±3D)
Whole blood for 
flow cytometry
X
X
X
X n
X
X
X
On 
progression
10.8.6.5
 
 
X
X
X
X n
X
On 
progression
10.8.6.3
 
X
X
X
X n
X
X
X
On 
progression
10.8.6.7
 
X
X
X
X n
X
X
X
On 
progression
10.8.6.7
Plasma for 
circulating tumour 
DNA
X
X
X
X n
X
X
X
On 
progression
10.8.6.6
 
 
h
X
8.7
PK and Immunogenicity
Part A: AZD8853 
PK
X
X
X
X
X
X
X n
X
X
X
X
10.8.5.1; 
Table 18
All Parts: 
AZD8853 ADA
X g
X g
X g
X g
X g Q12W
10.8.5.2; 
Table 19
Part B: AZD8853 
PK
X
X
X
X
X
X
X
X
X
X
10.8.5.1; 
Table 18
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
92 of 175
Visit Number
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13-Vn
Details
in
Section
Procedure/Study 
Day
D1
Pre-
Dose
D1
Post-
Dose
D2
D8
D15
D22
D29
D36
D43
D64
D85
D106
D127+
Q3W
Week
1
1
1
2
3
4
5
6
7
10
13
16
19+
Cycle Number 
and
Cycle Day a
C1D1
b
C1D1
C1D2
C1D8
(±1D)
C1D15
(±1D)
C2D1
(±1D)
C2D8
(±1D)
C2
D15
(±1D)
C3D1
(±3D)
C4D1
(±3D)
C5D1
(±3D)
C6D1
(±3D)
C7D1-CnD1
(±3D)
Part C: AZD8853 
PK
X
X
X
X
X
X
X
10.8.5.1; 
Table 18
Study Treatment Administration
AZD8853 
administration 
(Q3W)
X
X
X
X
X
X
Q3W
6.1
Part B only: CD8+ PET (select and validated sites only)
CD8+ PET Tracer 
Administration
X o
Appendix
I
Whole body PET 
scan
X o
Appendix
I
a
Any timing of safety assessment visit is relative to the day of most recent dosing (Day 1 of the latest cycle).
b
If screening assessments have been performed within the 72 hours prior to Day 1, then the assessment does not need to be performed pre-dose on Day 1. All safety laboratory 
results must be reviewed by the Investigator or physician designee prior to administration of the scheduled dose of study intervention. Pregnancy testing for WOCBP is 
required on all days of dosing.
c
For Part A only.
d
Weight on Day 1 post-dose is not needed.
e
To include CT or MRI slices through T12 and L3. Any timing of tumour assessment visit is relative to Cycle 1 Day 1.
f
Disease assessment should be performed on the week prior to next assessment cycle, always prior to dosing.
g
All collections must be pre-dose unless specified otherwise.
h
Sample can be taken at any point during study.
i
Free T4 and T3 measured if TSH is abnormal or if clinical suspicion of an AE related to the endocrine system.
j
A urine or serum pregnancy test is acceptable; if urine test is equivocal or positive then serum β-hCG testing should be performed for confirmation.
k
Required for participants with a history of hepatitis B or hepatitis C.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
93 of 175
l
Fresh paired biopsy samples will be taken as specified in all mandatory paired biopsy cohorts in Parts B but are optional for all other participants. 
 
. If they are taken during screening they will not need to be taken for Cycle 1 
Day 1 pre-dose.
m
The second paired biopsy sample should be collected on Cycle 2 Day 8 (±  days relative to Cycle 2 Day 8). For participants who are in the CD8+ PET cohort, the first and 
second biopsy should be taken within 
 hours after the first and second CD8+ PET scan, respectively. This second biopsy must still be collected if not done within the 
time windows described. 
n
To be taken at time of second paired biopsy.
o
Whole body PET imaging to occur before the initial dosing of study intervention (≤ 14 day) on Cycle 1 Day 1. Imaging to be done only after the participant’s eligibility for 
the study has been confirmed. PET imaging must be before pre-treatment biopsy. CD8+ PET Tracer [89Zirconium (Zr)-deferoxamine (Df)-crefmirlimab] to be ordered at 
least 72 hours before administration and PET imaging appointments should be booked accordingly. Tracer to be administered preferably 24 (±3) hours but not more than 
72 hours prior to whole body PET imaging. The duration between administration of the tracer and the PET scan should be the same at screening and at Day 29. If a 
participant holds or discontinues treatment prior to Day 29, if able, the participant should still have the PET scan as scheduled.
Abbreviations: ADA = antidrug antibody; AE = adverse event; CR = complete response; CT= computed tomography; D = Day; DNA= deoxyribonucleic acid; 
ECG = electrocardiogram; ECOG = eastern cooperative oncology group; EOT = end of treatment; GDF15 = growth differentiation factor 15; HbA1c = haemoglobin A1c; 
MRI = magnetic resonance imaging; n = visit number; NSCLC = non-small-cell lung cancer; 
; PK = pharmacokinetic; PR = partial 
response; Q3W = every 3 weeks; Q6W = every 6 weeks; Q9W = every 9 weeks; Q12W = every 12 weeks; Q26W = every 26 weeks; RNA = ribonucleic acid; RECIST = response 
evaluation criteria in solid tumours; SAE = serious adverse event; SD = stable disease; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; V = visit; 
WOCBP = woman of childbearing potential.
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
94 of 175
Table 14
Schedule of Activities – End of Treatment
Study Period
EOT
Follow-up Post EOT
LTFU
Details in 
Section
Procedure/Study Day
Day 30
(± 7 days)
Day 90
(± 7 days)
Q12W Post 
Day 90 Visit
Post EOT
Post Last Dose
Study Procedures and Examinations
Physical examination, including appetite assessment
X
X
X
8.2.1
ECOG performance status
X
X
X
8.2.2
Local 12-lead ECG (triplicate) 
X
8.2.4
Vital signs, including body weight
X
X
X
8.2.3
Assessment of AEs/SAEs
X
X
X
8.3
Concomitant medications
X
X
X
6.5
Disease Assessments
Disease assessment by RECIST v1.1 and SMI assessment a
X b
X c
X c
10.8.1
CT or MRI, brain (Required for participants with known brain metastasis and 
as clinically indicated for other participants)
X b
X c
X c
10.8.1
Safety Laboratories
Clinical chemistry
X
X
8.2.5
Haematology
X
X
8.2.5
HbA1c
X
X
8.2.5
Thyroid function tests (TSH, free T4, free T3) d
X
X
8.2.5
Urinalysis
X
X
8.2.5
Coagulation parameters (PT/aPTT/INR/d-Dimer/Fibrinogen)
X
X
8.2.5
Pregnancy test (WOCBP) e
X
X
X
8.2.5
Virology (Hepatitis B and C) f
X
8.2.5
Biomarker Evaluations
Collect on 
progression
10.8.6.1.3
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
95 of 175
Study Period
EOT
Follow-up Post EOT
LTFU
Details in 
Section
Procedure/Study Day
Day 30
(± 7 days)
Day 90
(± 7 days)
Q12W Post 
Day 90 Visit
Post EOT
Post Last Dose
Serum for GDF15 target engagement
X
X
X
10.8.5.3.1
Whole blood for 
 (refrigerated)
X
X
X
10.8.6.4
Whole blood for flow cytometry
X
X
X
10.8.6.5
X
X
X
10.8.6.3
X
X
X
10.8.6.7
X
X
X
10.8.6.7
Plasma for circulating tumour DNA
X
X
X
10.8.6.6
PK and Immunogenicity
Parts A, B and C: AZD8853 PK
X
10.8.5.1
Table 18
AZD8853 ADA
X
X
X
10.8.5.2
Table 19
EOT and Follow-up Assessment
Subsequent anti-cancer therapy
X
X
X
X
8.2.8
Survival status (by telephone, email, or clinic visit)
X
X
X 
X
8.2.8
a
To include CT or MRI slices through T12 and L3.
b
If CT or MRI scan for disease assessment is performed ≤ 14 days prior to the EOT visit, it will not be required at EOT visit.
c
Will not be performed if previously confirmed disease progression has been documented.
d
Free T4 and T3 measured if TSH is abnormal or if clinical suspicion of an AE related to the endocrine system.
e
A urine or serum pregnancy test is acceptable; if urine test is equivocal or positive then serum β-hCG testing should be performed for confirmation.
f
Required for participants with a history of hepatitis B or hepatitis C.
Abbreviations: ADA = antidrug antibody; AE = adverse event; aPTT = activated partial thromboplastin time; CT = computerized tomography; DNA = deoxyribonucleic acid; 
ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; GDF15 = growth differentiation factor 15; INR = international normalised 
ratio; LTFU = long Term Follow-up; MRI = magnetic resonance imaging; NSCLC = non-small-cell lung cancer; 
; 
PK = pharmacokinetics; PT = prothrombin time; Q12W = every 12 weeks; RNA = ribonucleic acid; RECIST = Response Evaluation Criteria in Solid Tumours; SAE = serious 
adverse event; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WOCBP = woman of childbearing potential.
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
98 of 175
Participants will be followed until either death, loss to follow-up, withdrawal of consent or 
end of study. This Substudy of the study will comprise of 3 main parts (Figure 3), as follows:
Part A: Dose Escalation
The dose-escalation part of the study may enrol up to 45 participants (assuming up to 5 dosing 
cohorts and 3-9 participants per cohort) with selected advanced/metastatic solid tumours 
(NSCLC, MSS-CRC and UC). AZD8853 will be administered as monotherapy at the selected 
dose by i.v. infusion on a Q3W schedule. All participants will be treated until progressive 
disease, unacceptable toxicity, or withdrawal of consent.
See Section 10.6.6.1 for the starting dose, dose escalation and stopping criteria.
Part B: PD/MoA Expansion
Dose levels that are deemed safe in Part A of the study and have shown preliminary evidence 
of circulating free GDF15 reduction can be expanded in this PD/MoA expansion part of the 
study which will enrol up to approximately 20 participants with NSCLC and 20 participants 
with MSS-CRC advanced/metastatic solid tumours into 2 dose expansions (Part B1 and 
Part B2; approximately 10 NSCLC and 10 MSS-CRC participants in each part).
See Section 10.6.7 for details on PD/MoA expansion.
Mandatory archival, pre- and on-treatment tumour biopsies, serum GDF15 samples, and other 
samples including PK for each participant will be required at pre-specified timepoints. 
Pre- and on-treatment CD8+ PET imaging will be performed to assess PD response. Up to
10 participants in Part B1 and up to 10 participants in Part B2 will be enrolled with evaluable 
data from paired biopsies. Data from Part A and Part B of this Substudy of the study will 
inform tumour types and dose levels most suitable to progress onto an efficacy expansion part.
The RP2D will be defined based on an updated PK/PD and safety analysis using data 
generated from both Part A and Part B of the study.
Cluster of Differentiation (CD)8+ Positron Emission Tomography (PET) Imaging 
In Part B of the study, selected sites will use CD8+ PET imaging in combination with 
mandatory paired biopsies to monitor changes in CD8 T cell infiltration following treatment,
to evaluate the correlation between the CD8 immune infiltrate present by IHC of biopsies with 
in vivo CD8 T cell localization by PET imaging using a 89Zirconium (Zr)-deferoxamine (Df)-
crefmirlimab. 
Selected sites will recruit approximately up to 20 participants combined in Parts B1 and B2, 
across MSS-CRC and NSCLC study participants. These selected sites should prioritize 
recruitment to the CD8+ PET cohort of Part B prior to enrolling to non-CD8+ PET slots.
For further details on the CD8+ PET imaging, refer to Appendix I. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
99 of 175
Part C: Efficacy Expansion
The efficacy expansion parts of the study will enrol up to approximately 40 participants in 
each expansion (Part C1 and Part C2). Relevant participants from Part B will count towards 
Part C efficacy expansions. These expansions may open either in parallel or sequentially at the 
Sponsor’s discretion.
See Section 10.6.7 for details on efficacy expansion.
Mandatory pre- and on-treatment serum GDF15 samples and other samples including PK will 
be required. Archival of FFPE tissue is mandatory for all participants. Fresh pre- and 
on-treatment biopsies at pre-specified timepoints are 
 in this part of the study.
10.4.2
Substudy 1 Justification for Dose
A starting dose of 300 mg is proposed for AZD8853. The selection of the dose was based on 
the observed toxicology data from the cynomolgus monkey and a population PK model.
The HNSTD in non-human primate was estimated to be 
 mg/kg following 
 weekly 
doses with no toxicity concerns. Following AZD8853 administration, 100% reduction in 
serum GDF15 was observed with no apparent toxicity in animals. No changes in 
immunophenotyping and cytokine amounts were seen in the cynomolgus toxicology study. 
The observed Cmax and AUC(0-168) at 
 mg/kg in cynomolgus monkey was 
 µg/mL
and 
 µg*h/mL. Based on FDA Guidance for Industry: S9 Nonclinical Evaluation for 
anti-cancer Pharmaceuticals a starting dose was calculated. 
 of the HNSTD was 
mg/m2, or a human equivalent dose of 
 mg/kg. For a 
 kg patient, this would equate 
to a 
 mg dose. An additional safety margin of 
-fold was applied to allow for a starting 
dose of 300 mg.
A population PK model was developed based on available PK and GDF15 data from 
cynomolgus monkeys. An allometric scaling, with an exponent of 0.85 for clearances and 1 
for volume of distributions was applied to translate relevant PK parameters from animals to 
humans. A target turnover model was used to predict the percentage decrease in free GDF15 
in serum (Lowe et al, 2009; Davda et al, 2010). At the proposed starting dose of 300 mg, the
predicted Cmax and AUC(0-168hr) in human were 
µg/mL and 
µg*hr/mL. Therefore a 
-fold safety margin on Cmax and 
-fold safety margin on AUC(0-168hr) is predicted. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
100 of 175
At the proposed starting dose of 300 mg the model predicted a reduction of GDF15 at Cmax 
and Ctrough of
% and 
% respectively. Doses of 1000 and 3000 mg are expected to reduce 
free GDF15 levels by 
% and 
%, respectively at Ctrough. A dose of 3000 mg is expected to 
have 
-fold safety margins on Cmax and 
-fold safety margins on AUC(0-168hr). Although a 
relatively high suppression of GDF15 is expected at Cmax, the levels of GDF15 are expected 
to recover rapidly given the fast turnover of GDF15 in humans (3 hours [Xiong et al, 2017], or 
24 minutes from cynomolgus monkeys). In addition, AZD8853 is not a T cell agonist or an 
innate immune agonist and GDF15 suppression is not expected to cause cascading 
immune-stimulatory effects. A cytokine release assay was not conducted as GDF15 is a 
soluble factor and is not expected to cause cross-linking of immune cells. No changes in 
immunophenotyping or cytokine analysis were seen during the 3-month cynomolgus 
toxicology study [Three Month Intravenous Toxicity Study Two Month Assessment of 
Recovery in the Cynomolgus Monkey (8447292)]. 
Overall given that AZD8853 has a clear safety profile in toxicological studies, relatively high 
safety margins based on both absolute dose and predicted human exposure and is not expected 
to cause cascading immune-stimulatory effects, a 300 mg dose is proposed as a first-in-human 
dose.
10.4.3
End of Substudy 1 Definition
The end of Substudy 1 is defined as the last scheduled visit or contact of the last participant 
enrolled in the Substudy.
10.5
Substudy 1 Population
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.
Main Consent
Informed consent must be obtained prior to any study specific assessments. After the 
participant signs the ICF, a participant enrolment number will be assigned.
Based on study design as outlined in Section 10.4.1, participants will be enrolled in the study. 
The main ICF for participants in this Substudy will include consent (mandatory and optional) 
for all biomarker samples as outlined in the SoA (Table 12, Table 13, and Table 14).
10.5.1
Substudy 1 Inclusion Criteria
In addition to the master study inclusion criteria listed in Section 5.1, participants are eligible 
to be included in this Substudy only if the further Substudy 1 criteria below also apply:
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
101 of 175
1
Histologically or cytologically documented unresectable, locally advanced (Stage III) or 
metastatic (Stage IV) NSCLC, metastatic (Stage IV) MSS-CRC or metastatic (Stage IV) 
UC.
2
Participants must meet all of the tumour-specific criteria below, with documented 
progression from previous therapy at study entry. Interval progression between 2 lines of 
therapy defines separate lines of therapy. Both standard and investigational treatments will 
count as lines of therapy when determining eligibility.
(a) Participants with NSCLC must:
i.
Have received at least one prior line of systemic therapy in the 
advanced/metastatic setting.
ii.
Have received at least one prior line of therapy which contained an anti-PD-
1/PD-L1 agent, with or without platinum-based chemotherapy.
iii.
Have documented test results for:
•
Sensitizing EGFR mutations and ALK fusions/rearrangements
•
Other genomic alterations which are part of a local standard of care and for 
which a locally approved standard of care targeted therapy exists (such as 
ROS proto-oncogene 1 [ROS1] fusions/rearrangements, neurotrophic receptor 
tyrosine kinase (NTRK) fusions, RET fusions/rearrangements, MET exon 14 
skipping mutations, BRAF V600E mutation, etc.). 
iv.
Have received targeted therapy according to the identified genomic alteration. 
Targeted therapy is not mandatory if it is not in the local standard of care, or if it 
is refused by the participant or contraindicated.
v.
For Parts B and C: PD/MoA and Efficacy Expansions:
No sensitizing EGFR mutations or ALK fusions/rearrangements (documented 
test result is mandatory).
(b) Participants with MSS-CRC:
i.
Must have documented MSS by local testing (genetic analysis or 
immunohistochemistry).
ii.
Must have received at least 2 prior lines of systemic therapy for 
advanced/metastatic disease.
•
Prior systemic therapies must include fluoropyrimidines, irinotecan and 
oxaliplatin, unless refused or contraindicated. Participants may or may not 
have received a vascular endothelial growth factor (VEGF) agent 
(eg, bevacizumab), a BRAF inhibitor and an EGFR therapy (eg, cetuximab or 
panitumumab), according to local standard or care.
iii.
Participants who have withdrawn from standard treatment due to unacceptable 
toxicity warranting discontinuation of treatment and precluding retreatment with 
the same agent prior to progression of disease will be eligible to enter the study.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
102 of 175
iv.
Participants who had received adjuvant chemotherapy and had recurrence during 
or within 6 months of completion of the adjuvant chemotherapy are allowed to 
count the adjuvant therapy as one prior line of chemotherapy.
(c) Participants with UC must:
i.
Have histological confirmation of unresectable, locally advanced or metastatic
UC (including any of the following: renal pelvis, ureters, urinary bladder, and/or 
urethra). Histological confirmation at initial diagnosis is acceptable. Participants 
must have received at least one prior line of systemic therapy including prior 
platinum-containing regimen and/or a checkpoint inhibitor therapy with 
anti-PD-1 or anti-PD-L1.
3
Participation in a clinical trial is determined to be the best option for next treatment based 
on prior response and/ or tolerability to standard of care in the opinion of the Investigator. 
4
Participants must provide archival tumour tissue (FFPE block or unstained slides if a block 
cannot be provisioned). Refer to Section 10.8.6.2 and the Laboratory Manual for 
additional details.
Part B only:
5
All participants must be willing to provide mandatory paired biopsies (pre and 
on-treatment biopsies). The biopsied lesion must be distinct from any lesion used in the 
RECIST v1.1 evaluation.
6
CD8+ PET Cohort Only: Participants must have at least one non-liver lesion, suitable for 
PET imaging and be willing to be assessed with CD8+ PET imaging at screening 
(pre-treatment) and designated on treatment timepoints.
10.5.2
Substudy 1 Exclusion Criteria 
In addition to the master study exclusion criteria listed in Section 5.2, participants are 
excluded from this Substudy if any of the further Substudy 1 criteria below also apply:
1. Participants who have received prior immunotherapy with anti-PD-1, anti-PD-L1, or 
anti-CTLA-4:
a) Must not have experienced a toxicity that led to permanent discontinuation of prior 
immunotherapy.
b) All AEs while receiving prior immunotherapy must have completely resolved or 
resolved to baseline prior to screening for this study.
c) Must not have experienced a ≥ Grade 3 imAE or a neurologic or ocular imAE of any 
grade while receiving prior immunotherapy. Note: Participants with an endocrine AE 
of ≤ Grade 2 are permitted to enrol if they are stably maintained on appropriate 
replacement therapy and are asymptomatic.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
103 of 175
d) Must not have required the use of additional immunosuppression other than 
corticosteroids for the management of an AE, not have experienced recurrence of an 
AE if re-challenged, and not currently require maintenance doses of > 10 mg 
prednisone or equivalent per day.
2. Participants with spinal cord compression or history of leptomeningeal carcinomatosis.
3. Participants with brain metastases unless treated, asymptomatic, stable, and not requiring 
continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 
4 weeks prior to the start of the study.
4.
):
Exclusion criteria for participation in the 
 component of the 
study include:
a)
.
b)
 
.
10.6
Substudy 1 Study Intervention
10.6.1
Study Intervention(s) Administered
10.6.1.1
Investigational Products
Please refer to Section 6.1 for AZD8853 details.
10.6.1.2
Investigational Imaging Agent
Imaging sites will be provided with an investigational imaging agent (Part B only), an 
anti-CD8 minibody (Mb) (Crefmirlimab) conjugated with Df and radiolabelled with Zr-89 
(89Zr-Df-crefmirlimab), for participants in the CD8+ PET imaging cohorts (see Appendix I for 
more details).
10.6.2
Preparation/Handling/Storage/Accountability
Please refer to Section 6.2 for details on preparation/handling/storage/accountability of study 
intervention.
10.6.3
Measures to Minimise Bias: Randomization and Blinding
Please refer to Section 6.3 for details on randomisation and blinding.
10.6.4
Study Intervention Compliance
Please refer to Section 6.4 for details on study intervention compliance.
10.6.5
Concomitant Therapy
Please refer to Section 6.5 for details on concomitant therapy.
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
104 of 175
10.6.6
Dose Modification
Discontinuation or withholding of study intervention will be implemented to manage potential 
immune-related and non-immune mediated AEs based on severity of treatment-emergent 
toxicities graded per NCI CTCAE v5.0. Dose reductions are not permitted. For any ≥ Grade 3 
AE that does not meet criteria for treatment discontinuation and whose causal relationship is 
attributable to the IMP, a single scheduled dose of IMP may be skipped (maximum of 
2 non-consecutive doses) to permit resolution and the next dose will be administered on the 
next scheduled date. Omitted doses will not be administered at a later date. If the toxicity does 
not resolve to ≤Grade 1 or baseline by the time of the next scheduled dose after skipping one
dose of IMP (ie, a total of 2 consecutive doses are skipped), the participant will be 
permanently discontinued from treatment.
Potential risks for AZD8853 are expected to be similar to those of other human monoclonal 
immunoglobulins, and include immune-mediated and non-immune-mediated risks. The 
overall dose modifications, are given below:

Grade 1
No dose modification.

Grade 2
Hold study intervention until resolution to Grade ≤ 1 or baseline.
-
If toxicity worsens, then treat as Grade 3 or Grade 4.
-
Study intervention can be resumed once event stabilises to Grade ≤ 1.
-
Consider whether study intervention should be permanently discontinued in Grade 2 
events with high likelihood for morbidity and/or mortality when they do not rapidly 
improve to Grade < 1 upon treatment.

Grade 3
Hold study intervention (see rules for Grade 2 events), or permanently 
discontinue as per AZD8853 TMG.

Grade 4
Permanently discontinue study intervention.
For detailed guidelines on management of toxicities and dose modifications (temporary or 
permanent discontinuation only) refer to AZD8853 TMGs provided to the sites as a separate 
document.
10.6.6.1
Starting Dose, Dose Escalation Scheme and Stopping Criteria
10.6.6.1.1 Starting Dose
The initial dose level of 300 mg is based upon findings from the 3-month GLP toxicology 
study in cynomolgus monkeys and predictions around GDF15 suppression (see Section
10.4.2). The first participant in Cohort 1 must complete 1 week on study post the AZD8853
administration (Cycle 1 Day 1) without any DLTs before additional participants may be
enrolled into the first cohort. A waiting period between additional participants in the cohort is 
not required. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
105 of 175
10.6.6.1.2 Safety Review Committee
Please refer to Section 9.6 for details on the SRC. 
10.6.6.1.3 Escalation Cohorts
Dose escalation will follow the mTPI-2 algorithm (Guo et al, 2017) as described below. Dose
escalation cohorts will initially enrol 3 to 5 participants per cohort (to ensure at least 
3 evaluable participants for dose-escalation decisions). A minimum of 3 participants must 
complete the DLT-evaluation period before making an escalation decision. A maximum of 
9 participants may be enrolled in each dose-escalation cohort.
1. The MTD will be determined based on assessment of DLT according to the mTPI-2 
algorithm (see Table 16). 
2. A minimum of 3 DLT-evaluable participants are required in each dose level unless 
unacceptable toxicity is encountered in the first 2 participants prior to enrolment of the 
third participant, which would require dose de-escalation per the mTPI-2 design. For a 
dose level that has fewer than 3 participants who are DLT-evaluable, participants will be 
replaced.
3. If a de-escalation decision is made, choice of de-escalation to the previous main dose level 
or an intermediate dose level below will be at the discretion of the SRC. In the eventuality 
that a decision is made to de-escalate back to a dose escalation level that was previously
deemed safe, in which additional participants (Part B1) have since been enrolled at that 
dose level, these participants will now be included in further dose-escalation decisions 
following mTPI-2 rules.
4. If a stay (“S”) decision is made, additional participants will be enrolled up to a maximum 
of 9 participants for a given dose level (typically in groups of 2 to 4 participants).
5. After the sentinel dosing of the first participant in the initial cohort, participants 2 and 3 
dosing will be staggered such that administration of the first dose is separated by at least 
48-hours before the next participant is dosed. In subsequent cohorts, a 48-hour separation 
in first dosing between participants is required for the first 3 participants in each cohort. 
Provided there are no serious or unexplained safety issues after the first 3 participants, as 
determined by the respective treating physician, participants may be enrolled concurrently 
or sequentially for the remainder of the cohort with the Sponsor’s agreement. 
Intra-participant dose escalation will not be allowed.
6. At the discretion of the Sponsor, dose escalation may be stopped before an MTD is 
reached. In this case, the doses for evaluation in the dose-expansion parts (Part B and 
Part C) may be chosen based on an assessment of available PK, PD, safety, or efficacy 
data.
7. The MTD will be determined by isotonic regression analysis applied to DLT rates 
observed during dose escalation using the mTPI-2 method (Guo et al, 2017).

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
106 of 175
The mTPI-2 employs a simple beta-binomial Bayesian model. Decision rules are based on 
calculating the UPM of three intervals corresponding to underdosing, proper dosing, and 
overdosing in terms of toxicity. The underdosing interval corresponds to a dose escalation, 
overdosing interval corresponds to a dose de-escalation, and proper dosing interval 
corresponds to staying at the current dose. Given an interval and a probability distribution, the 
UPM of that interval is defined as the probability of the interval divided by the length of the 
interval. The mTPI-2 design calculates the UPMs for the multiple equal toxicity intervals, and 
the one with the largest UPM implies the corresponding dose-finding decision. The design for 
the dose-escalation part of the Substudy 1 uses a target DLT rate of 
% and an equivalence 
interval of (
%, 
%) for dose-escalation/de-escalation decisions as well as MTD 
determination. A dose level will be considered unsafe, with no additional participants enrolled 
at that dose level, if it has an estimated 95% or more probability of exceeding the target DLT 
rate of 
% (ie, P [DLT > 
% data] > 95%) with at least 3 DLT-evaluable participants treated 
and evaluated at that dose level. In Table 16 dose escalation/de-escalation decision rules are 
computed based on the above information. 
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
107 of 175
Dose-escalation decisions guided by the mTPI-2 design with the targeted DLT rate =
 and the equivalence 
interval (EI) = (
). The table lists the decisions for up to 9 participants treated at a given dose. The 
column in this table represents the number of participants enrolled at the dose, and the row represents the number 
of DLTs at the same dose. The dose-escalation decisions are as follows: E: Escalate to the next higher dose; S: 
Stay at the current dose; D: De-escalate to the previous lower dose; DU: De-escalate to the previous lower dose 
and marking the current dose and its higher doses as unacceptably toxic so that they will never be used again in 
the remainder of the trial. 
10.6.7
Dose Expansion
Part B
The 2 dose expansion levels will be chosen based on peripheral target engagement and 
non-overlapping PK in order to evaluate intra-tumoural PD activity and help determine the 
RP2D. One dose expansion level will be the MTD/HPDD and one dose expansion level will 
be lower than the MTD/HPDD. Each dose level will enrol approximately 20 participants with 
NSCLC or MSS-CRC (enrolling approximately 10 participants in each tumour type). 
Expansions may open either in parallel or sequentially at Sponsor’s discretion. Expansions 
may start before the MTD/HPDD has been determined.
Part C
The two efficacy expansions will be determined based on emerging data from Part A and/or 
Part B and may include two indications at a single dose level or one indication at two dose 
levels. If the RP2D cannot be adequately determined from Part B and additional data (eg,
efficacy) is required to guide RP2D determination, then two dose levels in one indication will 
be investigated. If the RP2D is determined at the end of Part B, RP2D will be evaluated in 
two indications. Each efficacy expansion will enrol up to approximately 40 participants which 
may include up to 10 participants from the relevant Part B expansion. An interim analysis will 
take place after 20 participants (further details in Section 10.9.5).
10.6.7.1
Treatment Allocation in Dose Expansion Phase
Participants will not be randomised in this study; however, IxRS will be used in all parts of the 
study to ensure participants receive their allocated medication.
10.6.8
Definition of DLT
Dose limiting toxicity includes event(s) which happen during the 21 days of Cycle 1 of Part A
and represent ≥Grade 3 toxicity, as defined below, which is not clearly attributable to the 
disease under investigation, other concomitant medications, disease-related processes under 
investigation, or another non-drug-related aetiology, with modifications or exceptions noted 
below. 
The DLT evaluation period is from the first exposure of AZD8853 until the end of Cycle 1, 
which is 21 days. All DLTs must be documented as AEs, graded according to 
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
108 of 175
NCI CTCAE v5.0 and need to be followed until improvement to CTCAE Grade < 1. A 
minimum of at least 3 DLT-evaluable participants are required for the SRC to hold a 
dose-escalation vote.
An AE not listed below, or an AE meeting the DLT criteria below but occurring outside of the 
DLT period may be defined as a DLT-like event after consultation with the Sponsor and 
Investigators based on the emerging safety profile.
The following toxicities constitute a DLT:

Any death not clearly due to the underlying disease or extraneous causes.

Grade 4 adverse events of immune nature (imAE).

Any ≥Grade 3 non-infectious pneumonitis regardless of duration; diagnosis should 
include clinical evaluation, monitoring of oxygenation using pulse oximetry (resting and 
exertion), laboratory workup and high-resolution CT scan.

Any ≥Grade 3 non-infectious colitis irrespective of duration after confirmation by 
colonoscopy and histopathology.

Any Grade 3 imAE, including rash, pruritus, or diarrhoea (NOTE: this excludes colitis or 
pneumonitis, as these AEs are already defined above), that does not downgrade to 
Grade ≤ 2 within 7 days after onset of the event despite maximal supportive care 
including systemic corticosteroids.

Liver transaminase elevation:
i.
Criteria for all participants except participants with elevated transaminases 
(ALT/AST) at baseline/screening due to liver metastasis:

Isolated liver transaminase elevation > 5 × but ≤ 8 × ULN that does not 
downgrade to AST/ALT ≤ 3 x ULN within 14 days after onset with 
optimal medical management.

Isolated liver transaminase elevation > 8 × ULN regardless of duration 
or reversibility.

Any increase in AST or ALT > 3 × ULN and concurrent increase in 
TBL ≥ 2 × ULN, regardless of duration or reversibility, where no other 
reason, other than the study intervention, can be found to explain the 
combination of increases.
ii.
Criteria for participants with elevated transaminases (ALT/AST) at 
baseline/screening due to liver metastasis (inclusion criterion 8):

Isolated liver transaminase elevation > 2 × but ≤ 5 × baseline that does 
not downgrade to < 2 × baseline or less within 14 days after onset with
optimal medical management.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
109 of 175

Isolated liver transaminase elevation > 5 × baseline regardless of 
duration or reversibility.

Any increase in AST or ALT > 3 × baseline and concurrent increase in 
TBL ≥ 2 × ULN regardless of duration or reversibility, where no other 
reason, other than the study intervention, can be found to explain the 
combination of increases.

Grade 3 nausea, vomiting, or diarrhoea that does not resolve to Grade ≤ 1 within 3 days of 
initiation of maximal supportive care.

Neutropenia:
i.
≥Grade 3 febrile neutropenia regardless of duration ruling out the cause of fever 
due to non-infections events.
ii.
≥Grade 3 neutropenia, without associated fever or systemic infection, which 
does not improve by at least one grade within 5 days of onset.

Anaemia:
i.
Grade 4 anaemia regardless of duration.
ii.
Grade 3 anaemia that requires more than one transfusion of > 2 units of red 
blood cell.

Thrombocytopenia:
i.
≥Grade 4 thrombocytopenia lasting > 7 days.
ii.
≥Grade 3 thrombocytopenia, regardless of duration, associated with 
haemorrhage.

Thrombocytopenia in presence of anticoagulation therapy:
i.
Thrombocytopenia below Grade 3 lasting for 7 days, without additional risk 
factors. 

Any ≥Grade 3 neurotoxicity (to include but not limited to limbic encephalitis, autonomic 
neuropathy, including peripheral neuromotor syndromes such as myasthenia gravis and 
Guillain-Barré) regardless of duration.

Any ≥Grade 3 cardiotoxicity (to include but not limited to arrhythmias, myocarditis with 
cardiomyopathy, ventricular dysfunction) regardless of duration.

Any ≥Grade 3 ocular toxicity (including but not limited to iritis, uveitis, significant 
vision changes) regardless of duration.

Any other pre-existing toxicity that has worsened as compared to baseline that is 
clinically significant and unacceptable, does not respond to supportive care, results in a 
disruption of dosing schedule of more than 21 days or is judged to be a DLT by the SRC.
The DLT definition excludes the following conditions:

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
110 of 175

Grade ≥ 3 fatigue lasting ≤ 7 days.

Concurrent vitiligo or alopecia of any grade.

Grade 3 or Grade 4 lymphopenia, unless associated with infection.

Grade 3 or higher amylase or lipase that is not associated with symptoms or clinical 
manifestations of pancreatitis, irrespective of duration.

Grade 3 or higher electrolyte abnormality that lasts up to 72 hours, is not clinically 
complicated, and resolves spontaneously or responds to conventional medical 
interventions.
10.6.9
Definition of maximum tolerated dose
The MTD will be selected from all tried dose levels that have not been previously declared to 
be unsafe with a DU decision according to the mTPI-2 decision table. With this constraint, the 
MTD will be determined as the dose level with the DLT estimate closest to the target toxicity 
level of 
%.
In the case of dose levels with estimated toxicity of equal distance (tied dose levels) from the 
target toxicity of 
%, the following approach will be used (Ji et al, 2010): among all tied 
dose levels the highest dose level with target toxicity 
% will be selected, unless all tied 
dose levels have estimated toxicity 
%, in which case the lowest dose level will be 
selected.
10.6.10
Definition of DLT Evaluable Participant
For decisions on dose escalation, an evaluable participant is defined as a participant who has 
received AZD8853 and either:

Has received at least 75% of the AZD8853 infusion and has completed safety evaluation 
requirements during the DLT evaluation period of 21 days in Cycle 1. Participants who 
do not remain in the study up to this time for reasons other than DLT will be considered 
non-evaluable for DLT assessment.
OR

Has experienced a DLT during the DLT evaluation period.
Non-evaluable participants in the dose-escalation cohorts will be replaced in the same dose 
cohort if needed to ensure a minimum of 3 DLT-evaluable participants.
10.6.11
Intervention after the End of the Study
Please refer to Section 6.7 for details on intervention after the end of the study.
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
111 of 175
10.7
Substudy 1 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
10.7.1
Discontinuation of Study Intervention
Please refer to Section 7.1 for details on discontinuation of study intervention.
10.7.2
Participant Withdrawal from the Study
Any participant in Part A that is withdrawn and is not evaluable will be replaced to ensure a 
minimum number of 3 DLT-evaluable participants.
10.7.3
Lost to Follow-up
Please refer to Section 7.3 for lost to follow-up.
10.8
Substudy 1 Study Assessments and Procedures
In addition to the master study assessment and procedures listed in Section 8, the below 
Substudy specific assessments and procedures also apply. 

Approximately 86 mL of blood will be required for all screening tests which will be 
conducted during the 28-day screening period. Approximately 210 mL of blood 
(including 
) will be collected between Days 1 and 21 
of study intervention in Part A and Part B whereas during the same time period 
approximately 189 mL of blood (including 
) will be 
collected in Part C. No more than approximately 144 mL of blood will be drawn during 
any cycle or individual study visit after Cycle 1. The total volume to be collected will 
depend on the number of doses administered and the length of follow-up.

All efficacy assessments should continue until progression; however, if the participant is 
clinically stable then a confirmatory scan for progression could be performed per 
Investigator’s discretion, and assessments should also be performed when a participant’s 
study intervention has been stopped.
10.8.1
Efficacy Assessments
Please refer to Section 8.1 for the efficacy assessments
10.8.2
Safety Assessments
Details of all safety assessments are provided in Section 8.2, for the planned timepoints for the 
safety assessments refer to SoA (Table 12, Table 13, and Table 14).
10.8.2.1
Electrocardiograms
Please refer to Section 8.2.4 for details of ECGs. Table 17 provides the Substudy-specific 
sampling schedule of electrocardiograms.
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
112 of 175
Table 17
Sampling Schedule for Electrocardiograms
Cycle
Day
Sampling Time
Sampling Window
Parts A, B and C
1
1
Pre-dose
-2 hrs
1
0 hrs post EoI
+15 min
2
1
Pre-dose
-2 hrs
3
1
Pre-dose
-2 hrs
7-n
1
Pre-dose Q12W
-2 hrs
EOT
N/A
Up to 14 days post EOT
Abbreviation: EoI = end of infusion; EOT =end of treatment; hrs = hours; min = minutes; N/A = not applicable
10.8.3
Adverse Events and Serious Adverse Events
For details on AEs and SAEs, refer to Section 8.3.
10.8.4
Overdose
Please refer to Section 8.4 for details on overdose.
10.8.5
Human Biological Samples
10.8.5.1
Pharmacokinetics
Please refer to Section 8.5.1 for details of PK. Table 18 provides the Substudy-specific 
sampling schedule for the PK samples.
Table 18
Sampling Schedule for PK Samples
Cycle
Day
Sampling Time
Sampling PK Window
Part A
1
1
Pre-dose
-2 hrs
1
0 hrs post EoI
+5 min
1
15 min post EoI
±5 min
1
2 hrs post EoI
±5 min
1
6 hrs post EoI
±5 min
2
24 hrs post EoI
±5 min
8
168 hrs post EoI
±5 min
15
336 hrs post EoI
±5 min
2, 3, 4, 5, and 6
1
Pre-dose
-2 hrs
2, 3, 4, 5, and 6
1
0 hrs post EoI 
+5 min
2a
8
168 hrs post EoI
±5 min

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
113 of 175
Cycle
Day
Sampling Time
Sampling PK Window
EOT
N/A
90 days post EOT
±7 days
Part B
1
1
Pre-dose
-2 hrs
1
0 hrs post EoI 
+5 min
1
15 min post EoI
±5 min
1
2 hrs post EoI
±5 min
1
6 hrs post EoI
±5 min
2
24 hrs post EoI
±5 min
8
168 hrs post EoI
±5 min
15
336 hrs post EoI
±5 min
2,3,4,5, and 6
1
Pre-dose
-2 hrs
EOT
N/A
90 days post EOT
±7 days
Part C
1
1
Pre-dose
-2 hrs
1
0 hrs post EoI 
+5 min
2,3,4,5, and 6
1
Pre-dose
-2 hrs
EOT
N/A
90 days post EOT
±7 days
a
Taken at time of second paired biopsy
Abbreviation: EoI = end of infusion; EOT = end of treatment; hrs = hours; min = minutes; N/A = not applicable
10.8.5.2
Immunogenicity Assessments
Please refer to Section 8.5.2 for details of immunogenicity assessments. Table 19 provides the 
Substudy-specific sampling schedule for the ADA samples.
Table 19
Sampling Schedule for ADA Samples
Cycle
Day
Sampling Time
Sampling ADA Window
Parts A, B and C
1
1
Pre-dose
-2 hrs
2
1
Pre-dose
-2 hrs
3
1
Pre-dose
-2 hrs
5
1
Pre-dose
-2 hrs
7-n
1
Pre-dose Q12W
-2 hrs
EOT
N/A
Up to 14 days post EOT
EOT
N/A
30 days post EOT
±7 days
EOT
N/A
90 days post EOT
±7 days
Abbreviation: EOT = end of treatment; hrs = hours; N/A = not applicable; Q12W = every 12 weeks

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
114 of 175
10.8.5.3
Pharmacodynamics
Blood samples will be collected at specific timepoints mentioned in the SoA (Table 12, 
Table 13, and Table 14).
Further details on sample processing, handling and shipment will be provided in the 
Laboratory Manual.
For storage, re-use, and destruction of pharmacodynamic samples see Appendix C. 
10.8.5.3.1 GDF15 Assay for Target Engagement
As specified in the SoA for study visits (Table 12 and Table 13) and per the additional 
timepoints denoted in Table 20, samples for determination of free GDF15 in serum will be 
assayed by bioanalytical test sites operated by or on behalf of AstraZeneca, using an 
appropriately validated bioanalytical method. Full details of the method to be used will be 
described in a separate bioanalytical report.
Table 20
Sampling Schedule for GDF15 Target Engagement Samples
Cycle
Day
Sampling Time
Sampling PD Window
1
1
Pre-dose
-2 hrs
1
0 hrs post EoI
+5 min
1
15 min post EoI 
±5 min
1
2 hrs post EoI
±5 min
1
6 hrs post EoI
±5 min
2
24 hrs post EoI
±5 min
8
168 hrs post EoI
±5 min
15
336 hrs post EoI
±5 min
2, 3, 4, 5, and 6
1
Pre-dose
-2 hrs
2, 3, 4, 5, and 6
1
0 hrs post EoI 
+5 min
2a
8
168 hrs post EoI
±5 min
EOT
N/A
Up to 14 days post EOT
EOT
N/A
30 days post EOT
±7 days
EOT
N/A
90 days post EOT
±7 days
a
Taken at time of second paired biopsy
Abbreviations: EoI = end of infusion; EOT = end of treatment; hrs = hours; min = minutes; N/A = not applicable

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
115 of 175
10.8.6
10.8.6.1
Fresh Tumour Biopsy
Fresh tumour biopsy samples (both mandatory and 
) will be collected for participants 
enrolled in both the dose-escalation part (Part A) and the expansion parts (Part B and Part C). 
For mandatory and 
 biopsy participants, the associated pathology report(s) for fresh 
tumour samples will be required at screening and requested on-treatment for all participants 
enrolled into the study (details in the Laboratory Manual). If clinically feasible, at each fresh 
tumour sample timepoint, participants will undergo 4 core image-guided needle biopsies. 
Details for fresh tumour sample collection, processing, storage, and shipment are provided in 
the Laboratory Manual. Per institutional practice, image-guided fresh core needle tumour 
biopsies should be preferentially obtained from tumour tissues that are safely accessible, as 
determined by the Investigator, and are not obtained from sites that require significant risk 
procedures. Collection of tumour cells from fluid such as ascites or pleural effusion is not
permitted. Fine-needle aspirate specimens are not acceptable. For fresh tumour biopsies, the 
tumour lesion should not be used as a RECIST target lesion, unless this is the only soft tissue 
lesion. If a RECIST v1.1 TL is used for biopsy, the lesion must be ≥ 2 cm in the longest 
diameter and must be biopsied at least 2 weeks prior to baseline RECIST assessment. Sites 
should confirm adequacy of tumour biopsy material at the time of the procedure. The 
screening and on-treatment biopsy should be taken where possible from the same lesion to 
ensure consistency and reduce variability of the sample. Biopsies should not be taken from 
previously irradiated sites unless the lesions were progressing after radiation. Bone biopsies 
are not permitted.
All tumour biopsies will be collected, stored, and shipped as detailed in the Laboratory 
Manual.
10.8.6.1.1 Mandatory Fresh Paired Biopsies
Up to 40 participants in Part B will be required to provide tumour samples. These participants 
will be required (mandatory) to undergo a tumour biopsy pre-treatment and during treatment 
as described below. 

Cycle 1 Day 1 (≤ 14 days, must be before the initial dosing of study intervention) 

Cycle 2 Day 8 (± 5 days, must be after CD8+ PET imaging if participant is in the CD8+ 
PET cohort).

Informed consent must be obtained from any participant who agrees to provide tissue for 
mandatory tumour tissue sample testing.
10.8.6.1.2
.
 
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
116 of 175
. 
 
.
 
 
 
 
 
 
10.8.6.1.3
 
 
 
 
 
 
10.8.6.2
Mandatory Archival Tumour Samples
Sites must provision archival tumour tissue (FFPE blocks), with sufficient material to produce
approximately 40 slides. Provision of archival FFPE blocks is preferred, but if an archival 
block is not available, then approximately 40 unstained slides must be provided from another 
biopsy. Associated pathology report(s) for biopsy samples must be provided at screening for 
all participants. Central confirmation of the number of slides available is not required prior to 
participant dosing. However, sites should ensure that the archival block or other tissue sample 
has sufficient material, to the best of their knowledge, to produce the required number of 
slides. In the event that less than approximately 40 sections are thought to be available, then 
the CRA or Sponsor representative should be contacted. Please refer to the Laboratory Manual 
for details of acceptable sample types, processing, storage, and shipment of tissue samples.
10.8.6.3
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
117 of 175
 
10.8.6.4
Whole blood samples will be collected from all participants as described in the SoA, for 
preparation of 
 and are mandatory. A variety of assays include, but are not limited to, 
 
 
10.8.6.5
Whole Blood for Flow Cytometry
Whole blood samples will be collected from all participants as described in the SoA, for flow 
cytometry-based immunophenotyping of circulating lymphocytes and are mandatory. 
Populations to be assessed may include, but are not limited to: T cell subsets, B cell subsets, 
natural killer cells, DCs, and myeloid-derived suppressor cells. Markers will also be used to 
investigate the expression of immune checkpoint molecules and activation and proliferation 
status of immune cells.
10.8.6.6
Circulating Tumour DNA
Whole blood to extract plasma will be collected from all participants as described in the SoA, 
for, but not limited to, ctDNA analysis and is mandatory. The ctDNA samples will be analysed 
longitudinally for secondary and 
, and to 
 in 
 and 
.
10.8.6.7
Whole Blood for 
Whole blood to extract 
 will be collected from all participants as described 
in the SoA, for analysis of 
 and is 
mandatory. 
 
 
 
10.8.6.8
 Research
Already collected samples may be analysed on 
 thought to play a role in 
 
 to AZD8853.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
118 of 175
For storage, re-use and destruction of biomarker samples see Section 8.5 and Appendix C. 
10.8.6.9
 Future Scientific Research
Already collected samples may be analysed to support research beyond AZD8853 and is 
pursuant to agreement to a separate 
 for future scientific research. Future 
research is important to advance science and public health. At present, however, it is not 
possible to foresee all details of future scientific research projects. These future scientific 
research projects are beyond the scope of the clinical study.
10.8.7
Please refer to Master Protocol Section 8.7 for details on the 
 
10.8.8
Health Economics and Participant eConsent Opinions
Please refer to Section 8.8.
10.9
Substudy 1 Statistical Considerations
Statistical considerations as described in Section 9 will be followed in the analysis of 
Substudy 1, unless specifically stated in this section. Substudy-specific considerations are 
described in this section.
10.9.1
Statistical Hypotheses
Not applicable. 
10.9.2
Sample Size Determination
For dose escalation (Part A) cohorts of 3 to 9 evaluable participants will be enrolled. The total 
number of participants will depend on the number of non-evaluable participants and the 
number of dose escalations necessary in order to declare MTD/RP2D. It is anticipated that 
approximately up to 5 dose-escalation cohorts of up to 9 evaluable participants may be 
included resulting in an overall total of up to approximately 45 participants.
Dose escalation using mTPI-2 is visualised in Table 16.
In the PD/MoA expansions (Part B1 and B2) up to 10 participants may be enrolled in each of 
2 dose levels and 2 indications (NSCLC and MSS-CRC) for a total of approximately 
40 participants. It is estimated that this will provide at least 7 participants per indication and 
dose level with evaluable paired biopsies for PD assessment.
In the efficacy expansions (Part C1 and C2) up to 40 participants in each expansion will be 
enrolled for a total of 80 participants. This will be an additional 30 participants per expansion 
since 10 relevant participants may be included from the associated PD/MoA expansion. With 
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
119 of 175
 
Clopper et al, 1934) 
 
Across all parts of the study up to a total of 165 participants may be enrolled and treated with 
AZD8853 (145 participants if 20 participants from Part B are included in Part C). Additional 
participants may be required if additional expansions or dosing schedules are explored.
10.9.3
Population for Analyses
In addition, to the populations for analyses mentioned in Section 9.3, the definition of 
Substudy 1 specific populations for analyses is provided in Table 21. 
Table 21
Populations for Analyses
Population/Analysis set
Description
Endpoint/Output
PD
All participants who receive at least one dose of study 
intervention with baseline measurement and at least 
one reportable pharmacodynamic measurement.
PD endpoints
Abbreviation: PD = pharmacodynamics
10.9.4
Statistical Analyses
10.9.4.1
General Considerations
Data will be presented by dose cohort (Part A) and dose expansion (Part B and Part C); no 
direct statistical comparisons will be made between any cohorts or expansions.
Table 22 details which data will be analysed at each timepoint.
Table 22
Details of Analyses 
Analysis
Trigger
Data Type Included
Interim for efficacy expansions 
(Parts C1 and C2)
After the 20th participant in each 
expansion had the opportunity for 
2 on-treatment RECIST 
assessments or has discontinued or 
withdrawn from treatment
Efficacy
Safety
Primary analysis
At completion of each part 
(analysis will be conducted 
separately for each part)
All data
10.9.4.2
Efficacy Analyses
Please refer to Section 9.4.3 for efficacy analyses. 
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
120 of 175
10.9.4.3
Safety Analyses
Please refer to Section 9.4.2 for safety analyses.
10.9.4.4
Other Analyses
10.9.4.4.1 Pharmacodynamics
The secondary PD endpoint of change in circulating GDF15 serum levels from pre-treatment 
(baseline) to each post baseline timepoint as well as the maximum change will be summarised 
using descriptive statistics on actual and percent change. 
The secondary endpoint of change in CD8 tumour infiltration by IHC between the 
pre-treatment and on-treatment biopsy will be summarised using descriptive statistics for 
those participants with paired biopsies.
In general, PD variables based on 
 and fresh biopsy samples will be 
summarized using descriptive statistics on the PD Population. Summaries of change from 
baseline and percent change from baseline will be also be presented for PD variables as 
appropriate. Such summaries may be reported separately from the main CSR. Summaries and 
analyses for 
 may be reported outside the CSR in a separate report. 
Descriptive statistics will be the primary method for the biomarker analyses. Depending on 
the nature of the data, geometric mean and other appropriate statistical summaries might be 
used as well.
Analyses of PK/PD may include, but are not limited to, 
 
. Other 
 
. Where relevant, 
data collected from this study may be combined with other data from other studies for 
modelling purposes. All analysis results may be reported separately from the CSR.
Refer to Section 9.4.4.1 for information on PK and immunogenicity analyses. Further details 
on the analysis of immunogenicity, pharmacokinetics and pharmacodynamics will be provided 
in the SAP.
10.9.5
Interim Analyses
In the efficacy expansions (Part C1 and Part C2) an interim analysis will be performed after 
the 20th participant in each expansion has had the opportunity for 2 on-treatment RECIST 
assessments or has discontinued or withdrawn from treatment. Enrolment will continue while 
this analysis is ongoing. The analysis will provide tolerability and safety data and will also 
provide a reasonable chance to determine if there is a lack of efficacy. 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
121 of 175
 
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
122 of 175
11
SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
Appendix A
Regulatory, Ethical, and Study Oversight Considerations
A 1
Regulatory and Ethical Considerations

This study will be conducted in accordance with the protocol and with the following:
i.
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines
ii.
Applicable ICH GCP Guidelines
iii.
Applicable laws and regulations

The protocol, protocol amendments, ICF, IB, and other relevant documents (eg,
advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before the study is initiated.

Any amendments to the protocol will require IRB/IEC and applicable Regulatory 
Authority approval before implementation of changes made to the study design, except 
for changes necessary to eliminate an immediate hazard to study participants.

AstraZeneca will be responsible for obtaining the required authorisations to conduct the 
study from the concerned Regulatory Authority. This responsibility may be delegated to a 
CRO, but the accountability remains with AstraZeneca.

The Investigator will be responsible for providing oversight of the conduct of the study at 
the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European Regulation 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulations
Regulatory Reporting Requirements for Serious Adverse Events

Prompt notification by the Investigator to the Sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local Regulatory Authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the Regulatory Authority, IRB/IEC, and Investigators.

For all studies except those utilizing medical devices Investigator safety reports must be 
prepared for suspected unexpected serious adverse reactions according to local regulatory 
requirements and Sponsor policy and forwarded to Investigators as necessary.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
123 of 175
-
European Medical Device Regulation 2017/745 for clinical device research (if 
applicable), and all other applicable local regulations

An Investigator who receives an Investigator safety report describing a SAE or other 
specific safety information (eg, summary or listing of SAEs) from the Sponsor will 
review and then file it along with the IB or state other documents and will notify the 
IRB/IEC, if appropriate according to local requirements.
A 2
Financial Disclosure
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate Regulatory Authorities. Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study.
A 3
Informed Consent Process

The Investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorised representative and answer all questions regarding 
the study.
-
Sites participating in the CD8+ PET imaging portion of the study will be provided 
with separate Part B ICFs.

Participants must be informed that their participation is voluntary, and they are free to 
refuse to participate and may withdraw their consent at any time and for any reason 
during the study. Participants or their legally authorised representative will be required to 
sign a statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, Health Insurance Portability and Accountability Act 
requirements, where applicable, and the IRB/IEC or study centre.

The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorised person obtaining the informed consent must also sign the ICF.

Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study.

A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorised representative.
A participant who is rescreened is not required to sign another ICF if the rescreening occurs 
within 28 days from the previous ICF signature date.
The ICF will contain a separate section that addresses and documents the collection and use of 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
124 of 175
any mandatory and/or optional human biological samples. The Investigator or authorised 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they are free to refuse to 
participate in any optional samples or the future use and may withdraw their consent at any 
time and for any reason during the retention period.
A 4
Data Protection

Participants will be assigned a unique identifier by the Sponsor. Any participant records 
or datasets that are transferred to the Sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred.

The participant must be informed that his/her personal study-related data will be used by 
the Sponsor in accordance with local data protection law. The level of disclosure and use 
of their data must also be explained to the participant in the informed consent 

The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorised personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from Regulatory 
Authorities.
A 5
Committees Structure
No Data Monitoring Committee will be used in this study; however, a SRC will closely 
monitor participant safety on an ongoing basis. The SRC Members will include the following:

Principal Investigator, or delegate, who will chair the committee

Study Chair (if not Principal Investigator)

Principal Investigator or delegate from investigational site

AstraZeneca Medical Science Director or delegate

AstraZeneca Global Safety Physician, or delegate
The Sponsor or CRO Study Physician, or delegate, should always be present at the SRC.
The AstraZeneca Clinical Pharmacology Scientist, Study Statistician, Patient Safety Scientist, 
Study Leader and other AstraZeneca and non-AstraZeneca technical experts may also be 
invited as appropriate. The SRC Remit document for this study will define the exact 
membership and who will be present for decisions to be made.
A 6
Dissemination of Clinical Study Data
A description of this clinical study will be available on http://astrazenecaclinicaltrials.com and 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
125 of 175
http://www.clinicaltrials.gov as will the summary of the main study results when they are 
available. The clinical study and/or summary of main study results may also be available on 
other websites according to the regulations of the countries in which the main study is
conducted.
A 7
Data Quality Assurance

All participant data relating to the study will be recorded on the eCRF unless transmitted 
to the Sponsor or designee electronically (eg, laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the eCRF.

The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.

The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.

Monitoring details describing strategy (eg, risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) 
are provided in the Monitoring Plan.

The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.

The Sponsor assumes accountability for actions delegated to other individuals (eg, CRO).

Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by authorised site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator for 15 years after study completion unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor.
A 8
Source Documents

Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator’s site.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
126 of 175

Data reported on the eCRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.

All information in original records and certified copies of original records of clinical 
findings, observations, or other activities in a clinical study necessary for the 
reconstruction and evaluation of the study are defined as source documents. Source data 
are contained in source documents (original records or certified copies). 

A digital copy of all imaging scans should be stored as source documents.
A 9
Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants. The first act of recruitment is the first site open and will be the study start date.
The Sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed.
The Investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the Sponsor or Investigator may include but 
are not limited to:

Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor's procedures, or GCP guidelines

Inadequate recruitment of participants by the Investigator

Discontinuation of further study intervention development
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the Regulatory Authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The Investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up.
Participants from terminated sites will have the opportunity to be transferred to another site to 
continue the study.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
127 of 175
A 10
Publication Policy

The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor
before submission. This allows the Sponsor to protect proprietary information and to 
provide comments.

The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publication of multicentre studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
128 of 175
Appendix B
Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
B 1
Definition of Adverse Events
An AE is the development of any untoward medical occurrence in a patient or clinical study 
participant administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and unintended sign 
(eg, an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease 
temporally associated with the use of a medicinal product, whether or not considered related 
to the medicinal product. 
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence. An AE may occur at any time, including 
run-in or washout periods, even if no study treatment has been administered.
B 2
Definitions of Serious Adverse Event
A serious adverse event is an AE occurring during any study period (ie, run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria:

Results in death

Is immediately life-threatening

Requires in-participant hospitalisation or prolongation of existing hospitalisation 

Results in persistent or significant disability or incapacity

Is a congenital anomaly or birth defect

Is an important medical event that may jeopardise the participant or may require medical 
treatment to prevent one of the outcomes listed above.
Adverse events for malignant tumours reported during a study should generally be assessed 
as serious AEs. If no other seriousness criteria apply, the ‘Important Medical Event’ criterion 
should be used. In certain situations, however, medical judgement on an individual event basis 
should be applied to clarify that the malignant tumour event should be assessed and reported 
as a non-serious AE. For example, if the tumour is included as medical history and 
progression occurs during the study, but the progression does not change treatment and/or 
prognosis of the malignant tumour, the AE may not fulfil the attributes for being assessed as 
serious, although reporting of the progression of the malignant tumour as an AE is valid and 
should occur. Also, some types of malignant tumours, which do not spread remotely after a 
routine treatment that does not require hospitalization, may be assessed as non-serious; 
examples in adults include Stage 1 basal cell carcinoma and Stage 1A1 cervical cancer 
removed via cone biopsy.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
129 of 175
The above instruction applies only when the malignant tumour event in question is a new 
malignant tumour (ie, it is not the tumour for which entry into the study is a criterion and that 
is being treated by the investigational medicinal product under study and is not the 
development of new or progression of existing metastasis to the tumour under study). 
Malignant tumours that – as part of normal, if rare, progression – undergo transformation 
(eg, Richter’s transformation of B-cell chronic lymphocytic leukaemia into diffuse large 
B-cell lymphoma) should not be considered a new malignant tumour.
Life-threatening
‘Life-threatening’ means that the participant was at immediate risk of death from the AE as it 
occurred, or it is suspected that use or continued use of the product would result in the 
participant’s death. ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospitalisation
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the participant was enrolled in the study, provided that it did not deteriorate in 
an unexpected way during the study.
Important Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life-threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardise the participant or may 
require medical treatment to prevent one or more outcomes listed in the definition of serious. 
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.

Angioedema not severe enough to require intubation but requiring i.v. hydrocortisone 
treatment

Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with 
N-acetylcysteine

Intensive treatment in an emergency room or at home for allergic bronchospasm

Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsions that do not result in hospitalisation

Development of drug dependency or drug abuse

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
130 of 175
Intensity Rating Scale:
The grading scales found in the revised NCI CTCAE v5.0 will be utilised for all events with 
an assigned CTCAE grading. For those events without assigned CTCAE grades, the 
recommendation in the CTCAE criteria that converts mild, moderate and severe events into 
CTCAE grades should be used. A copy of the CTCAE can be downloaded from the Cancer 
Therapy Evaluation Program website (http://ctep.cancer.gov). The applicable version of 
CTCAE should be described clearly.
B 3
A Guide to Interpreting the Causality Question
When making an assessment of causality consider the following factors when deciding if there 
is a ‘reasonable possibility’ that an AE may have been caused by the drug.

Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relationship to the administration of the 
suspect drug?

Consistency with known drug profile. Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? Or could the AE be anticipated from its pharmacological 
properties?

De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose 
of the suspect drug?

No alternative cause. The AE cannot be reasonably explained by another aetiology such 
as the underlying disease, other drugs, other host or environmental factors.

Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZeneca would not normally recommend or support a 
re-challenge.

Laboratory tests. A specific laboratory investigation (if performed) has confirmed the 
relationship.
In difficult cases, other factors could be considered such as:

Is this a recognised feature of overdose of the drug?

Is there a known mechanism?
Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibility’ of a causal relationship for the individual case. The expression 
‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
131 of 175
The causality assessment is performed based on the available data including enough 
information to make an informed judgment. With no available facts or arguments to suggest a 
causal relationship, the event(s) will be assessed as ‘not related’.
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility.
B 4
Medication Error
For the purposes of this clinical study a medication error is an unintended failure or mistake in 
the treatment process for an AstraZeneca study drug that either causes harm to the participant 
or has the potential to cause harm to the participant. 
A medication error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study site staff or participant.
Medication error includes situations where an error:

Occurred

Was identified and intercepted before the participant received the drug

Did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:

Drug name confusion

Dispensing error eg, medication prepared incorrectly, even if it was not actually given to 
the participant

Drug not administered as indicated, for example, wrong route or wrong site of 
administration

Drug not taken as indicated eg, tablet dissolved in water when it should be taken as a 
solid tablet 

Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 

Wrong participant received the medication (excluding IRT]/RTSM errors)

Wrong drug administered to participant (excluding IRT/RTMS errors)
Examples of events that do not require reporting as medication errors in clinical studies:

Errors related to or resulting from IRT/RTMS - including those which lead to one of the 
above listed events that would otherwise have been a medication error 

Participant accidentally missed drug dose(s) eg, forgot to take medication

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
132 of 175

Accidental overdose (will be captured as an overdose)

Participant failed to return unused medication or empty packaging

Errors related to background and rescue medication, or standard-of-care medication in 
open label studies, even if an AstraZeneca product 
Medication errors are not regarded as AEs, but AEs may occur as a consequence of the 
medication error.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
133 of 175
Appendix C
Handling of Human Biological Samples
C 1
Chain of Custody
A full chain of custody is maintained for all samples throughout their lifecycle.
The Investigator at each centre keeps full traceability of collected biological samples from the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceability of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
AstraZeneca or delegated representatives will keep oversight of the entire life cycle through 
internal procedures, monitoring of study sites, auditing or process checks, and contractual 
requirements of external laboratory providers
Samples retained for further use will be stored in the AstraZeneca-assigned biobanks or other 
sample archive facilities and will be tracked by the appropriate AstraZeneca Team during for 
the remainder of the sample life cycle.
If required, AstraZeneca will ensure that remaining biological samples are returned to the site
according to local regulations or at the end of the retention period, whichever is the sooner.
C 2
Withdrawal of Informed Consent for Donated Biological Samples 
AstraZeneca ensures that biological samples are returned to the source or destroyed at the end 
of a specified period as described in the informed consent.
If a participant withdraws consent to the use of donated biological samples, the samples will 
be disposed of/destroyed/repatriated, and the action documented. If samples are already 
analysed, AstraZeneca is not obliged to destroy the results of this research.
Following withdrawal of consent for biological samples, further study participation should be 
considered in relation to the withdrawal processes outlined in the informed consent.
The Investigator:

Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to AstraZeneca or delegate.

Ensures that relevant human biological samples from that participant, if stored at the 
study site, are immediately identified, disposed of as appropriate, and the action 
documented.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
134 of 175

Ensures that the participant and AstraZeneca are informed about the sample disposal.
AstraZeneca ensures the organization(s) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action documented, and study site notified.
C 3
International Airline Transportation Association 6.2 Guidance 
Document
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
International Airline Transportation Association 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx) classifies infectious 
substances into 3 categories: Category A, Category B or Exempt
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals. 
Category A pathogens are, eg, Ebola, Lassa fever virus. Infectious substances meeting these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN 2814. Infectious substances which cause disease only in animals must be assigned to 
UN 2900:
Category B Infectious Substances are infectious substances that do not meet the criteria for 
inclusion in Category A. Category B pathogens are, eg, Hepatitis A, C, D, and E viruses. They 
are assigned the following UN number and proper shipping name

UN 3373 – Biological Substance, Category B

are to be packed in accordance with UN 3373 and IATA 650
Exempt - Substances which do not contain infectious substances or substances which are 
unlikely to cause disease in humans or animals are not subject to these regulations unless they 
meet the criteria for inclusion in another class.

Clinical study samples will fall into Category B or exempt under IATA regulations

Clinical study samples will routinely be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR-60-EN-PI650.pdf).

Biological samples transported in dry ice require additional dangerous goods specification 
for the dry-ice content

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
135 of 175
Appendix D
D 1

AstraZeneca intends to collect and store 
 
 
 
 

 
 

The results of 
 may be reported in a separate study summary.

The Sponsor will store the 
 in a secure storage space with adequate 
measures to protect confidentiality.
D 2
 Plan and Procedures
Selection of 
 Population

All participants will be asked to participate in this 
. Participation is 
voluntary and if a participant declines to participate there will be no penalty or loss of 
benefit. The participant will not be excluded from any aspect of the main study.
Inclusion Criteria
For inclusion in this 
, participants must fulfil all of the inclusion criteria 
described in the main body of the Master CSP and: Provide informed consent for the 
(refer to Section 5.1).
Exclusion Criteria

Exclusion from this 
 may be for any of the exclusion criteria specified in 
the main study (refer Section 5.2)
Withdrawal of Consent for 

Participants may withdraw from this 
 at any time, independent of any 
decision concerning participation in other aspects of the main study. Voluntary 
withdrawal will not prejudice further treatment. Procedures for withdrawal are outlined in 
Section 7.2 of the Master CSP.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
136 of 175
Collection of Samples for 

The blood sample for this 
 will be obtained from the participants at the 
visit specified in the relevant Substudy SoA. Although 
 is stable, early sample 
collection is preferred to avoid introducing bias through excluding participants who may 
withdraw due to an AE. If for any reason the sample is not drawn at the planned visit, it 
may be taken at any visit until the last study visit. Only one sample should be collected 
per participant for 
during the study.
Coding and Storage of 
 Samples

The processes adopted for the coding and storage of samples for 
 are 
important to maintain participant confidentiality. Samples will be stored for a maximum 
of 15 years, from the date of last participant last visit, after which they will be destroyed. 
is a finite resource that is used up during analyses. Samples will be stored and used 
until no further analyses are possible or the maximum storage time has been reached.

An additional second code will be assigned to the sample either before or at the time of 
 extraction replacing the information on the sample tube. Thereafter, the sample will 
be identifiable only by the second, unique number. This number is used to identify the 
sample and corresponding data at the AstraZeneca 
 laboratories, or at the 
designated organisation. No personal details identifying the individual will be available to 
any person (AstraZeneca employee or designated organisations working with the 
).

The link between the participant enrolment/randomisation code and the second number 
will be maintained and stored in a secure environment, with restricted access at 
AstraZeneca or designated organisations. The link will be used to identify the relevant 
 samples for analysis, facilitate correlation of 
 with clinical data, 
allow regulatory audit, and permit tracing of samples for destruction in the case of 
withdrawal of consent.
Ethical and Regulatory Requirements

The principles for ethical and regulatory requirements for the study, including this 
 component, are outlined in Appendix A.
Informed Consent

The 
 of this study is 
, and the participant may participate in 
other components of the main study without participating in this 
. To 
participate in the 
 of the study the participant must sign and date both 
the consent form for the main study and the addendum for the 
 
 of the study. Copies of both signed and dated consent forms must be given to 
the participant and the original filed at the study centre. The Principal Investigator(s) is 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
137 of 175
responsible for ensuring that consent is given freely, and that the participant understands 
that they may freely withdrawal from the 
 of the study at any time.
Participant Data Protection

AstraZeneca will not provide individual 
 results to participants, any insurance 
company, any employer, their family members, general physician unless required to do so 
by law.

Extra precautions are taken to preserve confidentiality and prevent 
 being 
linked to the identity of the participant. In exceptional circumstances, however, certain 
individuals might see both the 
 and the personal identifiers of a participant. 
For example, in the case of a medical emergency, an AstraZeneca Physician or an 
Investigator might know a participant’s identity and also have access to his or her 
 
. Regulatory Authorities may require access to the relevant files, though the 
participant’s medical information and the 
 would remain physically separate.
Data Management

Any 
 generated in this study will be stored at a secure system at AstraZeneca 
and/or designated organizations to analyse the samples.

AstraZeneca and its designated organisations may share summary results (such as 
 
) from this 
 with 
other researchers, such as hospitals, academic organisations or health insurance 
companies. This can be done by placing the results in scientific databases, where they can 
be combined with the results of similar studies to learn even more about health and 
disease. The researchers can only use this information for health-related research 
purposes. Researchers may see summary results, but they will not be able to see 
individual participant data or any personal identifiers. 

Some or all of the clinical datasets from the main study may be merged with the 
 
 in a suitable secure environment separate from the clinical database.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
138 of 175
Appendix E
Actions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E 1
Introduction
This Appendix describes the process to be followed in order to identify and appropriately 
report PHL cases and HL cases. It is not intended to be a comprehensive guide to the 
management of elevated liver biochemistries. 
Specific guidance on managing liver anomalies can be found in the Dose Modification section
of each Substudy in the CSP.
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The Investigator is responsible for determining whether a participant meets 
potential PHL criteria at any point during the study.
All sources of laboratory data are appropriate for the determination of PHL and HL events; 
this includes samples taken at scheduled study visits and other visits including all local 
laboratory evaluations even if collected outside of the study visits; for example, PHL criteria 
could be met by an elevated ALT from a central laboratory and/or elevated TBL from a local 
laboratory. 
The Investigator will also review AE data (for example, for AEs that may indicate elevations 
in liver biochemistry) for possible PHL events.
The Investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether HL criteria are met. 
Hy’s Law criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than DILI caused by the IMP. 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safety reporting processes.
E 2
Definitions
Potential Hy’s Law
Aspartate transaminase or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN at any point during 
the study following the start of study medication irrespective of an increase in ALP.
Hy’s Law
Aspartate transaminase or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other 
reason, other than the IMP, can be found to explain the combination of increases, eg, elevated 
ALP indicating cholestasis, viral hepatitis, another drug. 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
139 of 175
For PHL and HL the elevation in transaminases must precede or be coincident with (ie, on the 
same day) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
E 3
Identification of Potential Hy’s Law Cases
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any participant who meets any of the following identification criteria in 
isolation or in combination:

ALT ≥ 3 × ULN

AST ≥ 3 × ULN

TBL ≥ 2 × ULN
Local Laboratories Being Used:
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will:

Determine whether the participant meets PHL criteria (see Section E 2 for definition) by 
reviewing laboratory reports from all previous visits

Promptly enter the laboratory data into the laboratory eCRF
E 4
Follow-up
E 4.1
Potential Hy’s Law Criteria not Met
If the participant does not meet PHL criteria the Investigator will:

Inform the AstraZeneca representative that the participant has not met PHL criteria. 

Perform follow-up on subsequent laboratory results according to the guidance provided in 
the CSP.
E 4.2
Potential Hy’s Law Criteria Met
If the participant does meet PHL criteria the Investigator will:

Determine whether PHL criteria were met at any study visit prior to starting study 
treatment (see Section E 6)

Notify the AstraZeneca representative who will then inform the central Study Team 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
140 of 175

Within one day of PHL criteria being met, the Investigator will report the case as an SAE 
of PHL; serious criteria ‘Important medical event’ and causality assessment ‘yes/related’ 
according to CSP process for SAE reporting.

For participants that met PHL criteria prior to starting IMP, the Investigator is not 
required to submit a PHL SAE unless there is a significant change# in the participant’s 
condition

The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study participants’ follow-up (including any further laboratory testing) 
and the continuous review of data

Subsequent to this contact the Investigator will:
-
Monitor the participant until liver biochemistry parameters and appropriate 
clinical symptoms and signs return to normal or baseline levels, or as long as 
medically indicated. Completes follow-up SAE Form as required.
-
Investigate the aetiology of the event and perform diagnostic investigations as 
discussed with the Study Physician. 
-
Complete the three Liver eCRF Modules as information becomes available.
E 5
Review and Assessment of Potential Hy’s Law Cases
The instructions in this Section should be followed for all cases where PHL criteria are met.
As soon as possible after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the 
IMP, to ensure timely analysis and reporting to health authorities within 15 calendar days from 
date PHL criteria was met. The AstraZeneca Global Clinical Lead or equivalent and Global 
Safety Physician will also be involved in this review together with other subject matter experts 
as appropriate. 
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below.
Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE:

If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate eCRF

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
141 of 175

If the alternative explanation is an AE/SAE: update the previously submitted PHL SAE 
and AE eCRFs accordingly with the new information (reassessing event term; causality 
and seriousness criteria) following the AstraZeneca standard processes.
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP:

Send updated SAE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes.
-
The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply.
-
As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned.
If, there is an unavoidable delay, of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternative explanation until such time as an informed decision can be made:

Provides any further update to the previously submitted SAE of PHL, (report term now 
‘Hy’s Law case’) ensuring causality assessment is related to IMP and seriousness criteria 
is medically important, according to CSP process for SAE reporting.

Continue follow-up and review according to agreed plan. Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternative explanation for the liver biochemistry 
elevations is determined.
E 6
Actions Required When Potential Hy’s Law Criteria are Met 
Before and After Starting Study Treatment 
This section is applicable to participants with liver metastases who meet PHL criteria on study 
treatment, having previously met PHL criteria at a study visit prior to starting study treatment.
At the first on-study treatment occurrence of PHL criteria being met the Investigator will 
determine if there has been a significant change in the participants’ condition# compared with 
the last visit where PHL criteria were met#

If there is no significant change no action is required.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
142 of 175

If there is a significant change, notify the AstraZeneca representative, who will inform the 
central Study Team, then follow the subsequent process described in Section E 4.2.
E 7
Actions Required for Repeat Episodes of Potential Hy’s Law
This section is applicable when a participant meets PHL criteria on study treatment and has 
already met PHL criteria at a previous on-study treatment visit (Section E 6).
The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence. 
The Investigator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the following question:
Was the alternative cause for the previous occurrence of PHL criteria being met found 
to be the disease under study eg, chronic or progressing malignant disease, severe 
infection or liver disease?
If No: follow the process described in Section E 4.2 for reporting PHL as an SAE
If Yes: Determine if there has been a significant change in the participant’s condition#
compared with when PHL criteria were previously met

If there is no significant change no action is required

If there is a significant change follow the process described in Section E 4.2 for reporting 
PHL as an SAE
# A ‘significant’ change in the participant’s condition refers to a clinically relevant change in 
any of the individual liver biochemistry parameters (ALT, AST or TBL) in isolation or in 
combination, or a clinically relevant change in associated symptoms. The determination of 
whether there has been a significant change will be at the discretion of the Investigator, this 
may be in consultation with the Study Physician if there is any uncertainty.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
143 of 175
E 8
Laboratory Tests
Local Laboratory Tests
Additional standard chemistry and coagulation tests
Gamma-glutamyltransferase
Lactate dehydrogenase
Prothrombin time
INR
Viral hepatitis
IgM anti-HAV 
HBsAg
IgM and IgG anti-HBc 
HBV DNA a
IgG anti-HCV
HCV RNA b
IgM anti-HEV
HEV RNA
Other viral infections
IgM & IgG anti-cytomegalovirus
IgM & IgG anti-herpes simplex virus
IgM & IgG anti- anti-Epstein-Barr virus
Alcoholic hepatitis
CD-transferrin c
Autoimmune hepatitis
ANA
Anti-LKM
ASMA
Metabolic diseases
alpha-1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrin c
Transferrin saturation
a
HBV DNA is only recommended when IgG anti-HBc is positive
b
HCV RNA is only recommended when IgG anti-HCV is positive or inconclusive 
c
CD-transferrin and Transferrin are not available in China. Study teams should amend this list accordingly
Abbreviations: ANA = antinuclear antibody; ASMA = anti-Smooth Muscle Ab; CD = carbohydrate deficient 
transferrin; DNA = deoxyribonucleic acid; HAV = hepatitis A virus; HBc = hepatitis B core; HBV = hepatitis B 
virus; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HEV = hepatitis E virus; 
IgG = immunoglobulin G; IgM = immunoglobulin M; INR = international normalised ratio; 
LKM = Liver/Kidney Microsomal Ab; RNA = ribonucleic acid
E 9
References
Aithal et al, 2011
Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806-815.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
144 of 175
FDA Guidance for Industry, July 2009
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing 
clinical evaluation’. Available from; https://www.fda.gov/regulatory-information/search-fda-
guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
145 of 175
Appendix F
Guidelines For Evaluation of Objective Tumour Response 
Using RECIST 1.1 Criteria (Response Evaluation Criteria in 
Solid Tumours)
Introduction
This appendix details the implementation of RECIST v1.1 guidelines (Eisenhauer et al, 2009).
Investigator assessments will use the RECIST v1.1 guidelines described in this appendix.
Imaging modalities and acquisition specifications for RECIST v1.1
A summary of the imaging modalities that can be used for tumour assessment TLs, NTLs, and 
NLs is provided in Table 23.
Table 23
Summary of Imaging Modalities for Tumour Assessment
Target Lesions 
Non-Target Lesions
New Lesions
CT
MRI
CT
MRI
Plain X-ray
Chest X-ray
CT
MRI
Plain X-ray
Chest X-ray
Bone scan (Scintigraphy)
FDG-PET/CT
Abbreviations: CT = Computed tomography; FDG-PET/CT = 18F-Fluoro-deoxyglucose positron emission 
tomography/CT; MRI = Magnetic resonance imaging.
CT and MRI 
Computed tomography with i.v. contrast is the preferred imaging modality (although MRI 
with i.v. contrast is acceptable if CT is contraindicated) to generate reproducible anatomical 
images for tumour assessments (ie, for measurement of TLs, assessment of NTLs, and 
identification of NLs). It is essential that the same correct imaging modality, image acquisition 
parameters (eg, anatomic coverage, imaging sequences, etc.), imaging facility, tumour
assessor (eg, radiologist), and method of tumour assessment (eg, RECIST v1.1) are used 
consistently for each participant throughout the study. The use of the same scanner for serial 
scans is recommended, if possible. It is important to follow the image collection/tumour
assessment schedule as closely as possible (refer to the Schedules of Activities [SoAs; 
Table 12, Table 13, and Table 14]), and this on-study imaging schedule MUST be followed 
regardless of any delays in dosing or missed imaging visits. If an unscheduled assessment is 
performed (eg, to investigate clinical signs/symptoms of progression) and the participant has 
not progressed, every attempt should be made to perform the subsequent scan acquisitions at 
the next scheduled imaging visit.
Due to its inherent rapid acquisition (seconds), CT is the imaging modality of choice. Body 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
146 of 175
scans should be performed with breath-hold scanning techniques, if possible. Therefore, CT of 
the chest is recommended over MRI due to significant motion artifacts (eg, heart, major blood 
vessels, breathing) associated with MRI. MRI has excellent contrast and spatial and temporal 
resolutions; however, there are many image acquisition variables involved in MRI, which 
greatly impact image quality, lesion conspicuity, and measurement. Furthermore, the 
availability of MRI is variable globally. The modality used at follow-up should be the same as 
was used at baseline, and the lesions should be measured/assessed on the same pulse 
sequence. In general, local oncology diagnostic imaging parameters are applied for scan 
acquisition. It is beyond the scope of this appendix to prescribe specific MRI pulse sequence 
parameters for all scanners, body parts, and diseases.
The most critical CT and MRI image acquisition parameters for optimal tumour evaluation are 
anatomic coverage, contrast administration, slice thickness, and reconstruction interval.
a. Anatomic coverage: Optimal anatomic coverage for most solid tumours is the 
chest-abdomen (-pelvis). Coverage should encompass all areas of known predilection for 
metastases in the disease under evaluation and should additionally investigate areas that may 
be involved based on signs and symptoms of individual participants. Because a lesion later 
identified in a body part not scanned at baseline would be considered as a NL representing 
disease progression, careful consideration should be given to the extent of imaging coverage 
at baseline and at subsequent follow-up timepoints. This will enable better consistency not 
only of tumour measurements but also identification of new disease.
Required anatomical regions to be imaged for assessment of tumour burden (TLs and/or 
NTLs) at baseline and follow-up visits vary according to the study, and these timepoints are 
specified in the SoAs (Table 12, Table 13, and Table 14). Examples include the following:

Intravenous contrast-enhanced CT of chest-abdomen (including the entire liver and both 
adrenal glands) (-pelvis)

Non-contrast CT of chest and i.v. contrast-enhanced abdomen (including the entire liver 
and both adrenal glands) (-pelvis)

Intravenous contrast-enhanced CT or MRI of the head and neck

Intravenous contrast-enhanced MRI (preferred) or CT of the brain
For chest-abdomen (-pelvis) imaging, the following are scanning options in decreasing order 
of preference, with additional options (2 to 4) for consideration when participants have 
sensitivity to i.v. contrast or have compromised renal function:
1
Chest-abdomen (-pelvis) CT with i.v. CT contrast (most preferred)
2
Chest CT without i.v.-contrast + abdomen (-pelvis) MRI with i.v. MRI contrast, if CT i.v.
contrast (iodine based) is medically contraindicated at any time during the study

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
147 of 175
3
Chest-abdomen (-pelvis) CT without i.v. contrast, if both i.v. CT and MRI contrast are 
medically contraindicated, or the participant has compromised renal function
4
Chest-abdomen (-pelvis) MRI with i.v. MRI contrast, if CT cannot be performed at any 
time during the study
b. IV contrast administration: Optimal visualization and measurement of metastases in solid 
tumours require consistent administration (dose and rate) of i.v. contrast as well as timing of 
scanning. An adequate volume of a suitable contrast agent should be given so that the tumour
lesions are demonstrated to best effect and a consistent method is used on subsequent 
examinations for any given participant. Oral contrast is recommended to help visualize and 
differentiate structures in the abdomen and pelvis.
c. Slice thickness and reconstruction interval: It is recommended that CT or MRI scans be 
acquired/reconstructed as contiguous (no gap) slices with ≤5-mm thickness throughout the 
entire anatomic region of interest for optimal lesion measurements. Exceptionally, particular 
institutions may perform medically acceptable scans at slice thicknesses > 5 mm. If this 
occurs, the minimum size of measurable lesions at baseline should be twice the slice thickness 
of the baseline scans.
For CT scans, all window settings should be included in the assessment, particularly in the 
thorax where lung and soft tissue windows should be considered. When measuring lesions, the 
TL should be measured on the same window setting for repeated examinations throughout the 
study.
Chest X-Ray
Chest X-ray assessment will not be used for the assessment of TLs. Chest X-ray can, however, 
be used to assess NTLs and to identify the presence of NLs. However, there is preference that 
a higher resolution modality, such as CT, be used to confirm the presence of NLs.
Plain X-Ray
Plain X-ray may be used as a method of assessment for bone NTLs and to identify the 
presence of new bone lesions.
Isotopic Bone Scan
Bone lesions identified on an isotopic bone scan at baseline and confirmed by CT, MRI, or 
X-ray at baseline should be recorded as NTLs and followed by the same method per baseline 
assessment (CT, MRI, or X-ray).
Isotopic bone scans may be used as a method of assessment to identify the presence of new 
bone lesions at follow-up visits. NLs may be recorded in case positive hot-spots appear on a 
bone scan that were not present on a previous bone scan; however, a newly observed 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
148 of 175
equivocal hot-spot on a bone scan that cannot be verified with correlative imaging (CT, MRI, 
or X-ray) of the same anatomical region shall not be the only trigger for a progressive disease 
assessment at that timepoint.
FDG-PET/CT
18F-Fluoro-deoxyglucose positron emission tomography/CT scans may be used as a method 
for identifying new extrahepatic lesions (but not intrahepatic lesions) for RECIST v1.1 
assessments according to the following algorithm: NLs will be recorded where there is 
positive FDG uptake1 not present on baseline or prior FDG-PET/CT scan or in a location 
corresponding to a NL on a companion CT/MRI collected close in time to the FDG-PET/CT 
scan. The PET portion of the PET/CT introduces additional data that may bias an Investigator 
if it is not routinely or serially performed. Therefore, if there is no baseline or prior 
FDG-PET/CT scan available for comparison, and no evidence of NLs on companion CT/MRI 
scans, then follow-up CT/MRI assessments should continue as per the regular imaging 
schedule to verify the unequivocal presence of NLs.
At present, low-dose or attenuation correction CT portions of a combined FDG-PET/CT scan 
are of limited use in anatomically based efficacy assessments, and it is therefore suggested 
that they should not substitute for dedicated diagnostic contrast-enhanced CT scans for tumour
measurements by RECIST v1.1. In exceptional situations, if a site can document that the CT 
performed, as part of a PET/CT examination, is of identical diagnostic quality (with i.v.
contrast) to a dedicated diagnostic CT scan, then the CT portion of the PET/CT can be used 
for RECIST v1.1 tumour assessments. Caution that this is not recommended because the PET 
portion of the CT introduces additional (PET) data that may bias an Investigator if it is not 
routinely or serially performed.
Ultrasound 
Ultrasound examination will not be used for RECIST v1.1 assessment of tumours as it is not a 
reproducible acquisition method (operator dependent), is subjective in interpretation, and may 
not provide an accurate assessment of the true tumour size. Tumours identified by ultrasound 
                                               
1
A positive FDG-PET scan lesion should be reported only when an uptake (eg, SUV) greater than twice that 
of the surrounding tissue or liver is observed.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
149 of 175
will need to be assessed by correlative CT or MRI anatomical scan.
Other Tumour Assessments
Clinical Examination 
Clinical examination of skin/surface lesions (by visual inspection or manual palpation) will 
not be used for RECIST v1.1 assessments. Tumours identified by clinical examination will 
need to be assessed by correlative CT or MRI anatomical scans.
Endoscopy and Laparoscopy 
Endoscopy and laparoscopy will not be used for tumour assessments as they are not validated 
in the context of tumour assessment.
Histology and Cytology
Histology or tumour markers on tumour biopsy samples will not be used as part of the tumour
response assessment as per RECIST v1.1.
Results of cytological examination for the neoplastic origin of any effusion (eg, ascites, 
pericardial effusion, and pleural effusion) that appears or worsens during the study will not be 
used as part of the tumour response assessment as per RECIST v1.1.
Furthermore, an overall assessment of complete response (all other disease disappears/reverts 
to normal) would be changed to partial response if an effusion remains present radiologically.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
150 of 175
Measurability of Tumour Lesions at Baseline
RECIST 1.1 Measurable Lesions at Baseline:
A tumour lesion that can be accurately measured at baseline as ≥10 mm in the longest 
diameter for non-nodal lesions or ≥15 mm in short axis2 diameter for lymph node lesions with 
i.v. contrast-enhanced CT or MRI and that is suitable for accurate repeated measurements.
Please see additional RECIST v1.1 guidance below on measurability of intrahepatic 
hepatocellular carcinoma lesions and porta hepatis lymph nodes.
Non-measurable Lesions at Baseline:

Truly non-measurable lesions include the following:
−
Bone lesions (see exception below for soft tissue component)
−
Leptomeningeal disease
−
Ascites, pleural effusion, or pericardial effusion
−
Inflammatory breast disease
−
Lymphangitic involvement of skin or lung

All other lesions, including small lesions (longest diameter < 10 mm or pathological 
lymph nodes with ≥10-mm to < 15-mm short axis diameter at baseline3)

Previously irradiated lesions4

Brain metastasis
                                               
2
The short axis is defined as the longest in-plane axis perpendicular to the long axis.
3
Lymph nodes with < 10-mm short axis diameter are considered non-pathological and should not be 
recorded or followed as NTLs.
4
Localized post-radiation changes that affect lesion size may occur. Therefore, lesions that have been 
previously irradiated are typically considered non-measurable and as NTL at baseline and followed up as 
part of the NTL assessment.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
151 of 175
Special Considerations Regarding Lesion Measurability at Baseline:

Bone lesions
−
Bone scan, PET scan, or plain X-ray are not considered adequate imaging 
techniques to measure bone lesions; however, these techniques can be used to 
confirm the presence or disappearance of bone lesions.
−
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, can be considered measurable if the soft tissue component meets the 
definition of measurability.
−
Blastic lesions are considered non-measurable.

Cystic lesions thought to represent cystic metastases can be considered measurable 
lesions if they meet the criteria for measurability from a radiological point of view, but if 
non-cystic lesions are present in the same participant, these should be selected over cystic 
lesions as TLs.
RECIST v1.1 TL Selection at Baseline:
A maximum of 5 measurable lesions, with a maximum of 2 lesions per organ (including 
lymph nodes collectively considered as a single organ), representative of all lesions involved 
should be identified as TLs at baseline. Target lesions should be selected on the basis of their 
size (longest diameter for non-nodal lesions or short axis diameter for nodal lesions), but in 
addition should be those that lend themselves to reproducible repeated measurements. It may 
be the case that, on occasion, the largest lesion does not lend itself to reproducible 
measurement, in which circumstance the next largest lesion that can be measured reproducibly 
should be selected.
Lymph nodes, in any location (local/regional and distant), are collectively considered as a 
single organ, with a maximum of 2 lymph nodes as TLs. A bilateral organ (eg, adrenal glands), 
a segmented organ (eg, liver), or a multilobed organ (eg, lung) is each considered as a single 
organ.
The site and location of each TL should be documented, as well as the longest axis diameter 
for non-nodal lesions (or short axis diameter for lymph nodes). All measurements should be 
recorded in millimeters. At baseline, the sum of the diameters for all TLs will be calculated 
and reported as the baseline sum of diameters. At follow-up visits, the sum of diameters for all 
TLs will be calculated and reported as the follow-up sum of diameters.
Special cases for TL assessment at baseline:

For TLs measurable in 2 or 3 dimensions, always report the longest diameter. For 
pathological lymph nodes measurable in 2 or 3 dimensions, always report the short axis 
diameter.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
152 of 175

When lymph nodes are coalesced and no longer separable in a conglomerate mass, the 
vector of the longest diameter should be used to determine the perpendicular vector for 
the maximal short axis diameter of the coalesced mass. Non-nodal lesions that coalesce 
should similarly be assessed by the longest axis diameter.

Tumour lesions selected for fresh screening biopsy should not be selected as TLs, unless 
imaging occurred at least approximately 2 weeks after biopsy, allowing time for healing.

If the CT/MRI slice thickness used is > 5 mm, the minimum size of measurable disease at 
baseline should be twice the slice thickness of the baseline scan.

If a lesion has completely disappeared, the diameter should be recorded as 0 mm. If a 
lesion appears in the same location on a subsequent scan, it will be recorded as a NL.
RECIST 1.1 NTL Selection at Baseline:
All other lesions, including non-measurable lesions and surplus measurable lesions, not 
recorded as TLs should be identified as NTLs at baseline. Measurements of these lesions are 
not required, but the presence or absence of each should be noted throughout follow-up.
Evaluation of Tumour Response and Progression
RECIST v1.1 TL Assessment at Follow-up
This section defines the criteria used to determine objective tumour visit response for 
RECIST v1.1-defined TLs. The imaging modality, location, and scan date of each TL 
identified previously at baseline should be documented at follow-up visits with the long axis 
diameter for non-nodal lesions or short axis diameter for lymph node lesions. All 
measurements should be recorded in millimeters. The sum of the diameters for all TLs at each 
follow-up visit will be compared to the baseline sum of diameters (for response or stable 
disease) or to the smallest prior (nadir) sum of diameters (for progression).
Special cases for TL assessment at follow-up:

If a lesion has completely disappeared, the diameter should be recorded as 0 mm. If a 
lesion appears in the same location on a subsequent scan, it will be recorded as an NL.

If a TL splits into 2 or more parts, the sum of the diameters of those parts should be 
recorded.

If 2 or more TLs merge, then the sum of the diameters of the combined lesion should be 
recorded for 1 of the lesions and 0 mm recorded for the other lesion(s). If the merged TLs 
are non-nodal lesions, record the long axis diameter of the merged lesion. If pathologic 
lymph nodes coalesce and are no longer individually separable within a conglomerate 
mass, the vector of the longest diameter of the coalesced mass should be used to 
determine the perpendicular vector for the maximal short axis diameter.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
153 of 175

If a TL is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned. If an accurate measure can be given, this should be 
recorded, even if it is below 5 mm.

If a TL cannot be measured accurately due to it being too large, provide an estimate of the 
size of the lesion. The choice of “Too large to measure” in the case report form will 
trigger an overall visit response of progressive disease.

When a TL has had any intervention (eg, definitive radiotherapy, embolization, surgery, 
transarterial chemoembolization, etc.) during the study, the size of the TL should still be 
provided where possible and the intervention recorded in the RECIST v1.1 case report 
form for the current imaging visit and all subsequent visits. If a TL has been completely 
removed (surgery) or disappears, the longest diameter should be recorded as 0 mm.
Table 24
RECIST v1.1 Evaluation of Target Lesions
CR
Disappearance of all TLs since baseline. Any pathological lymph nodes 
selected as TLs must have a reduction in short axis diameter to 
< 10 mm.
PR
At least a 30% decrease in the sum of the diameters of TL, taking as 
reference the baseline sum of diameters.
SD
Neither sufficient decrease in the sum of diameters to qualify for PR nor 
sufficient increase to qualify for progressive disease.
Progressive Disease
At least a 20% increase in the sum of diameters of TLs, taking as 
reference the smallest previous sum of diameters (nadir)—This includes 
the baseline sum if that is the smallest on study. In addition to the 
relative increase of 20%, the sum must demonstrate an absolute increase 
of at least 5 mm from nadir.
NE
Only relevant if any of the TLs at follow-up were not assessed or not 
evaluable (eg, missing anatomy) or had a lesion intervention at this 
visit. Note: If the sum of diameters meets the progressive disease 
criteria, progressive disease overrides not evaluable as a TL response.
NA
Only relevant if no TLs present at baseline.
Abbreviations: CR = complete response; NA = not applicable; NE = not evaluable; PR = partial response; 
SD = stable disease; TL = target lesion.
RECIST v1.1 NTL Assessment at Follow-up
All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline. Measurements are not required for these lesions, but their status should be followed 
at subsequent visits. At each visit, an overall assessment of the NTL response should be 
recorded by the Investigator.
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in presence of stable disease or 

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
154 of 175
partial response in TLs, the overall tumour burden has increased sufficiently to merit 
unequivocal progression by NTLs. A modest ‘increase’ in the size of one or more NTLs is 
usually not sufficient to qualify for unequivocal progression status. The designation of overall 
progression solely on the basis of change in non-target disease in the face of SD or PR of 
target disease will therefore be extremely rare.
Table 25
RECIST 1.1 Evaluation of Non-Target Lesions
CR
Disappearance of all NTLs since baseline. All lymph nodes must be 
non-pathological in size (< 10 mm short axis).
Non-CR/non-progressive disease
Persistence of one or more NTLs.
Progression of disease
Unequivocal progression of existing NTLs. Unequivocal progression 
may be due to an important progression in 1 lesion only or in several 
lesions. In all cases, the progression MUST be clinically significant for 
the physician to consider changing (or stopping) therapy.
NE
Only relevant when one or some of the NTLs were not assessed and, in 
the Investigator’s opinion, they are not able to provide an evaluable 
overall NTL assessment at this visit.
Note: For participants without TLs at baseline, this is relevant if any of 
the NTLs were not assessed at this visit and the progression criteria 
have not been met.
NA
Only relevant if no NTLs present at baseline
Abbreviations: CR = Complete response; NA = Not applicable; NE = Not evaluable; NTL = Non-target lesion; 
TL = Target lesion.
RECIST v1.1 NL Identification at Follow-up
Details, including the imaging modality, the date of scan, and the location of any NLs will also 
be recorded in the case report form. The presence of one or more NLs is assessed as 
progression. The finding of a NL should be unequivocal, ie, not attributable to differences in 
scanning technique, change in imaging modality, or findings thought to represent something 
other than tumour. If a NL is equivocal, for example because of its small size, the treatment 
and tumour assessments should be continued until the previously (pre-existing) new lesion has 
been assessed as unequivocal at a follow-up visit, and then the progression date should be 
declared using the date of the initial scan when the NL first appeared.
A lesion identified at a follow-up assessment in an anatomical location that was not scanned at 
baseline is considered a NL and will indicate disease progression.
RECIST v1.1 Evaluation of Overall Visit Response at Follow-Up
Derivation of overall visit response as a result of the combined assessment of TLs, NTLs, and 
NLs uses the algorithm shown in Table 26.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
155 of 175
Table 26
RECIST v1.1 Overall Visit Response
Target Lesions
Non-Target Lesions
New Lesions
Overall Visit Response
CR
CR
No
CR
CR
NA
No
CR
NA
CR
No
CR
CR
Non-CR/Non-progressive 
disease
No
PR
CR
NE
No 
PR
PR
Non-progressive disease or 
NE or NA
No
PR
SD 
Non-progressive disease or 
NE or NA
No
SD
NA
Non-CR/Non-progressive 
disease
No
SD (non-CR/non-progressive 
disease)
NE
Non-progressive disease or 
NE
No
NE
NA
NE
No
NE
NA
NA
No
NED
Progressive disease
Any
Yes or No
Progressive disease
Any
Progressive disease
Yes or No
Progressive disease
Any
Any
Yes
Progressive disease
Abbreviation: CR = complete response; NA = not applicable; NE = not evaluable; NED = no evidence of 
diseases; PR = partial response; SD = stable disease; TL = target lesion.
a
Non-CR/Non-progressive disease for Overall Response if only non-target lesions (no TLs) are present at 
baseline.
Note: An overall assessment of Complete Response (all other disease disappears/reverts to normal) would be
changed to Partial Response if ascites remains present radiologically.
The following overall visit responses are possible depending on the extent of tumour disease 
at baseline:

For participants with TLs (at baseline): CR, PR, SD, progression of disease, or NE

For participants with NTLs only (at baseline): CR, Non-CR/Non-progressive disease, 
progressive disease, or NE

For participants with no disease at baseline: no evidence of disease (available as an option 
in the electronic case report form), progressive disease, or NE

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
156 of 175
Evaluation of Scans Subsequent to RECIST v1.1-defined Progression
A follow-up scan is left up to the Investigator’s discretion but, if performed, should be at least 
4 weeks after a RECIST v1.1-defined radiological progression and no later than the next 
regularly scheduled imaging visit. The follow-up scans provide additional information to the 
Investigator for patient management and further treatment decisions, and since the published 
RECIST v1.1 criteria (Eisenhauer et al, 2009) do not provide guidance on how to assess scans 
acquired after RECIST v1.1-defined progressive disease, supplemental instructions for 
Investigators on how to evaluate these follow-up scans are provided below. If the follow-up 
scan acquired after a RECIST v1.1 progressive disease scan meets any of the following 
criteria, it will be assigned an overall visit response of progressive disease, and if the scan 
does not meet any of these 4 criteria, the timepoint assessment will be non-progressive disease
(ie, CR, PR, SD, or NE).

≥20% increase and at least a 5-mm increase in the sum diameters of TLs compared with 
the nadir sum of diameters at 2 consecutive visits, and a further increase of ≥5 mm in the 
sum of diameters at the follow-up timepoint compared with the immediate prior timepoint

significant progression (worsening) of NTLs at the follow-up scan timepoint compared 
with the immediate prior timepoint

significant progression (worsening) of previously new lesions (pre-existing new lesions) 
at the follow-up scan timepoint compared with the immediate prior timepoint

additional unequivocal brand-new lesions at the follow-up scan timepoint
Central Imaging
Images, including unscheduled visit scans, will be collected on an ongoing basis and sent to an 
AstraZeneca-appointed iCRO for quality control, storage, and potentially for BICR. Digital 
copies of all original scans should be stored at the Investigator site as source documents.
Electronic image transfer from the sites to the iCRO is strongly encouraged. A BICR of 
images will be performed at the discretion of AstraZeneca. Results of these independent 
reviews will not be communicated to Investigators, and results of Investigator tumour
assessments will not be shared with the central reviewers. The management of participants
will be based in part upon the results of the tumour assessments conducted by the Investigator.
Further details of the BICR will be documented in an Independent Review Charter.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
157 of 175
Appendix G
Changes Related to Mitigation of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health 
Crisis
Note: Changes below should be implemented only during study disruptions due to any of or a 
combination of civil crisis, natural disaster, or public health crisis (eg, during quarantines and 
resulting site closures, regional travel restrictions and considerations if site personnel or study 
participants become infected with SARS-CoV-2 or similar pandemic infection) during which 
participants may not wish to or may be unable to visit the study site for study visits. These 
changes should only be implemented if allowable by local/regional guidelines and following 
notification from the Sponsor and instructions on how to perform these procedures will be 
provided at the time of implementation.
Please note that during civil crisis, natural disaster, or public health crisis, some study 
assessments and procedures may not be conducted due to international or local policies or 
guidelines, hospital or clinic restrictions and other measures implemented to ensure the 
participant’s safety. If in doubt, please contact the AstraZeneca Study Physician.
G 1
Reconsent of Study Participants During Study Interruptions
During study interruptions, it may not be possible for the participants to complete study visits 
and assessments on site and alternative means for carrying out the visits and assessments may 
be necessary, eg, remote visits. Reconsent should be obtained for the alternative means of 
carrying out visits and assessments and should be obtained prior to performing the procedures 
described in Sections G 2 to G 5. Local and regional regulations and/or guidelines regarding 
reconsent of study participants should be checked and followed. Reconsent may be verbal if 
allowed by local and regional guidelines (note, in the case of verbal reconsent the ICF should 
be signed at the participant’s next contact with the study site). Visiting the study sites for the 
sole purpose of obtaining reconsent should be avoided. 
G 2
Rescreening of Participants to Reconfirm Study Eligibility
Additional rescreening for screen failure due to study disruption can be performed in 
previously screened participants. The Investigator should confirm this with the designated 
study physician.
In addition, during study disruption there may be a delay between confirming eligibility of a 
participant and either enrolment into the study or commencing of dosing with IMP. If this 
delay is outside the screening window specified in schedule of assessments the participant will 
need to be rescreened to reconfirm eligibility before commencing study procedures. This will 
provide another opportunity to re-screen a participant in addition to that detailed in 
Section 5.4. The procedures detailed in the SoA must be undertaken to confirm eligibility 
using the same randomization number as for the participant.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
158 of 175
G 3
Home or Remote Visit to Replace On-site Visit (where applicable)
A qualified HCP from the study site or TPV service will visit the participants home/or other 
remote location as per local standard operating procedures, as applicable. Supplies will be 
provided for a safe and efficient visit. The qualified HCP will be expected to collect 
information per the CSP.
G 4
Telemedicine Visit to Replace On-site Visit (where applicable)
In this appendix, the term telemedicine visit refers to remote contact with the participants
using telecommunications technology including phone calls, virtual or video visits, and 
mobile health devices.
During a civil crisis, natural disaster, or public health crisis, on-site visits may be replaced by 
a telemedicine visit if allowed by local/regional guidelines. Having a telemedicine contact 
with the participants will allow AEs and concomitant medication, to be reported and 
documented.
G 5
Data Capture During Telemedicine or Home / Remote Visits
Data collected during telemedicine or home/remote visits will be captured by the qualified 
HCP from the study site or TPV service.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
159 of 175
Appendix H
National Institute of Allergy and Infectious Disease and Food 
Allergy and Anaphylaxis Network guidance for anaphylaxis 
diagnosis
The National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis 
Network define anaphylaxis as a serious allergic reaction that is rapid in onset and may cause 
death. They recognize 3 categories of anaphylaxis, with criteria designated to capture from 
80% of cases (category 1) to > 95% of all cases of anaphylaxis (for all 3 categories).

Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING:
(a) Respiratory compromise (eg, dyspnoea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia)
(b) Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence)

Two or more of the following that occur rapidly after exposure to a likely allergen for that 
participant (minutes to several hours):
(a) Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen 
lips-tongue-uvula)
(b) Respiratory compromise (eg, dyspnoea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia)
(c) Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence)
(d) Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)

Reduced BP after exposure to known allergen for that participant (minutes to several 
hours):
(a) Infants and children: low systolic BP (age-specific) or greater than 30% decrease in 
systolic BP
(b) Adults: systolic BP of less than 90 mmHg or greater than 30% decrease from that 
person’s baseline

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
160 of 175
I 2
Introduction
CCI
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
162 of 175
parameters, slice thickness and other parameters as well as instructions for how to submit 
images for review (Note: Important for the sites to follow the instruction in Imaging Manual).
I 5
Schema
Figure 4 illustrates CD8+ PET and mandatory biopsies timelines in Part B1 and Part B2: 
AZD8853 Expansion.
I 6
Benefit-Risk Assessment with 89Zr-Df-Crefmirlimab (CD8+ PET 
Tracer)
The safety monitoring practices employed in the main protocol (Section 8.2, Section 8.3) are 
adequate to protect the participant safety for this part of the study. Preclinical data, both 
in vivo and in vitro have demonstrated that 89Zr-Df-crefmirlimab had no measurable effect on 
T cell proliferation, activation or cytokine release. An imaging investigating the use of 
89Zr-Df-crefmirlimab as a non-interventional or a treatment modality is not likely to improve 
response to treatment. However, should CD8+ PET imaging show a direct correlation to TIL 
recruitment to the TME, future cancer patients may be spared from painful invasive biopsies. 
Moreover, a positive correlation to clinical outcome could, in the future, potentially allow 
more rapid assessment of whether patients are responding to therapy and allow physicians to 
make decisions earlier about continuing or switching therapies for their participants. 
Potential risks include infusion site reactions (eg, redness, itching and pain), allergic reaction 
(including anaphylaxis), renal failure, hepatic failure, arthritis, and/or hypotension. 
For information on all identified and potential risks of crefmirlimab refer to the current 
version of the 89Zr-Df-crefmirlimab IB.
I 7
Study Population
Parts B1 and B2 of the study have no additional inclusion/exclusion criteria for CD8+ PET
imaging compared to the overall study, except known allergies to CD8+ PET tracer. For 
further details on the study population refer to Section 10.5.
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
163 of 175
I 8
Investigational Imaging Agent
For participants enrolled in Parts B1 and B2 for CD8+ PET imaging, an investigational 
imaging agent will be utilized, an anti-CD8 minibody (crefmirlimab), conjugated with Df and 
radiolabelled with 89Zr (89Zr-Df-crefmirlimab): 

Pharmacological Class: A biological PET radioligand for detecting CD8+ T cells

Dosage Formulation: 
 
 
 
 
 

Route of Administration: i.v. infusion, between 5 to 10 minutes.
I 8.1
Investigational Product Storage
The dose will be delivered by a central manufacturing facility to the investigational site’s 
radio pharmacy or Nuclear Medicine Department. Each shipment of 89Zr-Df-crefmirlimab will 
arrive in a thermally controlled shipping system. Investigational product is stored in a secure 
refrigerator at 2°C to 8°C, housed inside a sealed lead pot until one hour before the time of 
infusion. The dose of 89Zr-Df-crefmirlimab should be dispensed and administered by the 
expiration time listed on the label.
I 8.2
Investigational Product Handling
The 89Zr-Df-crefmirlimab dose will be measured by the qualified personnel in a dose 
calibrator prior to dispensing. Then the syringe will be placed in a shielded carrier along with 
a designated i.v. infusion pump for radioactive infusion and administration. After the dose 
administration, the qualified personnel will return the syringe for residual measurement by the 
nuclear pharmacist at the site. Measured radioactivity values and times of measurement will 
be documented, as well as the total injected volume.
I 8.3
Treatment Administration
The dose of 89Zr-Df-crefmirlimab should be removed from the secure refrigerator 1 hour 
before the time of infusion in order for the dose to come to room temperature. A single dose of 
the investigational imaging agent, 89Zr-Df-crefmirlimab [
mL] will 
be drawn up into a syringe according to the site’s schedule of procedures. Site personnel will 
label the syringe with the completed investigational imaging agent label and log the dose in 
the radio pharmacy standard drug use logs.
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
164 of 175
For further information see the 89Zr-Df-crefmirlimab Imaging Manual.
I 9
Statistical Considerations
The sample size for CD8+ PET imaging is not based on statistical power calculations. It was 
determined by practical considerations and to provide data to enable the relationship between 
CD8+ PET imaging and the paired biopsy data to be explored, taking into account dropouts. 
Up to approximately 20 participants enrolled into Part B of the study will participate in CD8+ 
PET imaging. 
To meet objectives of CD8+ PET imaging, the following endpoint will be evaluated:

Standardized uptake value quantitative measures of tumour lesions (biopsied and non-
biopsied) and reference tissues; SUV values will be calculated at and between 
timepoints.
Positron emission tomography data are converted to lean body mass SUVs, using the 
participant’s height, weight, and injected activity. 
Descriptive statistics will be used to describe the SUV measurements of tissues of interest 
(eg, tumour, lymph node). Categorical data will be summarized by counts and percentages. 
Continuous variables will be summarized by mean, median, standard deviation, minimum, and 
maximum. 
The relationship between SUV measurements of tissue and 
 or 
IHC of innate, and adaptive immune cells/factors from tumour biopsies from the main 
protocol will be explored. 
Efficacy endpoints from the main protocol (ORR, DoR, PFS, and OS, where possible) will be 
assessed in relation to SUV measurements. 
Any results from such analyses may be reported separately from the CSR.
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
165 of 175
Appendix J
Abbreviations 
Abbreviation or special term
Explanation
ADA
Anti-drug antibody 
AE
Adverse event
AESI
Adverse event of special interest
ALK
Anaplastic lymphoma kinase gene
ALP
Alkaline phosphatase
ALT
Alanine transaminase
aPTT
Activated partial thromboplastin time
AST
Aspartate transaminase
AUC
Area under the curve
BICR
Blinded Independent Central Review
BMI
Body mass index
BoR
Best overall response
BP
Blood pressure
CAP
College of American Pathologists
CD4
Cluster of differentiation 4
CD8
Cluster of differentiation 8
CFR
Code of Federal Regulations
CI
Confidence interval
CLIA
Clinical laboratory improvement amendments
Cmax
Maximum concentration
CNS
Central nervous system
CONSORT
Consolidated standards of reporting trials
COVID-19
Coronavirus disease 2019
CPI
Checkpoint inhibitors
CR
Complete response
CRC
Colorectal cancer
CRO
Contract research organisation
CSP
Clinical study protocol
CSR
Clinical study report
CT
Computed tomography
CTCAE
Common terminology criteria for adverse events
ctDNA
Circulating tumour deoxyribonucleic acid
CTLA-4
cytotoxic T-lymphocyte associated protein 4
DC
Dendritic cells

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
166 of 175
Abbreviation or special term
Explanation
DCR
Disease control rate
DCO
Data cut-off
Df
Deferoxamine
DILI
Drug induced liver injury
DLT
Dose limiting toxicity
DNA
Deoxyribonucleic acid
DoR
Duration of response
ECG
Electrocardiogram
eCRF
Electronic case report form
ECOG
Eastern cooperative oncology group
EDC
Electronic data collection
EGFR
Estimated glomerular filtration rate
EMA
European medicines agency
EoI
End of infusion
EOT
End of treatment
FDA
Food and drug administration
FDG
18F-Fluoro-deoxyglucose
Fc
Fragment crystallizable
FFPE
Formalin-fixed paraffin-embedded
FTiH
First time in human
GCP
Good clinical practice
G-CSF
Granulocyte colony stimulating factor
GDF15
Growth differentiation factor 15
GLP
Good laboratory practice
GRFAL
Glial cell line-derived neurotrophic factor (GDNF) family receptor α-
like
HAV
Hepatitis A virus
Hb
Haemoglobin
HbA1c
Haemoglobin A1c
HBc
Hepatitis B core
HBV
Hepatitis B virus
HBsAg
Hepatitis B surface antigen
hCG
Human chorionic gonadotropin
HCP
Health care professional
HCV
Hepatitis C virus

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
167 of 175
Abbreviation or special term
Explanation
HEV
Hepatitis E virus
HIPAA
Health Insurance Portability and Accountability Act
HIV
Human immunodeficiency viruses
HL
Hy’s Law
HNSTD
Highest non-severely toxic dose
HPDD
Highest protocol defined dose
IATA
International Airline Transportation Association
IB
Investigator’s Brochure
ICD
Immune complex disease
ICF
Informed consent form
ICH
International Council for Harmonisation
iCRO
Imaging Contract Research Organisation
IEC
Independent Ethics Committee
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IHC
Immunohistochemistry
imAE
Immune mediated adverse event
IMP
Investigational medicinal product
INR
International normalised ratio
IRB
Institutional Review Board
IRR
Infusion related reactions
IxRS
Interactive voice/web response system
IRT/RTSM
Interactive Response Technology System/Randomisation and Trial 
Supply Management
i.v.
Intravenous
LTFU
Long term follow-up
mAb
Monoclonal antibody
MedDRA
Medical dictionary for regulatory activities
MoA
Mechanism of action
MSS
Microsatellite stable
MTD
Maximum tolerated dose
MRI
Magnetic resonance imaging
mTPI
Modified toxicity probability interval
CCI
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
168 of 175
Abbreviation or special term
Explanation
NASH
Non-alcoholic steatohepatitis
NCI
National Cancer Institute
NE
Not evaluable
NIMP
Non-investigational medicinal product
NK
Natural killer 
NL
New lesion
NSCLC
Non-small-cell lung cancer
NTL
Non-target lesions
OAE
Other significant adverse event
ORR
Objective response rate
OS
Overall Survival
OTC
Over-the-counter
PD
Pharmacodynamics
PD-1
Programmed cell death-1
PD-L1
Programmed death-ligand 1
PEF
Peak expiratory flow
PET
Positron emission tomography
PFS
Progression free survival
PHL
Potential Hy’s Law
PK
Pharmacokinetics
PR
Partial response
PT
Prothrombin time
Q3W
Every 3 weeks
Q9W
Every 9 weeks
Q12W
Every 12 weeks
Q26W
Every 26 weeks
QTcF
QT interval corrected for heart rate using Fridericia’s formula
RBC
Red blood cells
RECIST
Response evaluation criteria in solid tumours
RNA
Ribonucleic acid
RP2D
Recommended Phase 2 dose
RT-qPCR
Reverse transcription-quantitative polymerase chain reaction
SAE
Serious adverse event 
SAP
Statistical analysis plan
CCI
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
169 of 175
Abbreviation or special term
Explanation
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SD
Stable disease
SMI
Skeletal muscle index
SoA
Schedule of activities
SOC
System organ class
SRC
Safety review committee
SUV
Standardised uptake value
T3
Triiodothyronine
T4
Thyroxine
TBD
To be decided
TBL
Total bilirubin
TGF-β
Transforming growth factor beta
Th1
T helper type 1 cells
TIL
Tumour infiltrating lymphocyte
TL
Target lesion
TME
Tumour immune microenvironment
TMG
Toxicity management guidelines
TPV
Third party vendor
Treg
Regulatory T cells
TSH
Thyroid-stimulating hormone
UC
Urothelial carcinoma
ULN
Upper limit of normal
UPM
Unit probability mass
WBC
White blood cells
WOCBP
Women of childbearing potential
w/v
% weight per volume
Zr
Zirconium

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
170 of 175
Appendix K
Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 1 29 November 2021
Overall Rationale for the Amendment:
This amendment is considered to be a global substantial amendment based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of 
European Union. 
This protocol amendment incorporates changes requested by the United States Food and Drug 
Administration (FDA).
A high-level description of the changes is provided in the table below.
Section(s)
Description of Change
Title
Title updated to remove “Modular” language
Entire Protocol
•
References to “Core Protocol” changed to “Master Protocol” 
throughout the entire document
•
References to “Module 1” or “Module #” changed throughout 
the entire document to “Substudy 1” or “Substudy #”
•
Updated urothelial bladder cancer (UBC) to urothelial 
carcinoma (UC) throughout for consistency
•
Updates made for clarity and consistency, including the 
correction of grammar and/or spelling.
Sections 1 to 9
Changed from “Core Protocol” sections to “Master Protocol” sections
Sections 1.1, 4.1.1, 4.1.2
Addition of clarified study design details 
Sections 1.2, 10.1.1
Study schema in Figure 3 (Section 10.1.1), which provides details on 
Substudies, copied to Section 1.1 (Figure 2) 
Section 2.3.1
Sentence added to clarify that the TMG is provided as a separate 
document.
Section 4.4.1
Study Stopping Criteria updated to require halting enrolment in the 
event of unacceptable toxicity
Section 10
Changed from “Module 1” to “Substudy 1”
Section 10.8
Blood volumes updated.
Sections 10.1.2, Table 13; 10.8.5.1
Table 18
Additional pharmacokinetic (PK) timepoints added for Substudy 1 
Parts B and C
Sections 10.1.2 Table 13; 10.8.2.1
Table 17
Table added to clarify electrocardiogram collection timepoints
Section 10.1.2 Table 13
Correction of footnotes for clarity
Sections 10.4.1, 10.6.7
Clarified Recommended Phase 2 dose (RP2D) will be defined in 
Dose Expansion parts of the Substudy 1

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
171 of 175
Section(s)
Description of Change
Section 10.5.1
Growth differentiation factor 15 (GDF15) cut off of ≥ 
pg/mL 
specified
Section 10.6.8
•
Clarified language regarding relatedness of adverse events in the 
Dose limiting toxicity (DLT) definition
•
Removed DLT exception for Grade ≥3 endocrine disorders
•
Separated exception to DLT criteria for elevated amylase / 
lipase and electrolyte abnormalities
CCI

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
172 of 175
12
REFERENCES
Arfsten et al, 2019
Arfsten H, Cho A, Freitag C, Raderer M, Goliasch G, Bartko PE, et al. GDF-15 in solid vs 
non-solid treatment-naïve malignancies. Eur J Clin Invest. 2019;49(11):e13168.
Baine et al, 2015
Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, et al. Characterization of 
tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma 
specimens. Oncotarget. 2015 Sep 22;6(28):24990-5002.
Bauskin et al, 2006
Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage 
inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 
2006;66(10):4983-6.
Brown et al, 2003
Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum 
level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin 
Cancer Res. 2003;9(7):2642-50.
Campderrós et al, 2020
Campderrós L, Sánchez-Infantes D, Villarroya J, Nescolarde L, Bayès-Genis A, Cereijo R, et 
al. Altered GDF15 and FGF21 Levels in Response to Strenuous Exercise: A Study in 
Marathon Runners. Front Physiol. 2020 Nov 19;11:550102.
Clopper et al, 1934
Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the 
binomial. Biometrika. 1934;26(4):404-413.
Coll et al, 2020
Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the 
effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444-8.
Davda et al, 2010
Davda JP, Hansen RJ, Properties of a general PK/PD model of antibody-ligand interactions 
for therapeutic antibodies that bind to soluble endogenous targets, mAbs 2010;2(5).
EMA-CTFG-EC, 2021
Clinical Trials Facilitation and Coordination Group (CTFG), European Commission (EC). 
Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
pandemic, Version 4, 04 February 2021. 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-
10/guidanceclinicaltrials_covid19_en.pdf. Accessed October 2021. 2021.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
173 of 175
Eisenhauer et al, 2009
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 
2009 Jan;45(2):228-47.
Fu et al, 2019
Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B, et al. Prognostic value of tumor-infiltrating 
lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019 
Apr 3;8(7):1593806.
Guo et al, 2017
Guo W, Wang SJ, Yang S, Lynn H, Ji Y. A Bayesian interval dose-finding design addressing 
Ockham's razor: mTPI-2. Contemp Clin Trials. 2017;5823-33.
Ji et al, 2010
Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding 
trials. Clin Trials. 2010 Dec;7(6):653-63.
Kleinert et al, 2018
Kleinert M, Clemmensen C, Sjøberg KA, Carl CS, Jeppesen JF, Wojtaszewski JFP, et al. 
Exercise increases circulating GDF15 in humans. Mol Metab. 2018 Mar;9:187-191.
Kong et al, 2019
Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warrier SK, Ramsay RG, Heriot AG. 
Prognostic Impact of Tumor-Infiltrating Lymphocytes in Primary and Metastatic Colorectal 
Cancer: A Systematic Review and Meta-analysis. Dis Colon Rectum. 2019 Apr;62(4):498-
508.
Liu et al, 2016
Liu YN, Wang XB, Wang T, Zhang C, Zhang KP, Zhi XY, et al. Macrophage Inhibitory 
Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell 
Lung Cancer. Chin Med J (Engl). 2016 Sep 5;129(17):2026-32.
Lowe et al, 2009
Lowe P, Tannenbaum S, Wu K, Lloyd P, Sims J, On setting the first dose in man: Quantitating 
biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models, 
Basic & Clinical Pharmacology and Toxicology, 2009;106;195-209.
Mehta et al, 2014
Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, Fuchs CS, Ogino S, 
Giovannucci EL, Chan AT. A prospective study of macrophage inhibitory cytokine-1 (MIC-
1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014 Apr;106(4):dju016.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
174 of 175
Mehta et al, 2015
Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, et al. Association 
Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal 
Cancer and Mortality. Gastroenterology. 2015;149(3):614-22.
Roth et al, 2010
Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, et al. GDF-15 
contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010 
Aug 1;16(15):3851-9.
Rybar et al, 2016
Rybar D, Ng R, Fidler M, Kerns S, Sayidine S, Basu S et al. Cachexia Index utilization in 
patients with non-small cell lung cancer. Journal of Clinical Oncology. 
2016;34(15_suppl):e20642-e20642.
Traeger et al, 2019
Traeger L, Ellermann I, Wiethoff H, Ihbe J, Gallitz I, Eveslage M et al. Serum Hepcidin and 
GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and 
renal cell carcinoma. BMC Cancer. 2019;19(1):74.
Tang et al, 2021
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor 
immune microenvironment over blocking immune checkpoint in cancer immunotherapy. 
Signal Transduct Target Ther. 2021 Feb 20;6(1):72.
FDA 2021
US FDA. FDA Guidance on Conduct of Clinical Trials of Medical Products during 
COVID-19 Public Health Emergency. 30 August 2021. https://www.fda.gov/regulatory-
information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-
products-during-covid-19-public-health-emergency. Accessed October 2021. 2021.
Waldman et al, 2020
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic 
science to clinical practice. Nat Rev Immunol. 2020 Nov;20(11):651-668.
Wang et al, 2020
Wang S, Xie H, Gong Y, Kuang J, Yan L, Ruan G, Gao F, Gan J. The value of L3 skeletal 
muscle index in evaluating preoperative nutritional risk and long-term prognosis in colorectal 
cancer patients. Sci Rep. 2020 May 18;10(1):8153.
Wang et al, 2021
Wang Z, He L, Li W, Xu C, Zhang J, Wang D, et al. GDF15 induces immunosuppression via 
CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. 2021 
Sep;9(9):e002787.

Clinical Study Protocol - 3.0
AstraZeneca
AZD8853 - D9450C00001
CONFIDENTIAL AND PROPRIETARY
175 of 175
Wischhusen et al, 2020
Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From 
Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020;11:951.
Xia et al, 2020
Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 
2020 Apr;21(4):e180.
Xiong et al, 2017
Xiong Y, Walker K, Min X, Hale C, Tran T, Komorowski R, et al. Long-acting MIC-1/GDF15 
molecules to treat obesity: Evidence from mice to Monkeys, Sci. Transl. Med. 2017;9(412).
Yang et al, 2021
Ming Yang M, Tan L, Xie L, Hu S, Liu D, Wang J, et al. Factors That Improve Chest 
Computed Tomography-Defined Sarcopenia Prognosis in Advanced Non-Small Cell Lung 
Cancer. Front Oncol. 2021; 11:754975.
Yu et al, 2020
Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients with Cancer at a 
Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020;6(7):1108-10.
Zhang et al, 2020
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-
19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, 
China. Ann Oncol. 2020; 31(7):894-901.

SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d9450c00001-csp-v3
Document Title:
D9450C00001 Clinical Study Protocol Version 3
Document ID:
Doc ID-004636406
Version Label:
3.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)
Signed by
Meaning of Signature
13-Apr-2022 23:59 UTC
Content Approval
13-Apr-2022 14:14 UTC
Content Approval
13-Apr-2022 14:52 UTC
Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
PPD
PPD
PPD

Clinical Study Protocol - Addendum
AstraZeneca
AZD8853 - D9450C00001
Version 2.0, 24 June 2022
CONFIDENTIAL AND PROPRIETARY
1 of 2
Clinical Study Protocol – Addendum – Global No. 2
Study Intervention
AZD8853
Study Code
D9450C00001
Addendum Version
2.0
Date
24 June 2022
Global Addendum No. 2
A Phase I/IIa First-in-human, Open-label Study to Evaluate the
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary
Efficacy of AZD8853 in Participants with Selected
Advanced/Metastatic Solid Tumours
Sponsor Name: AstraZeneca
Legal Registered Address: AstraZeneca AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifier Number(s): 
IND number: 157890
EudraCT number: 2021-005438-41
Protocol Number: D9450C00001
Corresponding Protocol Versions:
Amendment 2.0, v3.0 (11 April 2022)
Amendment 1.0, v2.0 (03 December 2021)

Clinical Study Protocol - Addendum
AstraZeneca
AZD8853 - D9450C00001
Version 2.0, 24 June 2022
CONFIDENTIAL AND PROPRIETARY
2 of 2
1.
DOCUMENT HISTORY
DOCUMENT HISTORY
Document
Date
Global Addendum 2 (v2.0)
24 June 2022
Protocol Amendment 2 (v3.0)
11 April 2022
Global Addendum 1 (v1.0)
30 Mar 2022
Protocol Amendment 1 (v2.0)
03 Dec 2021
Overall Rationale for the Addendum:
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of European Union.
The primary reason for this addendum is to implement a washout period for prior radiotherapy 
and standard of care treatment. This addendum should be implemented immediately due to 
possible patient safety implications, regardless of current approved protocol version. 
These changes will be incorporated in the next global protocol amendment. 
Section # and Name
Description of Change with Reason
5.1 Inclusion Criteria –
Prior / Concomitant 
Therapy
Add 2 new criteria: 

Wide-field radiotherapy must be completed at least 28 days 
before the first dose of study intervention. However, limited-
field, palliative radiotherapy may be administered up to 7 days 
before the first dose of study intervention. 

Systemic standard of care (SOC) therapy must be completed at 
least 28 days, or 5-half-lives of the SOC therapy, whichever is 
shorter, prior to the first dose of study intervention. 
While the protocol has other defined washout periods, there is not a clear 
washout for radiotherapy and standard of care therapies. Clear washout 
periods are necessary for patient safety, and for supporting a clear safety 
profile. 

SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d9450c00001-csp-v2-addendum-global
Document Title:
D9450C00001 Clinical Study Protocol version 2 Addendum
Global
Document ID:
Doc ID-004840880
Version Label:
2.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)
Signed by
Meaning of Signature
30-Jun-2022 14:19 UTC
Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
PPD